<?xml version="1.0" encoding="UTF-8"?>
<!-- This is a template for a FHIR resource, and needs items (marked with "${}") replacing to make a real instance -->
<!-- The resulting instance is a Bundle of Bundles, each of which is a document (having a Composition, and supporting resources) -->
<!-- 2020-02-22 -->
<!-- This is for FHIR version R5 Preview 2 (May 2020) -->
<Bundle xmlns="http://hl7.org/fhir">
	<type value="collection"/>
	<!-- Repeat at this level per document -->
	<entry>
		<fullUrl value="urn:uuid:c7fb8474-f41e-4666-bce6-67e5c7ed8252"/>
		<!-- Top level of each document is a also FHIR Bundle, of type "document"
		 see http://hl7.org/fhir/documents.html, http://hl7.org/fhir/bundle.html
	 	 All the other resources for this document are within this. -->
		<resource>
            <Bundle>
            	<!-- When PUTing, some servers mandate an id here to match the existing id -->
            	<id value="85820e91-9e05-4e2c-9216-2b8da1f2de76"/>
				<!-- document bundles must have an identifier (bdl-9) -->
				<identifier>
					<!-- possibly different identifier types may be needed here -->
					<system value="http://ema.europa.eu/fhir/identifier/documentid"/>
					<value value="${instance.bundle[n].Identifier}"/>
				</identifier>
				<!-- fixed code -->
				<type value="document" /> 
            	<!-- document bundles must have a date (bdl-10) -->
            	<timestamp value="2021-06-01T17:46:11Z"/>
				<!-- a repeating set of entry elements, each with a FHIR resource inside -->
				<entry>
					<!-- fullUrl is mandatory for each entry in document Bundle. It is a random uuid. http://build.fhir.org/bundle.html#bundle-unique -->
					<fullUrl value="urn:uuid:9dbc59d8-9e9f-4891-953b-5e96e2024c71"/>
					<resource>
						<!-- the first resource must be Composition (bdl-11) -->
						<!-- This is the overall document structure. -->
						<!-- see definition http://hl7.org/fhir/composition.html, and similar for other resources -->
                        <Composition>
                        	<!-- images if requied within html text of this document -->
							
              
              <contained>
                          <Binary>
                            <id value="stylesheet0"/>
                            <!-- example format -->
                            <contentType value="stylesheet/css"/>
                            <!-- data is base 64 encoded, actual bytes of the image png file -->
                            <data value="<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:TimesNewRomanPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:2 2 8 3 7 5 5 2 3 4;}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"MT Extra";
	panose-1:5 5 1 2 1 2 5 2 2 2;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Alef;}
@font-face
	{font-family:"Amasis MT Pro";}
@font-face
	{font-family:"Amasis MT Pro Black";}
@font-face
	{font-family:"Amasis MT Pro Light";}
@font-face
	{font-family:"Amasis MT Pro Medium";}
@font-face
	{font-family:"Amatic SC";}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Aref Ruqaa";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:Assistant;}
@font-face
	{font-family:"Assistant ExtraBold";}
@font-face
	{font-family:"Assistant ExtraLight";}
@font-face
	{font-family:"Assistant Light";}
@font-face
	{font-family:"Assistant SemiBold";}
@font-face
	{font-family:Athiti;}
@font-face
	{font-family:"Athiti ExtraLight";}
@font-face
	{font-family:"Athiti Light";}
@font-face
	{font-family:"Athiti Medium";}
@font-face
	{font-family:"Athiti SemiBold";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Demi";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Bierstadt;}
@font-face
	{font-family:"Bierstadt Display";}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Charmonman;}
@font-face
	{font-family:Chonburi;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"EB Garamond";}
@font-face
	{font-family:"EB Garamond ExtraBold";}
@font-face
	{font-family:"EB Garamond Medium";}
@font-face
	{font-family:"EB Garamond SemiBold";}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:Fahkwang;}
@font-face
	{font-family:"Fahkwang ExtraLight";}
@font-face
	{font-family:"Fahkwang Light";}
@font-face
	{font-family:"Fahkwang Medium";}
@font-face
	{font-family:"Fahkwang SemiBold";}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:"Frank Ruhl Libre";}
@font-face
	{font-family:"Frank Ruhl Libre Black";}
@font-face
	{font-family:"Frank Ruhl Libre Light";}
@font-face
	{font-family:"Frank Ruhl Libre Medium";}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:"Goudy Type";}
@font-face
	{font-family:Grandview;}
@font-face
	{font-family:"Grandview Display";}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:Heebo;}
@font-face
	{font-family:"Heebo Black";}
@font-face
	{font-family:"Heebo ExtraBold";}
@font-face
	{font-family:"Heebo Light";}
@font-face
	{font-family:"Heebo Medium";}
@font-face
	{font-family:"Heebo Thin";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:Krub;}
@font-face
	{font-family:"Krub ExtraLight";}
@font-face
	{font-family:"Krub Light";}
@font-face
	{font-family:"Krub Medium";}
@font-face
	{font-family:"Krub SemiBold";}
@font-face
	{font-family:Lalezar;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Miriam Libre";}
@font-face
	{font-family:Mitr;}
@font-face
	{font-family:"Mitr ExtraLight";}
@font-face
	{font-family:"Mitr Light";}
@font-face
	{font-family:"Mitr Medium";}
@font-face
	{font-family:"Mitr SemiBold";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Open Sans";}
@font-face
	{font-family:"Open Sans ExtraBold";}
@font-face
	{font-family:"Open Sans Light";}
@font-face
	{font-family:"Open Sans SemiBold";}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:Pridi;}
@font-face
	{font-family:"Pridi ExtraLight";}
@font-face
	{font-family:"Pridi Light";}
@font-face
	{font-family:"Pridi Medium";}
@font-face
	{font-family:"Pridi SemiBold";}
@font-face
	{font-family:Prompt;}
@font-face
	{font-family:"Prompt Black";}
@font-face
	{font-family:"Prompt ExtraBold";}
@font-face
	{font-family:"Prompt ExtraLight";}
@font-face
	{font-family:"Prompt Light";}
@font-face
	{font-family:"Prompt Medium";}
@font-face
	{font-family:"Prompt SemiBold";}
@font-face
	{font-family:"Prompt Thin";}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Reem Kufi";}
@font-face
	{font-family:Roboto;}
@font-face
	{font-family:"Roboto Black";}
@font-face
	{font-family:"Roboto Condensed";}
@font-face
	{font-family:"Roboto Condensed Light";}
@font-face
	{font-family:"Roboto Condensed Medium";}
@font-face
	{font-family:"Roboto Light";}
@font-face
	{font-family:"Roboto Medium";}
@font-face
	{font-family:"Roboto Thin";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Seaford;}
@font-face
	{font-family:"Seaford Display";}
@font-face
	{font-family:"Secular One";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:Skeena;}
@font-face
	{font-family:"Skeena Display";}
@font-face
	{font-family:"Source Code Pro";}
@font-face
	{font-family:"Source Code Pro Black";}
@font-face
	{font-family:"Source Code Pro ExtraLight";}
@font-face
	{font-family:"Source Code Pro Light";}
@font-face
	{font-family:"Source Code Pro Medium";}
@font-face
	{font-family:"Source Code Pro Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Source Serif Pro";}
@font-face
	{font-family:"Source Serif Pro Black";}
@font-face
	{font-family:"Source Serif Pro ExtraLight";}
@font-face
	{font-family:"Source Serif Pro Light";}
@font-face
	{font-family:"Source Serif Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"Suez One";}
@font-face
	{font-family:Tenorite;}
@font-face
	{font-family:"Tenorite Display";}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:Trirong;}
@font-face
	{font-family:"Trirong Black";}
@font-face
	{font-family:"Trirong ExtraBold";}
@font-face
	{font-family:"Trirong ExtraLight";}
@font-face
	{font-family:"Trirong Light";}
@font-face
	{font-family:"Trirong Medium";}
@font-face
	{font-family:"Trirong SemiBold";}
@font-face
	{font-family:"Trirong Thin";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;}
h2
	{mso-style-link:"Heading 2 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
h4
	{mso-style-link:"Heading 4 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
h5
	{mso-style-link:"Heading 5 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:normal;}
h6
	{mso-style-link:"Heading 6 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:"Heading 7 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-link:"Heading 8 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-link:"Heading 9 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	font-size:9.0pt;
	font-family:"Arial",sans-serif;
	font-style:italic;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Footnote Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.MsoFootnoteReference
	{font-family:"Verdana",sans-serif;
	vertical-align:super;}
span.MsoPageNumber
	{font-family:"Times New Roman",serif;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-link:"Endnote Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{font-family:"Times New Roman",serif;
	color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:#954F72;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-link:"Document Map Char";
	margin:0in;
	background:navy;
	font-size:11.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:.5in;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:.5in;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	text-transform:uppercase;
	font-weight:bold;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-weight:bold;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-weight:bold;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	font-weight:bold;
	font-style:italic;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char";
	mso-style-link:"Heading 5";
	font-family:"Arial",sans-serif;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-link:"Heading 6";
	font-family:"Arial",sans-serif;
	font-style:italic;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-link:"Heading 7";
	font-family:"Arial",sans-serif;}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	mso-style-link:"Heading 8";
	font-family:"Arial",sans-serif;
	font-style:italic;}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	mso-style-link:"Heading 9";
	font-family:"Arial",sans-serif;
	font-style:italic;}
p.EMEATableCentered, li.EMEATableCentered, div.EMEATableCentered
	{mso-style-name:"EMEA Table Centered";
	margin:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEATableLeft, li.EMEATableLeft, div.EMEATableLeft
	{mso-style-name:"EMEA Table Left";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEABodyTextIndent, li.EMEABodyTextIndent, div.EMEABodyTextIndent
	{mso-style-name:"EMEA Body Text Indent";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEABodyText, li.EMEABodyText, div.EMEABodyText
	{mso-style-name:"EMEA Body Text";
	mso-style-link:"EMEA Body Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEATitle, li.EMEATitle, div.EMEATitle
	{mso-style-name:"EMEA Title";
	margin:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.EMEAHeading1NoIndent, li.EMEAHeading1NoIndent, div.EMEAHeading1NoIndent
	{mso-style-name:"EMEA Heading 1 No Indent";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.EMEAHeading3, li.EMEAHeading3, div.EMEAHeading3
	{mso-style-name:"EMEA Heading 3";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.EMEAHeading1, li.EMEAHeading1, div.EMEAHeading1
	{mso-style-name:"EMEA Heading 1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.EMEAHeading2, li.EMEAHeading2, div.EMEAHeading2
	{mso-style-name:"EMEA Heading 2";
	mso-style-link:"EMEA Heading 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.EMEAAddress, li.EMEAAddress, div.EMEAAddress
	{mso-style-name:"EMEA Address";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEAComment, li.EMEAComment, div.EMEAComment
	{mso-style-name:"EMEA Comment";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	mso-style-link:"Document Map";
	font-family:"Times New Roman",serif;}
p.EMEAHiddenTitlePIL, li.EMEAHiddenTitlePIL, div.EMEAHiddenTitlePIL
	{mso-style-name:"EMEA Hidden Title PIL";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.EMEAHiddenTitlePAC, li.EMEAHiddenTitlePAC, div.EMEAHiddenTitlePAC
	{mso-style-name:"EMEA Hidden Title PAC";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
span.BMSInstructionText
	{mso-style-name:"BMS Instruction Text";
	font-family:"Times New Roman",serif;
	color:red;
	display:none;
	font-style:italic;
	text-decoration:none;
	vertical-align:baseline;}
span.EMEASubscript
	{mso-style-name:"EMEA Subscript";
	vertical-align:sub;}
span.EMEASuperscript
	{mso-style-name:"EMEA Superscript";
	vertical-align:super;}
p.EMEATableHeader, li.EMEATableHeader, div.EMEATableHeader
	{mso-style-name:"EMEA Table Header";
	margin:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;
	font-family:"Times New Roman",serif;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;
	font-family:"Times New Roman",serif;}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	mso-style-link:"Endnote Text";
	font-family:"Times New Roman",serif;}
p.EMEATitlePAC, li.EMEATitlePAC, div.EMEATitlePAC
	{mso-style-name:"EMEA Title PAC";
	margin:0in;
	page-break-after:avoid;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
span.EMEABodyTextChar
	{mso-style-name:"EMEA Body Text Char";
	mso-style-link:"EMEA Body Text";
	font-family:"Times New Roman",serif;}
span.EMEAHeading2Char
	{mso-style-name:"EMEA Heading 2 Char";
	mso-style-link:"EMEA Heading 2";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Tahoma",sans-serif;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-link:"Footnote Text";}
p.news-date, li.news-date, div.news-date
	{mso-style-name:news-date;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-link:"Comment Text";}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-weight:bold;}
p.bodytextagency, li.bodytextagency, div.bodytextagency
	{mso-style-name:bodytextagency;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.BodytextAgency0, li.BodytextAgency0, div.BodytextAgency0
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.No-numheading1Agency, li.No-numheading1Agency, div.No-numheading1Agency
	{mso-style-name:"No-num heading 1 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:13.5pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.No-numheading2Agency, li.No-numheading2Agency, div.No-numheading2Agency
	{mso-style-name:"No-num heading 2 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;
	font-style:italic;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.BodytextAgencyCarattere, li.BodytextAgencyCarattere, div.BodytextAgencyCarattere
	{mso-style-name:"Body text \(Agency\) Carattere";
	mso-style-link:"Body text \(Agency\) Carattere Carattere";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyCarattereCarattere
	{mso-style-name:"Body text \(Agency\) Carattere Carattere";
	mso-style-link:"Body text \(Agency\) Carattere";
	font-family:"Verdana",sans-serif;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 841.95pt;
	margin:56.7pt 70.85pt 56.7pt 70.85pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>"/>
                          </Binary>
                        </contained>
                        <!-- this exension is necessary per image -->
                        <extension url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
                          <valueReference>
                            <reference value="#stylesheet0"/>
                          </valueReference>
                        </extension>
              
              <status value="final"/>
							<!-- document type -->
							<type>
								<coding>
									<system value="http://spor.ema.europa.eu/v1/lists/100000155531"/>
									<code value="${document[n].documentTypeCode}"/>
									<display value="${document[n].documentTypeDisplay}"/>
								</coding>
							</type>
							<subject>
								<!-- links to the List resource in this bundle - local url format -->
								<reference value="[]"/> <!-- local url format -->
								<!--reference value="${instance.bundle[n].listUuid}"/--> <!-- uuid url format. Possible alternate format may be neeed -->
							</subject>
                        	<!-- mandatory date of the document -->
                        	<date value="2021-02-01"/>
							<author>
								<identifier>
									<system value="http://spor.ema.europa.eu/v1/locations" />
									<value value="" />
								</identifier>
							</author>
                        	<title value="${document[n].title}"/>
							<relatesTo>
								<code value="appends"/>
								<targetReference>
									<!-- reference to another Composition -->
									<reference value="${document[n].relatesTo}"/>
								</targetReference>
							</relatesTo>
							<!-- main sections of the document, to follow the QRD template -->
	               			
<section>
	
		
			<title value="SUMMARY OF PRODUCT CHARACTERISTICS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; text-transform:uppercase'><br clear="all" style="page-break-before:always"/> </span></b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; text-transform:uppercase'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/>
			</div>
		</text>
		
		
    	    
				
			    
						
		               
<section>
			<title value="1.       NAME OF THE MEDICINAL PRODUCT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEABodyText"><span lang="EN-GB">Karvea 75 mg tablets.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="2.       QUALITATIVE AND QUANTITATIVE COMPOSITION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEABodyText"><span lang="EN-GB">Each tablet contains 75 mg of irbesartan.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Excipient with known effect</span></u><span lang="EN-GB">: 15.37 mg of lactose monohydrate per tablet.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">For the full list of excipients, see section 6.1.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="3.       PHARMACEUTICAL FORM"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Tablet.</span></p><p class="EMEABodyText"><span lang="EN-GB">White to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2771 engraved on the other side.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="4.       CLINICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="4.1     Therapeutic indications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Karvea is indicated in adults for the treatment of essential hypertension.</span></p><p class="EMEABodyText"><span lang="EN-GB">It is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen (see sections 4.3, 4.4, 4.5 and 5.1).</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.2     Posology and method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Posology</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">The usual recommended initial and maintenance dose is 150 mg once daily, with or without food. Karvea at a dose of 150 mg once daily generally provides a better 24 hour blood pressure control than 75 mg. However, initiation of therapy with 75 mg could be considered, particularly in haemodialysed patients and in the elderly over 75 years.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">In patients insufficiently controlled with 150 mg once daily, the dose of Karvea can be increased to 300 mg, or other antihypertensive agents can be added (see sections 4.3, 4.4, 4.5 and 5.1). In particular, the addition of a diuretic such as hydrochlorothiazide has been shown to have an additive effect with Karvea (see section 4.5).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">In hypertensive type 2 diabetic patients, therapy should be initiated at 150 mg irbesartan once daily and titrated up to 300 mg once daily as the preferred maintenance dose for treatment of renal disease.</span></p><p class="EMEABodyText"><span lang="EN-GB">The demonstration of renal benefit of Karvea in hypertensive type 2 diabetic patients is based on studies where irbesartan was used in addition to other antihypertensive agents, as needed, to reach target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Special Populations</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText"><i><span lang="EN-GB">Renal impairment</span></i></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">No dosage adjustment is necessary in patients with impaired renal function. A lower starting dose (75 mg) should be considered for patients undergoing haemodialysis (see section 4.4).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><i><span lang="EN-GB">Hepatic impairment</span></i></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. There is no clinical experience in patients with severe hepatic impairment.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><i><span lang="EN-GB">Older people</span></i></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Although consideration should be given to initiating therapy with 75 mg in patients over 75 years of age, dosage adjustment is not usually necessary for theolder people.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><i><span lang="EN-GB">Paediatric population</span></i></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">The safety and efficacy of Karvea in children aged 0 to 18 has not been established. Currently available data are described in sections 4.8, 5.1, and 5.2 but no recommendation on a posology can be made.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Method of Administration</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">For oral use.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.3     Contraindications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.</span></p><p class="EMEABodyText"><span lang="EN-GB">Second and third trimesters of pregnancy (see sections 4.4 and 4.6).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB"> The concomitant use of Karvea with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (glomerular filtration rate (GFR) &lt;60 ml/min/1.73m<sup>2</sup>) (see sections 4.5 and 5.1).</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.4     Special warnings and precautions for use"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Intravascular volume depletion</span></u><span lang="EN-GB">: symptomatic hypotension, especially after the first dose, may occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting. Such conditions should be corrected before the administration of Karvea.</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Renovascular hypertension</span></u><span lang="EN-GB">: there is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with medicinal products that affect the renin-angiotensin-aldosterone system. While this is not documented with Karvea, a similar effect should be anticipated with angiotensin-II receptor antagonists.</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Renal impairment and kidney transplantation</span></u><span lang="EN-GB">: when Karvea is used in patients with impaired renal function, a periodic monitoring of potassium and creatinine serum levels is recommended. There is no experience regarding the administration of Karvea in patients with a recent kidney transplantation.</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Hypertensive patients with type 2 diabetes and renal disease</span></u><span lang="EN-GB">:</span><span lang="EN-GB" style="layout-grid-mode:line"> the effects of irbesartan both on renal and cardiovascular events were not uniform across all subgroups, in an analysis carried out in the study with patients with advanced renal disease. In particular, they appeared less favourable in women and non-white subjects (see section 5.1).</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Dual blockade of the renin-angiotensin-aldosterone system (RAAS):</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB">T</span></u><span lang="EN-GB">here is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).  If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Hyperkalaemia</span></u><span lang="EN-GB">: as with other medicinal products that affect the renin-angiotensin-aldosterone system, hyperkalaemia may occur during the treatment with Karvea, especially in the presence of renal impairment, overt proteinuria due to diabetic renal disease, and/or heart failure. Close monitoring of serum potassium in patients at risk is recommended (see section 4.5).</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Hypoglycaemia: </span></u><span lang="EN-GB">Karvea may induce hypoglycaemia, particularly in diabetic patients. In patients treated with insulin or antidiabetics an appropriate blood glucose monitoring should be considered; a dose adjustment of insulin or antidiabetics may be required when indicated (see section 4.5).</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Lithium</span></u><span lang="EN-GB">: the combination of lithium and Karvea is not recommended (see section 4.5).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy</span></u><span lang="EN-GB">: as with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Primary aldosteronism</span></u><span lang="EN-GB">: patients with primary aldosteronism generally will not respond to antihypertensive medicinal products acting through inhibition of the renin-angiotensin system. Therefore, the use of Karvea is not recommended.</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">General</span></u><span lang="EN-GB">: in patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with angiotensinconverting enzyme inhibitors or angiotensin-II receptor antagonists that affect this system has been associated with acute hypotension, azotaemia, oliguria, or rarely acute renal failure (see section 4.5). As with any antihypertensive agent, excessive blood pressure decrease in patients with ischaemic cardiopathy or ischaemic cardiovascular disease could result in a myocardial infarction or stroke.</span></p><p class="EMEABodyText"><span lang="EN-GB">As observed for angiotensin converting enzyme inhibitors, irbesartan and the other angiotensin antagonists are apparently less effective in lowering blood pressure in black people than in non-blacks, possibly because of higher prevalence of low-renin states in the black hypertensive population (see section 5.1).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Pregnancy:</span></u><span lang="EN-GB"> angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. </span><span lang="EN-GB">Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with </span><span lang="EN-GB">AIIRAs</span><span lang="EN-GB"> should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Paediatric population</span></u><span lang="EN-GB">: irbesartan has been studied in paediatric populations aged 6 to 16 years old but the current data are insufficient to support an extension of the use in children until further data become available (see sections 4.8, 5.1 and 5.2).</span></p><p class="EMEABodyText"></p><p class="MsoNormal"><u><span lang="EN-GB">Excipients</span></u><span lang="FR">:</span></p><p class="EMEABodyText"><a name="_Hlk37089325"><span lang="FR">Karvea 75 mg tablet contains lactose. </span></a><span lang="EN-GB">Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="FR">Karvea 75 mg tablet contains sodium. </span><span lang="EN-GB">This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.5     Interaction with other medicinal products and other forms of interaction"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><u><span lang="EN-GB">Diuretics and other antihypertensive agents</span></u><span lang="EN-GB">: other antihypertensive agents may increase the hypotensive effects of irbesartan; however Karvea has been safely administered with other antihypertensive agents, such as beta-blockers, long-acting calcium channel blockers, and thiazide diuretics. Prior treatment with high dose diuretics may result in volume depletion and a risk of hypotension when initiating therapy with Karvea (see section 4.4).</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Aliskiren-containing products or ACE-inhibitors</span></u><span lang="EN-GB">: clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Potassium supplements and potassium-sparing diuretics</span></u><span lang="EN-GB">:based on experience with the use of other medicinal products that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium and is, therefore, not recommended (see section 4.4).</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Lithium</span></u><span lang="EN-GB">:reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors. Similar effects have been very rarely reported with irbesartan so far. Therefore, this combination is not recommended (see section 4.4). If the combination proves necessary, careful monitoring of serum lithium levels is recommended.</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Non-steroidal anti-inflammatory drugs</span></u><span lang="EN-GB">: w<span style="color:black">hen angiotensin II antagonists are administered simultaneously with non-steroidal anti-inflammatory drugs (i.e. selective COX-2 inhibitors, acetylsalicylic acid (&gt; 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.</span></span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">As with ACE inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function. The combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Repaglinide:</span></u><span lang="EN-GB" style="color:black"> irbesartan has the potential to inhibit OATP1B1. In a clinical study, it was reported that irbesartan increased the C<sub>max</sub> and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3‑fold, respectively, when administered 1 hour before repaglinide. In another study, no relevant pharmacokinetic interaction was reported, when the two drugs were co-administered. Therefore, dose adjustment of antidiabetic treatment such as repaglinide may be required (see section 4.4).</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Additional information on irbesartan interactions</span></u><span lang="EN-GB">: <span style="color:black">in clinical studies, the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic interactions were observed when irbesartan was coadministered with warfarin, a medicinal product metabolised by CYP2C9. The effects of CYP2C9 inducers such as rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The pharmacokinetic of digoxin was not altered by coadministration of irbesartan.</span></span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.6     Fertility, pregnancy and lactation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Pregnancy</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks may exist for this class of drugs. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Exposure to AIIRA therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).</span></p><p class="EMEABodyText"><span lang="EN-GB">Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3 and 4.4).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Breast-feeding</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText"><span lang="EN-GB">Because no information is available regarding the use of Karvea during breast-feeding, Karvea is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</span></p><p class="EMEABodyText"> </p><p class="EMEABodyText">It is unknown whether irbesartan or its metabolites are excreted in human milk. </p><p class="EMEABodyText"> </p><p class="EMEABodyText">Available pharmacodynamic/toxicological data in rats have shown excretion of irbesartan or its metabolites in milk (for details see 5.3).</p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Fertility</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Irbesartan had no effect upon fertility of treated rats and their offspring up to the dose levels inducing the first signs of parental toxicity (see section 5.3).</span> </p><p class="EMEABodyText"> </p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.7     Effects on ability to drive and use machines"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <div style="border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt"> <p class="EMEABodyText" style="border:none;padding:0in"><span lang="EN-GB">The use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4). The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 and 4.4).</span></p> </div><p class="EMEAHeading2"></p><p class="EMEABodyText"><span lang="EN-GB">Based on its pharmacodynamic properties, irbesartan is unlikely to affect the ability to drive and use machine. When driving vehicles or operating machines, it should be taken into account that dizziness or weariness may occur during treatment.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.8     Undesirable effects"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">In placebo-controlled trials in patients with hypertension, the overall incidence of adverse events did not differ between the irbesartan (56.2%) and the placebo groups (56.5%). Discontinuation due to any clinical or laboratory adverse event was less frequent for irbesartan-treated patients (3.3%) than for placebo-treated patients (4.5%). The incidence of adverse events was not related to dose (in the recommended dose range), gender, age, race, or duration of treatment.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">In diabetic hypertensive patients with microalbuminuria and normal renal function, orthostatic dizziness and orthostatic hypotension were reported in 0.5% of the patients (i.e., uncommon) but in excess of placebo.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">The following table presents the adverse drug reactions that were reported in placebo-controlled trials in which 1,965 hypertensive patients received irbesartan. Terms marked with a star (*) refer to the adverse reactions that were additionally reported in &gt; 2% of diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria and in excess of placebo.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">The frequency of adverse reactions listed below is defined using the following convention:</span></p><p class="EMEABodyText"><span lang="EN-GB">very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to &lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Adverse reactions additionally reported from post–marketing experience are also listed. These adverse reactions are derived from spontaneous reports.</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Blood and lymphatic system disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       anaemia, thrombocytopenia</span></p><p class="EMEABodyText" style="page-break-after:avoid"><i><u><span lang="EN-GB"></span></u></i></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Immune system disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       hypersensitivity reactions such as angioedema, rash, urticaria, anaphylactic reaction, anaphylactic shock</span></p><p class="EMEABodyText" style="page-break-after:avoid"><i><u><span lang="EN-GB"></span></u></i></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Metabolism and nutrition disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       hyperkalaemia, hypoglycaemia</span></p><p class="EMEABodyText"><i><u><span lang="EN-GB"></span></u></i></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Nervous system disorders</span></u></p><p class="EMEABodyText"><span lang="EN-GB">Common:         dizziness, orthostatic dizziness*</span></p><p class="EMEABodyText"><span lang="EN-GB">Not known:       vertigo, headache</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Ear and labyrinth disorder</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       tinnitus</span></p><p class="EMEABodyText" style="page-break-after:avoid"><i><u><span lang="EN-GB"></span></u></i></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Cardiac disorders</span></u></p><p class="EMEABodyText"><span lang="EN-GB">Uncommon:      tachycardia</span></p><p class="EMEABodyText" style="page-break-after:avoid"><i><u><span lang="EN-GB"></span></u></i></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Vascular disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Common:         orthostatic hypotension*</span></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Uncommon:      flushing</span></p><p class="EMEABodyText" style="page-break-after:avoid"><i><u><span lang="EN-GB"></span></u></i></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Respiratory, thoracic and mediastinal disorders</span></u></p><p class="EMEABodyText"><span lang="EN-GB">Uncommon:      cough</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Gastrointestinal disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Common:         nausea/vomiting</span></p><p class="EMEABodyText"><span lang="EN-GB">Uncommon:      diarrhoea, dyspepsia/heartburn</span></p><p class="EMEABodyText"><span lang="EN-GB">Not known:       dysgeusia</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Hepatobiliary disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Uncommon:      jaundice</span></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       hepatitis, abnormal liver function</span></p><p class="EMEABodyText" style="page-break-after:avoid"><i><u><span lang="EN-GB"></span></u></i></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Skin and subcutaneous tissue disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       leukocytoclastic vasculitis</span></p><p class="EMEABodyText" style="page-break-after:avoid"><i><u><span lang="EN-GB"></span></u></i></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Musculoskeletal and connective tissue disorders</span></u></p><p class="EMEABodyText"><span lang="EN-GB">Common:         musculoskeletal pain*</span></p><p class="EMEABodyText"><span lang="EN-GB">Not known:       arthralgia, myalgia (in some cases associated with increased plasma creatine kinase              levels), muscle cramps</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Renal and urinary disorders</span></u></p><p class="EMEABodyText" style="margin-left:1.0in;text-indent:-1.0in;page-break-after: avoid"><span lang="EN-GB">Not known:        impaired renal function including cases of renal failure in patients at risk (see section 4.4)</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Reproductive system and breast disorders</span></u></p><p class="EMEABodyText" style="text-align:justify"><span lang="EN-GB">Uncommon:      sexual dysfunction</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">General disorders and administration site conditions</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Common:         fatigue</span></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Uncommon:      chest pain</span></p><p class="EMEABodyText" style="page-break-after:avoid"><i><u><span lang="EN-GB"></span></u></i></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Investigations</span></u></p><p class="EMEABodyText" style="margin-left:1.0in;text-indent:-1.0in"><span lang="EN-GB">Very common:  Hyperkalaemia* occurred more often in diabetic patients treated with irbesartan than with placebo. In diabetic hypertensive patients with microalbuminuria and normal renal function, hyperkalaemia (≥ 5.5 mEq/L) occurred in 29.4% of the patients in the irbesartan 300 mg group and 22% of the patients in the placebo group. In diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria, hyperkalaemia (≥ 5.5 mEq/L) occurred in 46.3% of the patients in the irbesartan group and 26.3% of the patients in the placebo group.</span></p><p class="EMEABodyText" style="margin-left:1.0in;text-indent:-1.0in"><span lang="EN-GB">Common:         significant increases in plasma creatine kinase were commonly observed (1.7%) in irbesartan treated subjects. None of these increases were associated with identifiable clinical musculoskeletal events.<br/> In 1.7% of hypertensive patients with advanced diabetic renal disease treated with irbesartan, a decrease in haemoglobin*, which was not clinically significant, has been observed.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="EMEABodyText"><span lang="EN-GB">In a randomised trial of 318 hypertensive children and adolescents aged 6 to 16 years, the following adverse reactions occurred in the 3-week double-blind phase: headache (7.9%), hypotension (2.2%), dizziness (1.9%), cough (0.9%). In the 26-week open-label period of this trial the most frequent laboratory abnormalities observed were creatinine increases (6.5%) and elevated CK values in 2% of child recipients.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Reporting of suspected adverse reactions </span></u></p><p class="EMEABodyText"><span lang="EN-GB">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via <span style="background:silver">the national reporting system listed in Appendix V.</span> </span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.9     Overdose"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><span lang="EN-GB">Experience in adults exposed to doses of up to 900 mg/day for 8 weeks revealed no toxicity. The most likely manifestations of overdose are expected to be hypotension and tachycardia; bradycardia might also occur from overdose. No specific information is available on the treatment of overdose with Karvea. The patient should be closely monitored, and the treatment should be symptomatic and supportive. Suggested measures include induction of emesis and/or gastric lavage. Activated charcoal may be useful in the treatment of overdose. Irbesartan is not removed by haemodialysis.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="5.       PHARMACOLOGICAL PROPERTIES"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="5.1     Pharmacodynamic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Pharmacotherapeutic group: Angiotensin-II antagonists, plain.</span></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">ATC code: C09C A04.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Mechanism of action</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Irbesartan is a potent, orally active, selective angiotensin-II receptor (type AT<sub>1</sub>) antagonist. It is expected to block all actions of angiotensin-II mediated by the AT<sub>1</sub> receptor, regardless of the source or route of synthesis of angiotensin-II. The selective antagonism of the angiotensin-II (AT<sub>1</sub>) receptors results in increases in plasma renin levels and angiotensin-II levels, and a decrease in plasma aldosterone concentration. Serum potassium levels are not significantly affected by irbesartan alone at the recommended doses. Irbesartan does not inhibit ACE (kininase-II), an enzyme which generates angiotensin-II and also degrades bradykinin into inactive metabolites. Irbesartan does not require metabolic activation for its activity.</span></p><p class="EMEABodyText"></p><p class="EMEAHeading2"><u><span lang="EN-GB" style="font-weight:normal">Clinical efficacy</span></u></p><p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><i><span lang="EN-GB">Hypertension</span></i></p><p class="EMEABodyText"><span lang="EN-GB">Irbesartan lowers blood pressure with minimal change in heart rate. The decrease in blood pressure is dose-related for once a day doses with a tendency towards plateau at doses above 300 mg. Doses of 150-300 mg once daily lower supine or seated blood pressures at trough (i.e. 24 hours after dosing) by an average of 8-13/5-8 mm Hg (systolic/diastolic) greater than those associated with placebo.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Peak reduction of blood pressure is achieved within 3-6 hours after administration and the blood pressure lowering effect is maintained for at least 24 hours. At 24 hours the reduction of blood pressure was 60-70% of the corresponding peak diastolic and systolic responses at the recommended doses. Once daily dosing with 150 mg produced trough and mean 24 hour responses similar to twice daily dosing on the same total dose.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">The blood pressure lowering effect of Karvea is evident within 1-2 weeks, with the maximal effect occurring by 4-6 weeks after start of therapy. The antihypertensive effects are maintained during long term therapy. After withdrawal of therapy, blood pressure gradually returns toward baseline. Rebound hypertension has not been observed.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">The blood pressure lowering effects of irbesartan and thiazide-type diuretics are additive. In patients not adequately controlled by irbesartan alone, the addition of a low dose of hydrochlorothiazide (12.5 mg) to irbesartan once daily results in a further placebo-adjusted blood pressure reduction at trough of 7-10/3-6 mm Hg (systolic/diastolic).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">The efficacy of Karvea is not influenced by age or gender. As is the case with other medicinal products that affect the renin-angiotensin system, black hypertensive patients have notably less response to irbesartan monotherapy. When irbesartan is administered concomitantly with a low dose of hydrochlorothiazide (e.g. 12.5 mg daily), the antihypertensive response in black patients approaches that of white patients.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">There is no clinically important effect on serum uric acid or urinary uric acid secretion.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Reduction of blood pressure with 0.5 mg/kg (low), 1.5 mg/kg (medium) and 4.5 mg/kg (high) target titrated doses of irbesartan was evaluated in 318 hypertensive or at risk (diabetic, family history of hypertension) children and adolescents aged 6 to 16 years over a three week period. At the end of the three weeks the mean reduction from baseline in the primary efficacy variable, trough seated systolic blood pressure (SeSBP) was 11.7 mmHg (low dose), 9.3 mmHg (medium dose), 13.2 mmHg (high dose). No significant difference was apparent between these doses. Adjusted mean change of trough seated diastolic blood pressure (SeDBP) was as follows: 3.8 mmHg (low dose), 3.2 mmHg (medium dose), 5.6 mmHg (high dose). Over a subsequent two week period where patients were re-randomized to either active medicinal product or placebo, patients on placebo had increases of 2.4 and 2.0 mmHg in SeSBP and SeDBP compared to +0.1 and -0.3 mmHg changes respectively in those on all doses of irbesartan (see section 4.2).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><i><span lang="EN-GB">Hypertension and type 2 diabetes with renal disease</span></i></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText"><span lang="EN-GB">The “Irbesartan Diabetic Nephropathy Trial (IDNT)” shows that irbesartan decreases the progression of renal disease in patients with chronic renal insufficiency and overt proteinuria. IDNT was a double blind, controlled, morbidity and mortality trial comparing Karvea, amlodipine and placebo. In 1,715 hypertensive patients with type 2 diabetes, proteinuria ≥ 900 mg/day and serum creatinine ranging from 1.0-3.0 mg/dl, the long-term effects (mean 2.6 years) of Karvea on the progression of renal disease and all-cause mortality were examined. Patients were titrated from 75 mg to a maintenance dose of 300 mg Karvea</span><span lang="EN-GB" style='font-family:"Times",serif'>, from 2.5 mg to 10 mg amlodipine, or placebo</span><span lang="EN-GB"> as tolerated. Patients in all treatment groups typically received between 2 and 4 antihypertensive agents (e.g., diuretics, beta blockers, alpha blockers) to reach a predefined blood pressure goal of ≤ 135/85 mmHg or a 10 mmHg reduction in systolic pressure if baseline was &gt; 160 mmHg. Sixty per cent (60%) of patients in the placebo group reached this target blood pressure whereas this figure was 76% and 78% in the irbesartan and amlodipine groups respectively. Irbesartan significantly reduced the relative risk in the primary combined endpoint of doubling serum creatinine, end-stage renal disease (ESRD) or all-cause mortality. Approximately 33% of patients in the irbesartan group reached the primary renal composite endpoint compared to 39% and 41% in the placebo and amlodipine groups [20% relative risk reduction versus placebo (p = 0.024) and 23% relative risk reduction compared to amlodipine (p = 0.006)]. When the individual components of the primary endpoint were analysed, no effect in all cause mortality was observed, while a positive trend in the reduction in ESRD and a significant reduction in doubling of serum creatinine were observed.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB" style="layout-grid-mode:line">Subgroups consisting of gender, race, age, duration of diabetes, baseline blood pressure, serum creatinine, and albumin excretion rate were assessed for treatment effect. In the female and black subgroups which represented 32% and 26% of the overall study population respectively, a renal benefit was not evident, </span>although the confidence intervals do not exclude it. As for the secondary endpoint of fatal and non-fatal cardiovascular events, there was no difference among the three groups in the overall population, although an increased incidence of non-fatal MI was seen for women and a decreased incidence of non-fatal MI was seen in males in the irbesartan group versus the placebo-based regimen. An increased incidence of non-fatal MI and stroke was seen in females in the irbesartan-based regimen versus the amlodipine-based regimen, while hospitalization due to heart failure was reduced in the overall population. However, no proper explanation for these findings in women has been identified.</p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">The study of the “Effects of Irbesartan on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus (IRMA 2)” shows that irbesartan 300 mg delays progression to overt proteinuria in patients with microalbuminuria. IRMA 2 was a placebo-controlled double blind morbidity study in 590 patients with type 2 diabetes, microalbuminuria (30-300 mg/day) and normal renal function (serum creatinine ≤ 1.5 mg/dl in males and &lt; 1.1 mg/dl in females). The study examined the long-term effects (2 years) of Karvea on the progression to clinical (overt) proteinuria (urinary albumin excretion rate (UAER) &gt; 300 mg/day, and an increase in UAER of at least 30% from baseline). The predefined blood pressure goal was ≤ 135/85 mmHg. Additional antihypertensive agents (excluding ACE inhibitors, angiotensin II receptor antagonists and dihydropyridine calcium blockers) were added as needed to help achieve the blood pressure goal. While similar blood pressure was achieved in all treatment groups, fewer subjects in the irbesartan 300 mg group (5.2%) than in the placebo (14.9%) or in the irbesartan 150 mg group (9.7%) reached the endpoint of overt proteinuria, demonstrating a 70% relative risk reduction versus placebo (p = 0.0004) for the higher dose. An accompanying improvement in the glomerular filtration rate (GFR) was not observed during the first three months of treatment. The slowing in the progression to clinical proteinuria was evident as early as three months and continued over the 2 year period. Regression to normoalbuminuria (&lt; 30 mg/day) was more frequent in the Karvea 300 mg group (34%) than in the placebo group (21%).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><i><span lang="EN-GB">Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</span></i></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker. ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</span></p><p class="EMEABodyText"><span lang="EN-GB">These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.</span></p><p class="EMEABodyText"><span lang="EN-GB">ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</span></p><p class="EMEABodyText"><span lang="EN-GB">ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.2     Pharmacokinetic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Absorption</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">After oral administration, irbesartan is well absorbed: studies of absolute bioavailability gave values of approximately 60-80%. Concomitant food intake does not significantly influence the bioavailability of irbesartan. </span></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Distribution</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Plasma protein binding is approximately 96%, with negligible binding to cellular blood components. The volume of distribution is 53-93 litres. </span></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Biotransformation</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Following oral or intravenous administration of <sup><span style="position:relative; top:-1.0pt">14</span></sup>C irbesartan, 80-85% of the circulating plasma radioactivity is attributable to unchanged irbesartan. Irbesartan is metabolised by the liver via glucuronide conjugation and oxidation. The major circulating metabolite is irbesartan glucuronide (approximately 6%). <i>In vitro</i> studies indicate that irbesartan is primarily oxidised by the cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Linearity / non-linearity</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg. A less than proportional increase in oral absorption at doses beyond 600 mg (twice the maximal recommended dose) was observed; the mechanism for this is unknown. Peak plasma concentrations are attained at 1.5-2 hours after oral administration. The total body and renal clearance are 157‑176 and 3-3.5 ml/min, respectively. The terminal elimination half-life of irbesartan is 11-15 hours. Steady-state plasma concentrations are attained within 3 days after initiation of a once-daily dosing regimen. Limited accumulation of irbesartan (&lt; 20%) is observed in plasma upon repeated once-daily dosing. In a study, somewhat higher plasma concentrations of irbesartan were observed in female hypertensive patients. However, there was no difference in the half-life and accumulation of irbesartan. No dosage adjustment is necessary in female patients. Irbesartan AUC and C<span class="EMEASubscript">max</span> values were also somewhat greater in oldersubjects (≥ 65 years) than those of young subjects (18-40 years). However the terminal half-life was not significantly altered. No dosage adjustment is necessary in older people.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Elimination</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Irbesartan and its metabolites are eliminated by both biliary and renal pathways. After either oral or IV administration of <sup><span style="position:relative;top:-1.0pt">14</span></sup>C irbesartan, about 20% of the radioactivity is recovered in the urine, and the remainder in the faeces. Less than 2% of the dose is excreted in the urine as unchanged irbesartan.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText"><span lang="EN-GB">The pharmacokinetics of irbesartan were evaluated in 23 hypertensive children after the administration of single and multiple daily doses of irbesartan (2 mg/kg) up to a maximum daily dose of 150 mg for four weeks. Of those 23 children, 21 were evaluable for comparison of pharmacokinetics with adults (twelve children over 12 years, nine children between 6 and 12 years). Results showed that C<span class="EMEASubscript">max</span>, AUC and clearance rates were comparable to those observed in adult patients receiving 150 mg irbesartan daily. A limited accumulation of irbesartan (18%) in plasma was observed upon repeated once daily dosing.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Renal impairment</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">In patients with renal impairment or those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan are not significantly altered. Irbesartan is not removed by haemodialysis.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Hepatic impairment</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">In patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly altered.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Studies have not been performed in patients with severe hepatic impairment.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.3Preclinical safety data"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">There was no evidence of abnormal systemic or target organ toxicity at clinically relevant doses. In non-clinical safety studies, high doses of irbesartan (≥ 250 mg/kg/day in rats and ≥ 100 mg/kg/day in macaques) caused a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit). At very high doses (≥ 500 mg/kg/day) degenerative changes in the kidney (such as interstitial nephritis, tubular distension, basophilic tubules, increased plasma concentrations of urea and creatinine) were induced by irbesartan in the rat and the macaque and are considered secondary to the hypotensive effects of the medicinal product which led to decreased renal perfusion. Furthermore, irbesartan induced hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at ≥ 90 mg/kg/day, in macaques at ≥ 10 mg/kg/day). All of these changes were considered to be caused by the pharmacological action of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia/ hypertrophy of the renal juxtaglomerular cells does not appear to have any relevance.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">There was no evidence of mutagenicity, clastogenicity or carcinogenicity.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Fertility and reproductive performance were not affected in studies of male and female rats even at oral doses of irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), including mortality at the highest dose. No significant effects on the number of corpora lutea, implants, or live foetuses were observed. Irbesartan did not affect survival, development, or reproduction of offspring. Studies in animals indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses. Irbesartan is excreted in the milk of lactating rats.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Animal studies with irbesartan showed transient toxic effects (increased renal pelvic cavitation, hydroureter or subcutaneous oedema) in rat foetuses, which were resolved after birth. In rabbits, abortion or early resorption were noted at doses causing significant maternal toxicity, including mortality. No teratogenic effects were observed in the rat or rabbit.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="6.       PHARMACEUTICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="6.1     List of excipients"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Microcrystalline cellulose</span></p><p class="EMEABodyText"><span lang="EN-GB">Croscarmellose sodium</span></p><p class="EMEABodyText"><span lang="EN-GB">Lactose monohydrate</span></p><p class="EMEABodyText"><span lang="EN-GB">Magnesium stearate</span></p><p class="EMEABodyText"><span lang="EN-GB">Colloidal hydrated silica</span></p><p class="EMEABodyText"><span lang="EN-GB">Pregelatinised maize starch</span></p><p class="EMEABodyText"><span lang="EN-GB">Poloxamer 188</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.2     Incompatibilities"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not applicable.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.3     Shelf life"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">3 years.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.4     Special precautions for storage"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Do not store above 30°C.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.5     Nature and contents of container"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><span lang="EN-GB">Cartons of 14 tablets in PVC/PVDC/Aluminium blisters.</span></p><p class="EMEABodyText"><span lang="EN-GB">Cartons of 28 tablets in PVC/PVDC/Aluminium blisters.</span></p><p class="EMEABodyText"><span lang="EN-GB">Cartons of 56 tablets in PVC/PVDC/Aluminium blisters.</span></p><p class="EMEABodyText"><span lang="EN-GB">Cartons of 98 tablets in PVC/PVDC/Aluminium blisters.</span></p><p class="EMEABodyText"><span lang="EN-GB">Cartons of 56 x 1 tablet in PVC/PVDC/Aluminium perforated unit dose blisters.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Not all pack sizes may be marketed.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.6     Special precautions for disposal"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="7.       MARKETING AUTHORISATION HOLDER"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEAAddress"><span lang="FR">sanofi-aventis groupe<br/> 54, rue La Boétie<br/> F-75008 Paris - France</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="8.       MARKETING AUTHORISATION NUMBERS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEABodyText" style="text-align:justify"><span lang="NO-BOK">EU/1/97/049/001-003<br/> EU/1/97/049/010<br/> EU/1/97/049/013</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="9.       DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEABodyText"><span lang="EN-GB">Date of first authorisation: 27 August 1997<br/> Date of latest renewal: 27 August 2007</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="10.     DATE OF REVISION OF THE TEXT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu</span></p><p class="MsoNormal"></p><b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; text-transform:uppercase'><br clear="all" style="page-break-before:always"/> </span></b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; text-transform:uppercase'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
	
		
		
    	    
				
			    
						
		               
<section>
			<title value="1.       NAME OF THE MEDICINAL PRODUCT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEABodyText"><span lang="EN-GB">Karvea 150 mg tablets.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="2.       QUALITATIVE AND QUANTITATIVE COMPOSITION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEABodyText"><span lang="EN-GB">Each tablet contains 150 mg of irbesartan.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Excipient with known effect</span></u><span lang="EN-GB">: 30.75 mg of lactose monohydrate per tablet.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">For the full list of excipients, see section 6.1.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="3.       PHARMACEUTICAL FORM"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Tablet.</span></p><p class="EMEABodyText"><span lang="EN-GB">White to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2772 engraved on the other side.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="4.       CLINICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="4.1     Therapeutic indications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Karvea is indicated in adults for the treatment of essential hypertension.</span></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText"><span lang="EN-GB">It is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen (see sections 4.3, 4.4, 4.5 and 5.1).</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.2     Posology and method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Posology</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">The usual recommended initial and maintenance dose is 150 mg once daily, with or without food. Karvea at a dose of 150 mg once daily generally provides a better 24 hour blood pressure control than 75 mg. However, initiation of therapy with 75 mg could be considered, particularly in haemodialysed patients and in the elderly over 75 years.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">In patients insufficiently controlled with 150 mg once daily, the dose of Karvea can be increased to 300 mg, or other antihypertensive agents can be added (see sections 4.3, 4.4, 4.5 and 5.1). In particular, the addition of a diuretic such as hydrochlorothiazide has been shown to have an additive effect with Karvea (see section 4.5).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">In hypertensive type 2 diabetic patients, therapy should be initiated at 150 mg irbesartan once daily and titrated up to 300 mg once daily as the preferred maintenance dose for treatment of renal disease.</span></p><p class="EMEABodyText"><span lang="EN-GB">The demonstration of renal benefit of Karvea in hypertensive type 2 diabetic patients is based on studies where irbesartan was used in addition to other antihypertensive agents, as needed, to reach target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Special Populations</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText"><i><span lang="EN-GB">Renal impairment</span></i></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">No dosage adjustment is necessary in patients with impaired renal function. A lower starting dose (75 mg) should be considered for patients undergoing haemodialysis (see section 4.4).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><i><span lang="EN-GB">Hepatic impairment</span></i></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. There is no clinical experience in patients with severe hepatic impairment.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><i><span lang="EN-GB">Older people</span></i></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Although consideration should be given to initiating therapy with 75 mg in patients over 75 years of age, dosage adjustment is not usually necessary for older people.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><i><span lang="EN-GB">Paediatric population</span></i></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">The safety and efficacy of Karvea in children aged 0 to 18 has not been established. Currently available data are described in sections 4.8, 5.1, and 5.2 but no recommendation on a posology can be made.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Method of Administration</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">For oral use.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.3     Contraindications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.</span></p><p class="EMEABodyText"><span lang="EN-GB">Second and third trimesters of pregnancy (see sections 4.4 and 4.6).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB"> The concomitant use of Karvea with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (glomerular filtration rate (GFR) &lt;60 ml/min/1.73m<sup>2</sup>) (see sections 4.5 and 5.1).</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.4     Special warnings and precautions for use"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Intravascular volume depletion</span></u><span lang="EN-GB">: symptomatic hypotension, especially after the first dose, may occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting. Such conditions should be corrected before the administration of Karvea.</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Renovascular hypertension</span></u><span lang="EN-GB">: there is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with medicinal products that affect the renin-angiotensin-aldosterone system. While this is not documented with Karvea, a similar effect should be anticipated with angiotensin-II receptor antagonists.</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Renal impairment and kidney transplantation</span></u><span lang="EN-GB">: when Karvea is used in patients with impaired renal function, a periodic monitoring of potassium and creatinine serum levels is recommended. There is no experience regarding the administration of Karvea in patients with a recent kidney transplantation.</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Hypertensive patients with type 2 diabetes and renal disease</span></u><span lang="EN-GB">:</span><span lang="EN-GB" style="layout-grid-mode:line"> the effects of irbesartan both on renal and cardiovascular events were not uniform across all subgroups, in an analysis carried out in the study with patients with advanced renal disease. In particular, they appeared less favourable in women and non-white subjects (see section 5.1).</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Dual blockade of the renin-angiotensin-aldosterone system (RAAS</span></u><span lang="EN-GB">): <u>t</u>here is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).  If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Hyperkalaemia</span></u><span lang="EN-GB">: as with other medicinal products that affect the renin-angiotensin-aldosterone system, hyperkalaemia may occur during the treatment with Karvea, especially in the presence of renal impairment, overt proteinuria due to diabetic renal disease, and/or heart failure. Close monitoring of serum potassium in patients at risk is recommended (see section 4.5).</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Hypoglycaemia: </span></u><span lang="EN-GB">Karvea may induce hypoglycaemia, particularly in diabetic patients. In patients treated with insulin or antidiabetics an appropriate blood glucose monitoring should be considered; a dose adjustment of insulin or antidiabetics may be required when indicated (see section 4.5).</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Lithium</span></u><span lang="EN-GB">: the combination of lithium and Karvea is not recommended (see section 4.5).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy</span></u><span lang="EN-GB">: as with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Primary aldosteronism</span></u><span lang="EN-GB">: patients with primary aldosteronism generally will not respond to antihypertensive medicinal products acting through inhibition of the renin-angiotensin system. Therefore, the use of Karvea is not recommended.</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">General</span></u><span lang="EN-GB">: in patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with angiotensinconverting enzyme inhibitors or angiotensin-II receptor antagonists that affect this system has been associated with acute hypotension, azotaemia, oliguria, or rarely acute renal failure (see section 4.5). As with any antihypertensive agent, excessive blood pressure decrease in patients with ischaemic cardiopathy or ischaemic cardiovascular disease could result in a myocardial infarction or stroke.</span></p><p class="EMEABodyText"><span lang="EN-GB">As observed for angiotensin converting enzyme inhibitors, irbesartan and the other angiotensin antagonists are apparently less effective in lowering blood pressure in black people than in non-blacks, possibly because of higher prevalence of low-renin states in the black hypertensive population (see section 5.1).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Pregnancy:</span></u><span lang="EN-GB"> angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. </span><span lang="EN-GB">Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with </span><span lang="EN-GB">AIIRAs</span><span lang="EN-GB"> should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</span></p><p class="EMEABodyText"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Paediatric population</span></u><span lang="EN-GB">: irbesartan has been studied in paediatric populations aged 6 to 16 years old but the current data are insufficient to support an extension of the use in children until further data become available (see sections 4.8, 5.1 and 5.2).</span></p><p class="EMEABodyText"></p><p class="MsoNormal"><u><span lang="EN-GB">Excipients</span></u><span lang="FR">:</span></p><p class="EMEABodyText"><span lang="FR">Karvea 150 mg tablet contains lactose. </span><span lang="EN-GB">Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="FR">Karvea 150 mg tablet contains sodium. </span><span lang="EN-GB">This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.5     Interaction with other medicinal products and other forms of interaction"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><u><span lang="EN-GB">Diuretics and other antihypertensive agents</span></u><span lang="EN-GB">: other antihypertensive agents may increase the hypotensive effects of irbesartan; however Karvea has been safely administered with other antihypertensive agents, such as beta-blockers, long-acting calcium channel blockers, and thiazide diuretics. Prior treatment with high dose diuretics may result in volume depletion and a risk of hypotension when initiating therapy with Karvea (see section 4.4).</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Aliskiren-containing productsand ACE-inhibitors</span></u><span lang="EN-GB">:.clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Potassium supplements and potassium-sparing diuretics</span></u><span lang="EN-GB">:based on experience with the use of other medicinal products that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium and is, therefore, not recommended (see section 4.4).</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Lithium</span></u><span lang="EN-GB">:reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors. Similar effects have been very rarely reported with irbesartan so far. Therefore, this combination is not recommended (see section 4.4). If the combination proves necessary, careful monitoring of serum lithium levels is recommended.</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Non-steroidal anti-inflammatory drugs</span></u><span lang="EN-GB">: w<span style="color:black">hen angiotensin II antagonists are administered simultaneously with non-steroidal anti-inflammatory drugs (i.e. selective COX-2 inhibitors, acetylsalicylic acid (&gt; 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.</span></span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">As with ACE inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function. The combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Repaglinide:</span></u><span lang="EN-GB" style="color:black"> irbesartan has the potential to inhibit OATP1B1. In a clinical study, it was reported that irbesartan increased the C<sub>max</sub> and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3‑fold, respectively, when administered 1 hour before repaglinide. In another study, no relevant pharmacokinetic interaction was reported, when the two drugs were co-administered. Therefore, dose adjustment of antidiabetic treatment such as repaglinide may be required (see section 4.4).</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Additional information on irbesartan interactions</span></u><span lang="EN-GB">: <span style="color:black">in clinical studies, the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic interactions were observed when irbesartan was coadministered with warfarin, a medicinal product metabolised by CYP2C9. The effects of CYP2C9 inducers such as rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The pharmacokinetic of digoxin was not altered by coadministration of irbesartan.</span></span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.6     Fertility, pregnancy and lactation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Pregnancy</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks may exist for this class of drugs. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Exposure to AIIRA therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.</span></p><p class="EMEABodyText"><span lang="EN-GB">Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3 and 4.4).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Breast-feeding</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText"><span lang="EN-GB">Because no information is available regarding the use of Karvea during breast-feeding, Karvea is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</span></p><p class="EMEABodyText"> </p><p class="EMEABodyText">It is unknown whether irbesartan or its metabolites are excreted in human milk. </p><p class="EMEABodyText">Available pharmacodynamic/toxicological data in rats have shown excretion of irbesartan or its metabolites in milk (for details see 5.3).</p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Fertility</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Irbesartan had no effect upon fertility of treated rats and their offspring up to the dose levels inducing the first signs of parental toxicity (see section 5.3).</span> </p><p class="EMEABodyText"> </p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.7     Effects on ability to drive and use machines"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <div style="border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt"> <p class="EMEABodyText" style="border:none;padding:0in"><span lang="EN-GB">The use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4). The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 and 4.4).</span></p> </div><p class="EMEAHeading2"></p><p class="EMEABodyText"><span lang="EN-GB">Based on its pharmacodynamic properties, irbesartan is unlikely to affect the ability to drive and use machnes. When driving vehicles or operating machines, it should be taken into account that dizziness or weariness may occur during treatment.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.8     Undesirable effects"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">In placebo-controlled trials in patients with hypertension, the overall incidence of adverse events did not differ between the irbesartan (56.2%) and the placebo groups (56.5%). Discontinuation due to any clinical or laboratory adverse event was less frequent for irbesartan-treated patients (3.3%) than for placebo-treated patients (4.5%). The incidence of adverse events was not related to dose (in the recommended dose range), gender, age, race, or duration of treatment.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">In diabetic hypertensive patients with microalbuminuria and normal renal function, orthostatic dizziness and orthostatic hypotension were reported in 0.5% of the patients (i.e., uncommon) but in excess of placebo.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">The following table presents the adverse drug reactions that were reported in placebo-controlled trials in which 1,965 hypertensive patients received irbesartan. Terms marked with a star (*) refer to the adverse reactions that were additionally reported in &gt; 2% of diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria and in excess of placebo.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">The frequency of adverse reactions listed below is defined using the following convention:</span></p><p class="EMEABodyText"><span lang="EN-GB">very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to &lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Adverse reactions additionally reported from post–marketing experience are also listed. These adverse reactions are derived from spontaneous reports.</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Blood and lymphatic system disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       anaemia, thrombocytopenia </span></p><p class="EMEABodyText" style="page-break-after:avoid"><i><u><span lang="EN-GB"></span></u></i></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Immune system disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       hypersensitivity reactions such as angioedema, rash, urticaria, anaphylactic reaction, anaphylactic shock</span></p><p class="EMEABodyText" style="page-break-after:avoid"><i><u><span lang="EN-GB"></span></u></i></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Metabolism and nutrition disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       hyperkalaemia, hypoglycaemia</span></p><p class="EMEABodyText"><i><u><span lang="EN-GB"></span></u></i></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Nervous system disorders</span></u></p><p class="EMEABodyText"><span lang="EN-GB">Common:         dizziness, orthostatic dizziness*</span></p><p class="EMEABodyText"><span lang="EN-GB">Not known:       vertigo, headache</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Ear and labyrinth disorder</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       tinnitus</span></p><p class="EMEABodyText" style="page-break-after:avoid"><i><u><span lang="EN-GB"></span></u></i></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Cardiac disorders</span></u></p><p class="EMEABodyText"><span lang="EN-GB">Uncommon:      tachycardia</span></p><p class="EMEABodyText" style="page-break-after:avoid"><i><u><span lang="EN-GB"></span></u></i></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Vascular disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Common:         orthostatic hypotension*</span></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Uncommon:      flushing</span></p><p class="EMEABodyText" style="page-break-after:avoid"><i><u><span lang="EN-GB"></span></u></i></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Respiratory, thoracic and mediastinal disorders</span></u></p><p class="EMEABodyText"><span lang="EN-GB">Uncommon:      cough</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Gastrointestinal disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Common:         nausea/vomiting</span></p><p class="EMEABodyText"><span lang="EN-GB">Uncommon:      diarrhoea, dyspepsia/heartburn</span></p><p class="EMEABodyText"><span lang="EN-GB">Not known:       dysgeusia</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Hepatobiliary disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Uncommon:      jaundice</span></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       hepatitis, abnormal liver function</span></p><p class="EMEABodyText" style="page-break-after:avoid"><i><u><span lang="EN-GB"></span></u></i></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Skin and subcutaneous tissue disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       leukocytoclastic vasculitis</span></p><p class="EMEABodyText" style="page-break-after:avoid"><i><u><span lang="EN-GB"></span></u></i></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Musculoskeletal and connective tissue disorders</span></u></p><p class="EMEABodyText"><span lang="EN-GB">Common:         musculoskeletal pain*</span></p><p class="EMEABodyText" style="margin-left:1.0in;text-indent:-1.0in"><span lang="EN-GB">Not known:       arthralgia, myalgia (in some cases associated with increased plasma creatine kinase levels), muscle cramps</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Renal and urinary disorders</span></u></p><p class="EMEABodyText" style="margin-left:1.0in;text-indent:-1.0in;page-break-after: avoid"><span lang="EN-GB">Not known:        impaired renal function including cases of renal failure in patients at risk (see section 4.4)</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Reproductive system and breast disorders</span></u></p><p class="EMEABodyText" style="text-align:justify"><span lang="EN-GB">Uncommon:      sexual dysfunction</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">General disorders and administration site conditions</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Common:         fatigue</span></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Uncommon:      chest pain</span></p><p class="EMEABodyText" style="page-break-after:avoid"><i><u><span lang="EN-GB"></span></u></i></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Investigations</span></u></p><p class="EMEABodyText" style="margin-left:1.0in;text-indent:-1.0in"><span lang="EN-GB">Very common:  Hyperkalaemia* occurred more often in diabetic patients treated with irbesartan than with placebo. In diabetic hypertensive patients with microalbuminuria and normal renal function, hyperkalaemia (≥ 5.5 mEq/L) occurred in 29.4% of the patients in the irbesartan 300 mg group and 22% of the patients in the placebo group. In diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria, hyperkalaemia (≥ 5.5 mEq/L) occurred in 46.3% of the patients in the irbesartan group and 26.3% of the patients in the placebo group.</span></p><p class="EMEABodyText" style="margin-left:1.0in;text-indent:-1.0in"><span lang="EN-GB">Common:         significant increases in plasma creatine kinase were commonly observed (1.7%) in irbesartan treated subjects. None of these increases were associated with identifiable clinical musculoskeletal events.<br/> In 1.7% of hypertensive patients with advanced diabetic renal disease treated with irbesartan, a decrease in haemoglobin*, which was not clinically significant, has been observed.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="EMEABodyText"><span lang="EN-GB">In a randomised trial of 318 hypertensive children and adolescents aged 6 to 16 years, the following adverse reactions occurred in the 3-week double-blind phase: headache (7.9%), hypotension (2.2%), dizziness (1.9%), cough (0.9%). In the 26-week open-label period of this trial the most frequent laboratory abnormalities observed were creatinine increases (6.5%) and elevated CK values in 2% of child recipients.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Reporting of suspected adverse reactions </span></u></p><p class="EMEABodyText"><span lang="EN-GB">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via <span style="background:silver">the national reporting system listed in Appendix V.</span> </span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.9     Overdose"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><span lang="EN-GB">Experience in adults exposed to doses of up to 900 mg/day for 8 weeks revealed no toxicity. The most likely manifestations of overdose are expected to be hypotension and tachycardia; bradycardia might also occur from overdose. No specific information is available on the treatment of overdose with Karvea. The patient should be closely monitored, and the treatment should be symptomatic and supportive. Suggested measures include induction of emesis and/or gastric lavage. Activated charcoal may be useful in the treatment of overdose. Irbesartan is not removed by haemodialysis.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="5.       PHARMACOLOGICAL PROPERTIES"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="5.1     Pharmacodynamic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Pharmacotherapeutic group: Angiotensin-II antagonists, plain.</span></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">ATC code: C09C A04.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Mechanism of action</span></u></p><p class="EMEABodyText"><span lang="EN-GB">Irbesartan is a potent, orally active, selective angiotensin-II receptor (type AT<sub>1</sub>) antagonist. It is expected to block all actions of angiotensin-II mediated by the AT<sub>1</sub> receptor, regardless of the source or route of synthesis of angiotensin-II. The selective antagonism of the angiotensin-II (AT<sub>1</sub>) receptors results in increases in plasma renin levels and angiotensin-II levels, and a decrease in plasma aldosterone concentration. Serum potassium levels are not significantly affected by irbesartan alone at the recommended doses. Irbesartan does not inhibit ACE (kininase-II), an enzyme which generates angiotensin-II and also degrades bradykinin into inactive metabolites. Irbesartan does not require metabolic activation for its activity.</span></p><p class="EMEABodyText"></p><p class="EMEAHeading2"><u><span lang="EN-GB" style="font-weight:normal">Clinical efficacy</span></u></p><p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><i><span lang="EN-GB">Hypertension</span></i></p><p class="EMEABodyText"><span lang="EN-GB">Irbesartan lowers blood pressure with minimal change in heart rate. The decrease in blood pressure is dose-related for once a day doses with a tendency towards plateau at doses above 300 mg. Doses of 150-300 mg once daily lower supine or seated blood pressures at trough (i.e. 24 hours after dosing) by an average of 8-13/5-8 mm Hg (systolic/diastolic) greater than those associated with placebo.</span></p><p class="EMEABodyText"><span lang="EN-GB">Peak reduction of blood pressure is achieved within 3-6 hours after administration and the blood pressure lowering effect is maintained for at least 24 hours. At 24 hours the reduction of blood pressure was 60-70% of the corresponding peak diastolic and systolic responses at the recommended doses. Once daily dosing with 150 mg produced trough and mean 24 hour responses similar to twice daily dosing on the same total dose.</span></p><p class="EMEABodyText"><span lang="EN-GB">The blood pressure lowering effect of Karvea is evident within 1-2 weeks, with the maximal effect occurring by 4-6 weeks after start of therapy. The antihypertensive effects are maintained during long term therapy. After withdrawal of therapy, blood pressure gradually returns toward baseline. Rebound hypertension has not been observed.</span></p><p class="EMEABodyText"><span lang="EN-GB">The blood pressure lowering effects of irbesartan and thiazide-type diuretics are additive. In patients not adequately controlled by irbesartan alone, the addition of a low dose of hydrochlorothiazide (12.5 mg) to irbesartan once daily results in a further placebo-adjusted blood pressure reduction at trough of 7-10/3-6 mm Hg (systolic/diastolic).</span></p><p class="EMEABodyText"><span lang="EN-GB">The efficacy of Karvea is not influenced by age or gender. As is the case with other medicinal products that affect the renin-angiotensin system, black hypertensive patients have notably less response to irbesartan monotherapy. When irbesartan is administered concomitantly with a low dose of hydrochlorothiazide (e.g. 12.5 mg daily), the antihypertensive response in black patients approaches that of white patients.</span></p><p class="EMEABodyText"><span lang="EN-GB">There is no clinically important effect on serum uric acid or urinary uric acid secretion.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Reduction of blood pressure with 0.5 mg/kg (low), 1.5 mg/kg (medium) and 4.5 mg/kg (high) target titrated doses of irbesartan was evaluated in 318 hypertensive or at risk (diabetic, family history of hypertension) children and adolescents aged 6 to 16 years over a three week period. At the end of the three weeks the mean reduction from baseline in the primary efficacy variable, trough seated systolic blood pressure (SeSBP) was 11.7 mmHg (low dose), 9.3 mmHg (medium dose), 13.2 mmHg (high dose). No significant difference was apparent between these doses. Adjusted mean change of trough seated diastolic blood pressure (SeDBP) was as follows: 3.8 mmHg (low dose), 3.2 mmHg (medium dose), 5.6 mmHg (high dose). Over a subsequent two week period where patients were re-randomized to either active medicinal product or placebo, patients on placebo had increases of 2.4 and 2.0 mmHg in SeSBP and SeDBP compared to +0.1 and -0.3 mmHg changes respectively in those on all doses of irbesartan (see section 4.2).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><i><span lang="EN-GB">Hypertension and type 2 diabetes with renal disease</span></i></p><p class="EMEABodyText"><span lang="EN-GB">The “Irbesartan Diabetic Nephropathy Trial (IDNT)” shows that irbesartan decreases the progression of renal disease in patients with chronic renal insufficiency and overt proteinuria. IDNT was a double blind, controlled, morbidity and mortality trial comparing Karvea, amlodipine and placebo. In 1,715 hypertensive patients with type 2 diabetes, proteinuria ≥ 900 mg/day and serum creatinine ranging from 1.0-3.0 mg/dl, the long-term effects (mean 2.6 years) of Karvea on the progression of renal disease and all-cause mortality were examined. Patients were titrated from 75 mg to a maintenance dose of 300 mg Karvea</span><span lang="EN-GB" style='font-family:"Times",serif'>, from 2.5 mg to 10 mg amlodipine, or placebo</span><span lang="EN-GB"> as tolerated. Patients in all treatment groups typically received between 2 and 4 antihypertensive agents (e.g., diuretics, beta blockers, alpha blockers) to reach a predefined blood pressure goal of ≤ 135/85 mmHg or a 10 mmHg reduction in systolic pressure if baseline was &gt; 160 mmHg. Sixty per cent (60%) of patients in the placebo group reached this target blood pressure whereas this figure was 76% and 78% in the irbesartan and amlodipine groups respectively. Irbesartan significantly reduced the relative risk in the primary combined endpoint of doubling serum creatinine, end-stage renal disease (ESRD) or all-cause mortality. Approximately 33% of patients in the irbesartan group reached the primary renal composite endpoint compared to 39% and 41% in the placebo and amlodipine groups [20% relative risk reduction versus placebo (p = 0.024) and 23% relative risk reduction compared to amlodipine (p = 0.006)]. When the individual components of the primary endpoint were analysed, no effect in all cause mortality was observed, while a positive trend in the reduction in ESRD and a significant reduction in doubling of serum creatinine were observed.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB" style="layout-grid-mode:line">Subgroups consisting of gender, race, age, duration of diabetes, baseline blood pressure, serum creatinine, and albumin excretion rate were assessed for treatment effect. In the female and black subgroups which represented 32% and 26% of the overall study population respectively, a renal benefit was not evident, </span>although the confidence intervals do not exclude it. As for the secondary endpoint of fatal and non-fatal cardiovascular events, there was no difference among the three groups in the overall population, although an increased incidence of non-fatal MI was seen for women and a decreased incidence of non-fatal MI was seen in males in the irbesartan group versus the placebo-based regimen. An increased incidence of non-fatal MI and stroke was seen in females in the irbesartan-based regimen versus the amlodipine-based regimen, while hospitalization due to heart failure was reduced in the overall population. However, no proper explanation for these findings in women has been identified.</p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">The study of the “Effects of Irbesartan on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus (IRMA 2)” shows that irbesartan 300 mg delays progression to overt proteinuria in patients with microalbuminuria. IRMA 2 was a placebo-controlled double blind morbidity study in 590 patients with type 2 diabetes, microalbuminuria (30-300 mg/day) and normal renal function (serum creatinine ≤ 1.5 mg/dl in males and &lt; 1.1 mg/dl in females). The study examined the long-term effects (2 years) of Karvea on the progression to clinical (overt) proteinuria (urinary albumin excretion rate (UAER) &gt; 300 mg/day, and an increase in UAER of at least 30% from baseline). The predefined blood pressure goal was ≤ 135/85 mmHg. Additional antihypertensive agents (excluding ACE inhibitors, angiotensin II receptor antagonists and dihydropyridine calcium blockers) were added as needed to help achieve the blood pressure goal. While similar blood pressure was achieved in all treatment groups, fewer subjects in the irbesartan 300 mg group (5.2%) than in the placebo (14.9%) or in the irbesartan 150 mg group (9.7%) reached the endpoint of overt proteinuria, demonstrating a 70% relative risk reduction versus placebo (p = 0.0004) for the higher dose. An accompanying improvement in the glomerular filtration rate (GFR) was not observed during the first three months of treatment. The slowing in the progression to clinical proteinuria was evident as early as three months and continued over the 2 year period. Regression to normoalbuminuria (&lt; 30 mg/day) was more frequent in the Karvea 300 mg group (34%) than in the placebo group (21%).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><i><span lang="EN-GB">Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</span></i></p><p class="EMEABodyText"><span lang="EN-GB">Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker. ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</span></p><p class="EMEABodyText"><span lang="EN-GB">These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.</span></p><p class="EMEABodyText"><span lang="EN-GB">ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</span></p><p class="EMEABodyText"><span lang="EN-GB">ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.2     Pharmacokinetic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Absorption</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">After oral administration, irbesartan is well absorbed: studies of absolute bioavailability gave values of approximately 60-80%. Concomitant food intake does not significantly influence the bioavailability of irbesartan. </span></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Distribution</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Plasma protein binding is approximately 96%, with negligible binding to cellular blood components. The volume of distribution is 53-93 litres. </span></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Biotransformation</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Following oral or intravenous administration of <sup><span style="position:relative; top:-1.0pt">14</span></sup>C irbesartan, 80-85% of the circulating plasma radioactivity is attributable to unchanged irbesartan. Irbesartan is metabolised by the liver via glucuronide conjugation and oxidation. The major circulating metabolite is irbesartan glucuronide (approximately 6%). <i>In vitro</i> studies indicate that irbesartan is primarily oxidised by the cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Linearity/ non-linearity</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg. A less than proportional increase in oral absorption at doses beyond 600 mg (twice the maximal recommended dose) was observed; the mechanism for this is unknown. Peak plasma concentrations are attained at 1.5-2 hours after oral administration. The total body and renal clearance are 157-176 and 3-3.5 ml/min, respectively. The terminal elimination half-life of irbesartan is 11-15 hours. Steady-state plasma concentrations are attained within 3 days after initiation of a once-daily dosing regimen. Limited accumulation of irbesartan (&lt; 20%) is observed in plasma upon repeated once-daily dosing. In a study, somewhat higher plasma concentrations of irbesartan were observed in female hypertensive patients. However, there was no difference in the half-life and accumulation of irbesartan. No dosage adjustment is necessary in female patients. Irbesartan AUC and C<span class="EMEASubscript">max</span> values were also somewhat greater in oldersubjects (≥ 65 years) than those of young subjects (18-40 years). However the terminal half-life was not significantly altered. No dosage adjustment is necessary in older people.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Elimination</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Irbesartan and its metabolites are eliminated by both biliary and renal pathways. After either oral or IV administration of <sup><span style="position:relative;top:-1.0pt">14</span></sup>C irbesartan, about 20% of the radioactivity is recovered in the urine, and the remainder in the faeces. Less than 2% of the dose is excreted in the urine as unchanged irbesartan.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText"><span lang="EN-GB">The pharmacokinetics of irbesartan were evaluated in 23 hypertensive children after the administration of single and multiple daily doses of irbesartan (2 mg/kg) up to a maximum daily dose of 150 mg for four weeks. Of those 23 children, 21 were evaluable for comparison of pharmacokinetics with adults (twelve children over 12 years, nine children between 6 and 12 years). Results showed that C<span class="EMEASubscript">max</span>, AUC and clearance rates were comparable to those observed in adult patients receiving 150 mg irbesartan daily. A limited accumulation of irbesartan (18%) in plasma was observed upon repeated once daily dosing.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Renal impairment</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">In patients with renal impairment or those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan are not significantly altered. Irbesartan is not removed by haemodialysis.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Hepatic impairment</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">In patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly altered.</span></p><p class="EMEABodyText"><span lang="EN-GB">Studies have not been performed in patients with severe hepatic impairment.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.3Preclinical safety data"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">There was no evidence of abnormal systemic or target organ toxicity at clinically relevant doses. In non-clinical safety studies, high doses of irbesartan (≥ 250 mg/kg/day in rats and ≥ 100 mg/kg/day in macaques) caused a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit). At very high doses (≥ 500 mg/kg/day) degenerative changes in the kidney (such as interstitial nephritis, tubular distension, basophilic tubules, increased plasma concentrations of urea and creatinine) were induced by irbesartan in the rat and the macaque and are considered secondary to the hypotensive effects of the medicinal product which led to decreased renal perfusion. Furthermore, irbesartan induced hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at ≥ 90 mg/kg/day, in macaques at ≥ 10 mg/kg/day). All of these changes were considered to be caused by the pharmacological action of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia/ hypertrophy of the renal juxtaglomerular cells does not appear to have any relevance.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">There was no evidence of mutagenicity, clastogenicity or carcinogenicity.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Fertility and reproductive performance were not affected in studies of male and female rats even at oral doses of irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), including mortality at the highest dose. No significant effects on the number of corpora lutea, implants, or live foetuses were observed. Irbesartan did not affect survival, development, or reproduction of offspring. Studies in animals indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses. Irbesartan is excreted in the milk of lactating rats.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Animal studies with irbesartan showed transient toxic effects (increased renal pelvic cavitation, hydroureter or subcutaneous oedema) in rat foetuses, which were resolved after birth. In rabbits, abortion or early resorption were noted at doses causing significant maternal toxicity, including mortality. No teratogenic effects were observed in the rat or rabbit.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="6.       PHARMACEUTICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="6.1     List of excipients"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Microcrystalline cellulose</span></p><p class="EMEABodyText"><span lang="EN-GB">Croscarmellose sodium</span></p><p class="EMEABodyText"><span lang="EN-GB">Lactose monohydrate</span></p><p class="EMEABodyText"><span lang="EN-GB">Magnesium stearate</span></p><p class="EMEABodyText"><span lang="EN-GB">Colloidal hydrated silica</span></p><p class="EMEABodyText"><span lang="EN-GB">Pregelatinised maize starch</span></p><p class="EMEABodyText"><span lang="EN-GB">Poloxamer 188</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.2     Incompatibilities"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not applicable.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.3     Shelf life"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">3 years.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.4     Special precautions for storage"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Do not store above 30°C.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.5     Nature and contents of container"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><span lang="EN-GB">Cartons of 14 tablets in PVC/PVDC/Aluminium blisters.</span></p><p class="EMEABodyText"><span lang="EN-GB">Cartons of 28 tablets in PVC/PVDC/Aluminium blisters.</span></p><p class="EMEABodyText"><span lang="EN-GB">Cartons of 56 tablets in PVC/PVDC/Aluminium blisters.</span></p><p class="EMEABodyText"><span lang="EN-GB">Cartons of 98 tablets in PVC/PVDC/Aluminium blisters.</span></p><p class="EMEABodyText"><span lang="EN-GB">Cartons of 56 x 1 tablet in PVC/PVDC/Aluminium perforated unit dose blisters.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Not all pack sizes may be marketed.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.6     Special precautions for disposal"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="7.       MARKETING AUTHORISATION HOLDER"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEAAddress"><span lang="FR">sanofi-aventis groupe<br/> 54, rue La Boétie<br/> F-75008 Paris - France</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="8.       MARKETING AUTHORISATION NUMBERS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEABodyText" style="text-align:justify"><span lang="NO-BOK">EU/1/97/049/004-006<br/> EU/1/97/049/011<br/> EU/1/97/049/014</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="9.       DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEABodyText"><span lang="EN-GB">Date of first authorisation: 27 August 1997<br/> Date of latest renewal: 27 August 2007</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="10.     DATE OF REVISION OF THE TEXT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu</span></p><p class="MsoNormal"></p><b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; text-transform:uppercase'><br clear="all" style="page-break-before:always"/> </span></b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; text-transform:uppercase'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
	
		
		
    	    
				
			    
						
		               
<section>
			<title value="1.       NAME OF THE MEDICINAL PRODUCT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEABodyText"><span lang="EN-GB">Karvea 300 mg tablets.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="2.       QUALITATIVE AND QUANTITATIVE COMPOSITION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEABodyText"><span lang="EN-GB">Each tablet contains 300 mg of irbesartan.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Excipient with known effect</span></u><span lang="EN-GB">: 61.50 mg of lactose monohydrate per tablet.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">For the full list of excipients, see section 6.1.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="3.       PHARMACEUTICAL FORM"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Tablet.</span></p><p class="EMEABodyText"><span lang="EN-GB">White to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2773 engraved on the other side.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="4.       CLINICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="4.1     Therapeutic indications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Karvea is indicated in adults for the treatment of essential hypertension.</span></p><p class="EMEABodyText"><span lang="EN-GB">It is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen (see sections 4.3, 4.4, 4.5 and 5.1).</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.2     Posology and method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Posology</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">The usual recommended initial and maintenance dose is 150 mg once daily, with or without food. Karvea at a dose of 150 mg once daily generally provides a better 24 hour blood pressure control than 75 mg. However, initiation of therapy with 75 mg could be considered, particularly in haemodialysed patients and in the elderly over 75 years.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">In patients insufficiently controlled with 150 mg once daily, the dose of Karvea can be increased to 300 mg, or other antihypertensive agents can be added (see sections 4.3, 4.4, 4.5 and 5.1). In particular, the addition of a diuretic such as hydrochlorothiazide has been shown to have an additive effect with Karvea (see section 4.5).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">In hypertensive type 2 diabetic patients, therapy should be initiated at 150 mg irbesartan once daily and titrated up to 300 mg once daily as the preferred maintenance dose for treatment of renal disease.</span></p><p class="EMEABodyText"><span lang="EN-GB">The demonstration of renal benefit of Karvea in hypertensive type 2 diabetic patients is based on studies where irbesartan was used in addition to other antihypertensive agents, as needed, to reach target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Special Populations</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText"><i><span lang="EN-GB">Renal impairment</span></i></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">No dosage adjustment is necessary in patients with impaired renal function. A lower starting dose (75 mg) should be considered for patients undergoing haemodialysis (see section 4.4).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><i><span lang="EN-GB">Hepatic impairment</span></i></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. There is no clinical experience in patients with severe hepatic impairment.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><i><span lang="EN-GB">Older people</span></i></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Although consideration should be given to initiating therapy with 75 mg in patients over 75 years of age, dosage adjustment is not usually necessary for older people.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><i><span lang="EN-GB">Paediatric population</span></i></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">The safety and efficacy of Karvea in children aged 0 to 18 has not been established. Currently available data are described in sections 4.8, 5.1, and 5.2 but no recommendation on a posology can be made.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Method of Administration</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">For oral use.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.3     Contraindications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.</span></p><p class="EMEABodyText"><span lang="EN-GB">Second and third trimesters of pregnancy (see sections 4.4 and 4.6).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">The concomitant use of Karvea with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (glomerular filtration rate (GFR) &lt;60 ml/min/1.73m<sup>2</sup>) (see sections 4.5 and 5.1).</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.4     Special warnings and precautions for use"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Intravascular volume depletion</span></u><span lang="EN-GB">: symptomatic hypotension, especially after the first dose, may occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting. Such conditions should be corrected before the administration of Karvea.</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Renovascular hypertension</span></u><span lang="EN-GB">: there is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with medicinal products that affect the renin-angiotensin-aldosterone system. While this is not documented with Karvea, a similar effect should be anticipated with angiotensin-II receptor antagonists.</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Renal impairment and kidney transplantation</span></u><span lang="EN-GB">: when Karvea is used in patients with impaired renal function, a periodic monitoring of potassium and creatinine serum levels is recommended. There is no experience regarding the administration of Karvea in patients with a recent kidney transplantation.</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Hypertensive patients with type 2 diabetes and renal disease</span></u><span lang="EN-GB">:</span><span lang="EN-GB" style="layout-grid-mode:line"> the effects of irbesartan both on renal and cardiovascular events were not uniform across all subgroups, in an analysis carried out in the study with patients with advanced renal disease. In particular, they appeared less favourable in women and non-white subjects (see section 5.1).</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Dual blockade of the renin-angiotensin-aldosterone system (RAAS):</span></u><span lang="EN-GB"> there is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).  If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Hyperkalaemia</span></u><span lang="EN-GB">: as with other medicinal products that affect the renin-angiotensin-aldosterone system, hyperkalaemia may occur during the treatment with Karvea, especially in the presence of renal impairment, overt proteinuria due to diabetic renal disease, and/or heart failure. Close monitoring of serum potassium in patients at risk is recommended (see section 4.5).</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Hypoglycaemia</span></u><span lang="EN-GB">: Karvea may induce hypoglycaemia, particularly in diabetic patients. In patients treated with insulin or antidiabetics an appropriate blood glucose monitoring should be considered; a dose adjustment of insulin or antidiabetics may be required when indicated (see section 4.5).</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Lithium</span></u><span lang="EN-GB">: the combination of lithium and Karvea is not recommended (see section 4.5).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy</span></u><span lang="EN-GB">: as with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Primary aldosteronism</span></u><span lang="EN-GB">: patients with primary aldosteronism generally will not respond to antihypertensive medicinal products acting through inhibition of the renin-angiotensin system. Therefore, the use of Karvea is not recommended.</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">General</span></u><span lang="EN-GB">: in patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with angiotensinconverting enzyme inhibitors or angiotensin-II receptor antagonists that affect this system has been associated with acute hypotension, azotaemia, oliguria, or rarely acute renal failure (see section 4.5). As with any antihypertensive agent, excessive blood pressure decrease in patients with ischaemic cardiopathy or ischaemic cardiovascular disease could result in a myocardial infarction or stroke.</span></p><p class="EMEABodyText"><span lang="EN-GB">As observed for angiotensin converting enzyme inhibitors, irbesartan and the other angiotensin antagonists are apparently less effective in lowering blood pressure in black people than in non-blacks, possibly because of higher prevalence of low-renin states in the black hypertensive population (see section 5.1).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Pregnancy:</span></u><span lang="EN-GB"> angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. </span><span lang="EN-GB">Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with </span><span lang="EN-GB">AIIRAs</span><span lang="EN-GB"> should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Paediatric population</span></u><span lang="EN-GB">: irbesartan has been studied in paediatric populations aged 6 to 16 years old but the current data are insufficient to support an extension of the use in children until further data become available (see sections 4.8, 5.1 and 5.2).</span></p><p class="EMEABodyText"></p><p class="MsoNormal"><u><span lang="EN-GB">Excipients</span></u><span lang="FR">:</span></p><p class="EMEABodyText"><span lang="FR">Karvea 300 mg tablet contains lactose. </span><span lang="EN-GB">Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="FR">Karvea 300 mg tablet contains sodium. </span><span lang="EN-GB">This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.5     Interaction with other medicinal products and other forms of interaction"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><u><span lang="EN-GB">Diuretics and other antihypertensive agents</span></u><span lang="EN-GB">: other antihypertensive agents may increase the hypotensive effects of irbesartan; however Karvea has been safely administered with other antihypertensive agents, such as beta-blockers, long-acting calcium channel blockers, and thiazide diuretics. Prior treatment with high dose diuretics may result in volume depletion and a risk of hypotension when initiating therapy with Karvea (see section 4.4).</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Aliskiren-containing products or ACE-inhibitors</span></u><span lang="EN-GB">: clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Potassium supplements and potassium-sparing diuretics</span></u><span lang="EN-GB">:based on experience with the use of other medicinal products that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium and is, therefore, not recommended (see section 4.4).</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Lithium</span></u><span lang="EN-GB">:reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors. Similar effects have been very rarely reported with irbesartan so far. Therefore, this combination is not recommended (see section 4.4). If the combination proves necessary, careful monitoring of serum lithium levels is recommended.</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Non-steroidal anti-inflammatory drugs</span></u><span lang="EN-GB">: w<span style="color:black">hen angiotensin II antagonists are administered simultaneously with non-steroidal anti-inflammatory drugs (i.e. selective COX-2 inhibitors, acetylsalicylic acid (&gt; 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.</span></span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">As with ACE inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function. The combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Repaglinide:</span></u><span lang="EN-GB" style="color:black"> irbesartan has the potential to inhibit OATP1B1. In a clinical study, it was reported that irbesartan increased the C<sub>max</sub> and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3‑fold, respectively, when administered 1 hour before repaglinide. In another study, no relevant pharmacokinetic interaction was reported, when the two drugs were co-administered. Therefore, dose adjustment of antidiabetic treatment such as repaglinide may be required (see section 4.4).</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText"><u><span lang="EN-GB">Additional information on irbesartan interactions</span></u><span lang="EN-GB">: <span style="color:black">in clinical studies, the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic interactions were observed when irbesartan was coadministered with warfarin, a medicinal product metabolised by CYP2C9. The effects of CYP2C9 inducers such as rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The pharmacokinetic of digoxin was not altered by coadministration of irbesartan.</span></span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.6     Fertility, pregnancy and lactation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Pregnancy</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks may exist for this class of drugs. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Exposure to AIIRA therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).</span></p><p class="EMEABodyText"><span lang="EN-GB">Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.</span></p><p class="EMEABodyText"><span lang="EN-GB">Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3 and 4.4).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Breast-feeding</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText"><span lang="EN-GB">Because no information is available regarding the use of Karvea during breast-feeding, Karvea is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</span></p><p class="EMEABodyText"> </p><p class="EMEABodyText">It is unknown whether irbesartan or its metabolites are excreted in human milk. </p><p class="EMEABodyText">Available pharmacodynamic/toxicological data in rats have shown excretion of irbesartan or its metabolites in milk (for details see 5.3).</p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Fertility</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Irbesartan had no effect upon fertility of treated rats and their offspring up to the dose levels inducing the first signs of parental toxicity (see section 5.3).</span> </p><p class="EMEABodyText"> </p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.7     Effects on ability to drive and use machines"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <div style="border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt"> <p class="EMEABodyText" style="border:none;padding:0in"><span lang="EN-GB">The use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4). The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 and 4.4).</span></p> </div><p class="EMEAHeading2"></p><p class="EMEABodyText"><span lang="EN-GB">Based on its pharmacodynamic properties, irbesartan is unlikely to affect the abilityto drive and use machine. When driving vehicles or operating machines, it should be taken into account that dizziness or weariness may occur during treatment.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.8     Undesirable effects"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">In placebo-controlled trials in patients with hypertension, the overall incidence of adverse events did not differ between the irbesartan (56.2%) and the placebo groups (56.5%). Discontinuation due to any clinical or laboratory adverse event was less frequent for irbesartan-treated patients (3.3%) than for placebo-treated patients (4.5%). The incidence of adverse events was not related to dose (in the recommended dose range), gender, age, race, or duration of treatment.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">In diabetic hypertensive patients with microalbuminuria and normal renal function, orthostatic dizziness and orthostatic hypotension were reported in 0.5% of the patients (i.e., uncommon) but in excess of placebo.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">The following table presents the adverse drug reactions that were reported in placebo-controlled trials in which 1,965 hypertensive patients received irbesartan. Terms marked with a star (*) refer to the adverse reactions that were additionally reported in &gt; 2% of diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria and in excess of placebo.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">The frequency of adverse reactions listed below is defined using the following convention:</span></p><p class="EMEABodyText"><span lang="EN-GB">very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to &lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Adverse reactions additionally reported from post–marketing experience are also listed. These adverse reactions are derived from spontaneous reports.</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Blood and lymphatic system disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       anaemia, thrombocytopenia</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Immune system disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       hypersensitivity reactions such as angioedema, rash, urticaria, anaphylactic reaction, anaphylactic shock</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Metabolism and nutrition disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       hyperkalaemia, hypoglycaemia</span></p><p class="EMEABodyText"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Nervous system disorders</span></u></p><p class="EMEABodyText"><span lang="EN-GB">Common:         dizziness, orthostatic dizziness*</span></p><p class="EMEABodyText"><span lang="EN-GB">Not known:       vertigo, headache</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Ear and labyrinth disorder</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       tinnitus</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Cardiac disorders</span></u></p><p class="EMEABodyText"><span lang="EN-GB">Uncommon:      tachycardia</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Vascular disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Common:         orthostatic hypotension*</span></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Uncommon:      flushing</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Respiratory, thoracic and mediastinal disorders</span></u></p><p class="EMEABodyText"><span lang="EN-GB">Uncommon:      cough</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Gastrointestinal disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Common:         nausea/vomiting</span></p><p class="EMEABodyText"><span lang="EN-GB">Uncommon:      diarrhoea, dyspepsia/heartburn</span></p><p class="EMEABodyText"><span lang="EN-GB">Not known:       dysgeusia</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Hepatobiliary disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Uncommon:      jaundice</span></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       hepatitis, abnormal liver function</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Skin and subcutaneous tissue disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       leukocytoclastic vasculitis</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Musculoskeletal and connective tissue disorders</span></u></p><p class="EMEABodyText"><span lang="EN-GB">Common:         musculoskeletal pain*</span></p><p class="EMEABodyText" style="margin-left:1.0in;text-indent:-1.0in"><span lang="EN-GB">Not known:       arthralgia, myalgia (in some cases associated with increased plasma creatine kinase levels), muscle cramps</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Renal and urinary disorders</span></u></p><p class="EMEABodyText" style="margin-left:1.0in;text-indent:-1.0in;page-break-after: avoid"><span lang="EN-GB">Not known:        impaired renal function including cases of renal failure in patients at risk (see section 4.4)</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Reproductive system and breast disorders</span></u></p><p class="EMEABodyText" style="text-align:justify"><span lang="EN-GB">Uncommon:      sexual dysfunction</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">General disorders and administration site conditions</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Common:         fatigue</span></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Uncommon:      chest pain</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Investigations</span></u></p><p class="EMEABodyText" style="margin-left:1.0in;text-indent:-1.0in"><span lang="EN-GB">Very common:  Hyperkalaemia* occurred more often in diabetic patients treated with irbesartan than with placebo. In diabetic hypertensive patients with microalbuminuria and normal renal function, hyperkalaemia (≥ 5.5 mEq/L) occurred in 29.4% of the patients in the irbesartan 300 mg group and 22% of the patients in the placebo group. In diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria, hyperkalaemia (≥ 5.5 mEq/L) occurred in 46.3% of the patients in the irbesartan group and 26.3% of the patients in the placebo group.</span></p><p class="EMEABodyText" style="margin-left:1.0in;text-indent:-1.0in"><span lang="EN-GB">Common:         significant increases in plasma creatine kinase were commonly observed (1.7%) in irbesartan treated subjects. None of these increases were associated with identifiable clinical musculoskeletal events.<br/> In 1.7% of hypertensive patients with advanced diabetic renal disease treated with irbesartan, a decrease in haemoglobin*, which was not clinically significant, has been observed.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="EMEABodyText"><span lang="EN-GB">In a randomised trial of 318 hypertensive children and adolescents aged 6 to 16 years, the following adverse reactions occurred in the 3-week double-blind phase: headache (7.9%), hypotension (2.2%), dizziness (1.9%), cough (0.9%). In the 26-week open-label period of this trial the most frequent laboratory abnormalities observed were creatinine increases (6.5%) and elevated CK values in 2% of child recipients.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Reporting of suspected adverse reactions </span></u></p><p class="EMEABodyText"><span lang="EN-GB">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via <span style="background:silver">the national reporting system listed in Appendix V.</span> </span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.9     Overdose"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><span lang="EN-GB">Experience in adults exposed to doses of up to 900 mg/day for 8 weeks revealed no toxicity. The most likely manifestations of overdose are expected to be hypotension and tachycardia; bradycardia might also occur from overdose. No specific information is available on the treatment of overdose with Karvea. The patient should be closely monitored, and the treatment should be symptomatic and supportive. Suggested measures include induction of emesis and/or gastric lavage. Activated charcoal may be useful in the treatment of overdose. Irbesartan is not removed by haemodialysis.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="5.       PHARMACOLOGICAL PROPERTIES"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="5.1     Pharmacodynamic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Pharmacotherapeutic group: Angiotensin-II antagonists, plain.</span></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">ATC code: C09C A04.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Mechanism of action</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Irbesartan is a potent, orally active, selective angiotensin-II receptor (type AT<sub>1</sub>) antagonist. It is expected to block all actions of angiotensin-II mediated by the AT<sub>1</sub> receptor, regardless of the source or route of synthesis of angiotensin-II. The selective antagonism of the angiotensin-II (AT<sub>1</sub>) receptors results in increases in plasma renin levels and angiotensin-II levels, and a decrease in plasma aldosterone concentration. Serum potassium levels are not significantly affected by irbesartan alone at the recommended doses. Irbesartan does not inhibit ACE (kininase-II), an enzyme which generates angiotensin-II and also degrades bradykinin into inactive metabolites. Irbesartan does not require metabolic activation for its activity.</span></p><p class="EMEABodyText"></p><p class="EMEAHeading2"><u><span lang="EN-GB" style="font-weight:normal">Clinical efficacy</span></u></p><p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><i><span lang="EN-GB">Hypertension</span></i></p><p class="EMEABodyText"><span lang="EN-GB">Irbesartan lowers blood pressure with minimal change in heart rate. The decrease in blood pressure is dose-related for once a day doses with a tendency towards plateau at doses above 300 mg. Doses of 150-300 mg once daily lower supine or seated blood pressures at trough (i.e. 24 hours after dosing) by an average of 8-13/5-8 mm Hg (systolic/diastolic) greater than those associated with placebo.</span></p><p class="EMEABodyText"><span lang="EN-GB">Peak reduction of blood pressure is achieved within 3-6 hours after administration and the blood pressure lowering effect is maintained for at least 24 hours. At 24 hours the reduction of blood pressure was 60-70% of the corresponding peak diastolic and systolic responses at the recommended doses. Once daily dosing with 150 mg produced trough and mean 24 hour responses similar to twice daily dosing on the same total dose.</span></p><p class="EMEABodyText"><span lang="EN-GB">The blood pressure lowering effect of Karvea is evident within 1-2 weeks, with the maximal effect occurring by 4-6 weeks after start of therapy. The antihypertensive effects are maintained during long term therapy. After withdrawal of therapy, blood pressure gradually returns toward baseline. Rebound hypertension has not been observed.</span></p><p class="EMEABodyText"><span lang="EN-GB">The blood pressure lowering effects of irbesartan and thiazide-type diuretics are additive. In patients not adequately controlled by irbesartan alone, the addition of a low dose of hydrochlorothiazide (12.5 mg) to irbesartan once daily results in a further placebo-adjusted blood pressure reduction at trough of 7-10/3-6 mm Hg (systolic/diastolic).</span></p><p class="EMEABodyText"><span lang="EN-GB">The efficacy of Karvea is not influenced by age or gender. As is the case with other medicinal products that affect the renin-angiotensin system, black hypertensive patients have notably less response to irbesartan monotherapy. When irbesartan is administered concomitantly with a low dose of hydrochlorothiazide (e.g. 12.5 mg daily), the antihypertensive response in black patients approaches that of white patients.</span></p><p class="EMEABodyText"><span lang="EN-GB">There is no clinically important effect on serum uric acid or urinary uric acid secretion.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Reduction of blood pressure with 0.5 mg/kg (low), 1.5 mg/kg (medium) and 4.5 mg/kg (high) target titrated doses of irbesartan was evaluated in 318 hypertensive or at risk (diabetic, family history of hypertension) children and adolescents aged 6 to 16 years over a three week period. At the end of the three weeks the mean reduction from baseline in the primary efficacy variable, trough seated systolic blood pressure (SeSBP) was 11.7 mmHg (low dose), 9.3 mmHg (medium dose), 13.2 mmHg (high dose). No significant difference was apparent between these doses. Adjusted mean change of trough seated diastolic blood pressure (SeDBP) was as follows: 3.8 mmHg (low dose), 3.2 mmHg (medium dose), 5.6 mmHg (high dose). Over a subsequent two week period where patients were re-randomized to either active medicinal product or placebo, patients on placebo had increases of 2.4 and 2.0 mmHg in SeSBP and SeDBP compared to +0.1 and -0.3 mmHg changes respectively in those on all doses of irbesartan (see section 4.2).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><i><span lang="EN-GB">Hypertension and type 2 diabetes with renal disease</span></i></p><p class="EMEABodyText"><span lang="EN-GB">The “Irbesartan Diabetic Nephropathy Trial (IDNT)” shows that irbesartan decreases the progression of renal disease in patients with chronic renal insufficiency and overt proteinuria. IDNT was a double blind, controlled, morbidity and mortality trial comparing Karvea, amlodipine and placebo. In 1,715 hypertensive patients with type 2 diabetes, proteinuria ≥ 900 mg/day and serum creatinine ranging from 1.0-3.0 mg/dl, the long-term effects (mean 2.6 years) of Karvea on the progression of renal disease and all-cause mortality were examined. Patients were titrated from 75 mg to a maintenance dose of 300 mg Karvea</span><span lang="EN-GB" style='font-family:"Times",serif'>, from 2.5 mg to 10 mg amlodipine, or placebo</span><span lang="EN-GB"> as tolerated. Patients in all treatment groups typically received between 2 and 4 antihypertensive agents (e.g., diuretics, beta blockers, alpha blockers) to reach a predefined blood pressure goal of ≤ 135/85 mmHg or a 10 mmHg reduction in systolic pressure if baseline was &gt; 160 mmHg. Sixty per cent (60%) of patients in the placebo group reached this target blood pressure whereas this figure was 76% and 78% in the irbesartan and amlodipine groups respectively. Irbesartan significantly reduced the relative risk in the primary combined endpoint of doubling serum creatinine, end-stage renal disease (ESRD) or all-cause mortality. Approximately 33% of patients in the irbesartan group reached the primary renal composite endpoint compared to 39% and 41% in the placebo and amlodipine groups [20% relative risk reduction versus placebo (p = 0.024) and 23% relative risk reduction compared to amlodipine (p = 0.006)]. When the individual components of the primary endpoint were analysed, no effect in all cause mortality was observed, while a positive trend in the reduction in ESRD and a significant reduction in doubling of serum creatinine were observed.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB" style="layout-grid-mode:line">Subgroups consisting of gender, race, age, duration of diabetes, baseline blood pressure, serum creatinine, and albumin excretion rate were assessed for treatment effect. In the female and black subgroups which represented 32% and 26% of the overall study population respectively, a renal benefit was not evident, </span>although the confidence intervals do not exclude it. As for the secondary endpoint of fatal and non-fatal cardiovascular events, there was no difference among the three groups in the overall population, although an increased incidence of non-fatal MI was seen for women and a decreased incidence of non-fatal MI was seen in males in the irbesartan group versus the placebo-based regimen. An increased incidence of non-fatal MI and stroke was seen in females in the irbesartan-based regimen versus the amlodipine-based regimen, while hospitalization due to heart failure was reduced in the overall population. However, no proper explanation for these findings in women has been identified.</p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">The study of the “Effects of Irbesartan on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus (IRMA 2)” shows that irbesartan 300 mg delays progression to overt proteinuria in patients with microalbuminuria. IRMA 2 was a placebo-controlled double blind morbidity study in 590 patients with type 2 diabetes, microalbuminuria (30-300 mg/day) and normal renal function (serum creatinine ≤ 1.5 mg/dl in males and &lt; 1.1 mg/dl in females). The study examined the long-term effects (2 years) of Karvea on the progression to clinical (overt) proteinuria (urinary albumin excretion rate (UAER) &gt; 300 mg/day, and an increase in UAER of at least 30% from baseline). The predefined blood pressure goal was ≤ 135/85 mmHg. Additional antihypertensive agents (excluding ACE inhibitors, angiotensin II receptor antagonists and dihydropyridine calcium blockers) were added as needed to help achieve the blood pressure goal. While similar blood pressure was achieved in all treatment groups, fewer subjects in the irbesartan 300 mg group (5.2%) than in the placebo (14.9%) or in the irbesartan 150 mg group (9.7%) reached the endpoint of overt proteinuria, demonstrating a 70% relative risk reduction versus placebo (p = 0.0004) for the higher dose. An accompanying improvement in the glomerular filtration rate (GFR) was not observed during the first three months of treatment. The slowing in the progression to clinical proteinuria was evident as early as three months and continued over the 2 year period. Regression to normoalbuminuria (&lt; 30 mg/day) was more frequent in the Karvea 300 mg group (34%) than in the placebo group (21%).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><i><span lang="EN-GB">Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</span></i></p><p class="EMEABodyText"><span lang="EN-GB">Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker. ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</span></p><p class="EMEABodyText"><span lang="EN-GB">These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.</span></p><p class="EMEABodyText"><span lang="EN-GB">ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</span></p><p class="EMEABodyText"><span lang="EN-GB">ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.2     Pharmacokinetic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Absorption</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">After oral administration, irbesartan is well absorbed: studies of absolute bioavailability gave values of approximately 60-80%. Concomitant food intake does not significantly influence the bioavailability of irbesartan. </span></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Distribution</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Plasma protein binding is approximately 96%, with negligible binding to cellular blood components. The volume of distribution is 53-93 litres. </span></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Biotransformation</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Following oral or intravenous administration of <sup><span style="position:relative; top:-1.0pt">14</span></sup>C irbesartan, 80-85% of the circulating plasma radioactivity is attributable to unchanged irbesartan. Irbesartan is metabolised by the liver via glucuronide conjugation and oxidation. The major circulating metabolite is irbesartan glucuronide (approximately 6%). <i>In vitro</i> studies indicate that irbesartan is primarily oxidised by the cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Linearity / non-linearity</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg. A less than proportional increase in oral absorption at doses beyond 600 mg (twice the maximal recommended dose) was observed; the mechanism for this is unknown. Peak plasma concentrations are attained at 1.5-2 hours after oral administration. The total body and renal clearance are 157-176 and 3-3.5 ml/min, respectively. The terminal elimination half-life of irbesartan is 11-15 hours. Steady-state plasma concentrations are attained within 3 days after initiation of a once-daily dosing regimen. Limited accumulation of irbesartan (&lt; 20%) is observed in plasma upon repeated once-daily dosing. In a study, somewhat higher plasma concentrations of irbesartan were observed in female hypertensive patients. However, there was no difference in the half-life and accumulation of irbesartan. No dosage adjustment is necessary in female patients. Irbesartan AUC and C<span class="EMEASubscript">max</span> values were also somewhat greater in oldersubjects (≥ 65 years) than those of young subjects (18-40 years). However the terminal half-life was not significantly altered. No dosage adjustment is necessary in older people.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Elimination</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Irbesartan and its metabolites are eliminated by both biliary and renal pathways. After either oral or IV administration of <sup><span style="position:relative;top:-1.0pt">14</span></sup>C irbesartan, about 20% of the radioactivity is recovered in the urine, and the remainder in the faeces. Less than 2% of the dose is excreted in the urine as unchanged irbesartan.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText"><span lang="EN-GB">The pharmacokinetics of irbesartan were evaluated in 23 hypertensive children after the administration of single and multiple daily doses of irbesartan (2 mg/kg) up to a maximum daily dose of 150 mg for four weeks. Of those 23 children, 21 were evaluable for comparison of pharmacokinetics with adults (twelve children over 12 years, nine children between 6 and 12 years). Results showed that C<span class="EMEASubscript">max</span>, AUC and clearance rates were comparable to those observed in adult patients receiving 150 mg irbesartan daily. A limited accumulation of irbesartan (18%) in plasma was observed upon repeated once daily dosing.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Renal impairment</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">In patients with renal impairment or those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan are not significantly altered. Irbesartan is not removed by haemodialysis.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Hepatic impairment</span></u><span lang="EN-GB">:</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">In patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly altered.</span></p><p class="EMEABodyText"><span lang="EN-GB">Studies have not been performed in patients with severe hepatic impairment.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.3Preclinical safety data"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">There was no evidence of abnormal systemic or target organ toxicity at clinically relevant doses. In non-clinical safety studies, high doses of irbesartan (≥ 250 mg/kg/day in rats and ≥ 100 mg/kg/day in macaques) caused a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit). At very high doses (≥ 500 mg/kg/day) degenerative changes in the kidney (such as interstitial nephritis, tubular distension, basophilic tubules, increased plasma concentrations of urea and creatinine) were induced by irbesartan in the rat and the macaque and are considered secondary to the hypotensive effects of the medicinal product which led to decreased renal perfusion. Furthermore, irbesartan induced hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at ≥ 90 mg/kg/day, in macaques at ≥ 10 mg/kg/day). All of these changes were considered to be caused by the pharmacological action of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia/ hypertrophy of the renal juxtaglomerular cells does not appear to have any relevance.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">There was no evidence of mutagenicity, clastogenicity or carcinogenicity.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Fertility and reproductive performance were not affected in studies of male and female rats even at oral doses of irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), including mortality at the highest dose. No significant effects on the number of corpora lutea, implants, or live foetuses were observed. Irbesartan did not affect survival, development, or reproduction of offspring. Studies in animals indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses. Irbesartan is excreted in the milk of lactating rats.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Animal studies with irbesartan showed transient toxic effects (increased renal pelvic cavitation, hydroureter or subcutaneous oedema) in rat foetuses, which were resolved after birth. In rabbits, abortion or early resorption were noted at doses causing significant maternal toxicity, including mortality. No teratogenic effects were observed in the rat or rabbit.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="6.       PHARMACEUTICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="6.1     List of excipients"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Microcrystalline cellulose</span></p><p class="EMEABodyText"><span lang="EN-GB">Croscarmellose sodium</span></p><p class="EMEABodyText"><span lang="EN-GB">Lactose monohydrate</span></p><p class="EMEABodyText"><span lang="EN-GB">Magnesium stearate</span></p><p class="EMEABodyText"><span lang="EN-GB">Colloidal hydrated silica</span></p><p class="EMEABodyText"><span lang="EN-GB">Pregelatinised maize starch</span></p><p class="EMEABodyText"><span lang="EN-GB">Poloxamer 188</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.2     Incompatibilities"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not applicable.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.3     Shelf life"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">3 years.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.4     Special precautions for storage"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Do not store above 30°C.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.5     Nature and contents of container"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><span lang="EN-GB">Cartons of 14 tablets in PVC/PVDC/Aluminium blisters.</span></p><p class="EMEABodyText"><span lang="EN-GB">Cartons of 28 tablets in PVC/PVDC/Aluminium blisters.</span></p><p class="EMEABodyText"><span lang="EN-GB">Cartons of 56 tablets in PVC/PVDC/Aluminium blisters.</span></p><p class="EMEABodyText"><span lang="EN-GB">Cartons of 98 tablets in PVC/PVDC/Aluminium blisters.</span></p><p class="EMEABodyText"><span lang="EN-GB">Cartons of 56 x 1 tablet in PVC/PVDC/Aluminium perforated unit dose blisters.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Not all pack sizes may be marketed.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.6     Special precautions for disposal"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="7.       MARKETING AUTHORISATION HOLDER"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEAAddress"><span lang="FR">sanofi-aventis groupe<br/> 54, rue La Boétie<br/> F-75008 Paris - France</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="8.       MARKETING AUTHORISATION NUMBERS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEABodyText" style="text-align:justify"><span lang="NO-BOK">EU/1/97/049/007-009<br/> EU/1/97/049/012<br/> EU/1/97/049/015</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="9.       DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEABodyText"><span lang="EN-GB">Date of first authorisation: 27 August 1997<br/> Date of latest renewal: 27 August 2007</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="10.     DATE OF REVISION OF THE TEXT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu</span></p><p class="MsoNormal"></p><b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; text-transform:uppercase'><br clear="all" style="page-break-before:always"/> </span></b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; text-transform:uppercase'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
	
		
		
    	    
				
			    
						
		               
<section>
			<title value="1.       NAME OF THE MEDICINAL PRODUCT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEABodyText"><span lang="EN-GB">Karvea 75 mg film-coated tablets.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="2.       QUALITATIVE AND QUANTITATIVE COMPOSITION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEABodyText"><span lang="EN-GB">Each film-coated tablet contains 75 mg of irbesartan.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Excipient with known effect</span></u><span lang="EN-GB">: 25.50 mg of lactose monohydrate per film-coated tablet.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">For the full list of excipients, see section 6.1.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="3.       PHARMACEUTICAL FORM"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Film-coated tablet.</span></p><p class="EMEABodyText"><span lang="EN-GB">White to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2871 engraved on the other side.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="4.       CLINICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="4.1     Therapeutic indications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Karvea is indicated in adults for the treatment of essential hypertension.</span></p><p class="EMEABodyText"><span lang="EN-GB">It is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen (see sections 4.3, 4.4, 4.5 and 5.1).</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.2     Posology and method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Posology</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">The usual recommended initial and maintenance dose is 150 mg once daily, with or without food. Karvea at a dose of 150 mg once daily generally provides a better 24 hour blood pressure control than 75 mg. However, initiation of therapy with 75 mg could be considered, particularly in haemodialysed patients and in the elderly over 75 years.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">In patients insufficiently controlled with 150 mg once daily, the dose of Karvea can be increased to 300 mg, or other antihypertensive agents can be added (see sections 4.3, 4.4, 4.5 and 5.1). In particular, the addition of a diuretic such as hydrochlorothiazide has been shown to have an additive effect with Karvea (see section 4.5).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">In hypertensive type 2 diabetic patients, therapy should be initiated at 150 mg irbesartan once daily and titrated up to 300 mg once daily as the preferred maintenance dose for treatment of renal disease.</span></p><p class="EMEABodyText"><span lang="EN-GB">The demonstration of renal benefit of Karvea in hypertensive type 2 diabetic patients is based on studies where irbesartan was used in addition to other antihypertensive agents, as needed, to reach target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Special Populations</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText"><i><span lang="EN-GB">Renal impairment</span></i></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">No dosage adjustment is necessary in patients with impaired renal function. A lower starting dose (75 mg) should be considered for patients undergoing haemodialysis (see section 4.4).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><i><span lang="EN-GB">Hepatic impairment</span></i></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. There is no clinical experience in patients with severe hepatic impairment.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><i><span lang="EN-GB">Older people</span></i></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Although consideration should be given to initiating therapy with 75 mg in patients over 75 years of age, dosage adjustment is not usually necessary for older people.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><i><span lang="EN-GB">Paediatric population</span></i></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">The safety and efficacy of Karvea in children aged 0 to 18 has not been established. Currently available data are described in section 4.8, 5.1 and 5.2 but no recommendation on a posology can be made.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Method of Administration</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">For oral use.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.3     Contraindications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.</span></p><p class="EMEABodyText"><span lang="EN-GB">Second and third trimesters of pregnancy (see sections 4.4 and 4.6).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB"> The concomitant use of Karvea with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (glomerular filtration rate (GFR) &lt;60 ml/min/1.73m<sup>2</sup>) (see sections 4.5 and 5.1).</span></p><p class="EMEAHeading2"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.4     Special warnings and precautions for use"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Intravascular volume depletion</span></u><span lang="EN-GB">: symptomatic hypotension, especially after the first dose, may occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting. Such conditions should be corrected before the administration of Karvea.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Renovascular hypertension</span></u><span lang="EN-GB">: there is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with medicinal products that affect the renin-angiotensin-aldosterone system. While this is not documented with Karvea, a similar effect should be anticipated with angiotensin-II receptor antagonists.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Renal impairment and kidney transplantation</span></u><span lang="EN-GB">: when Karvea is used in patients with impaired renal function, a periodic monitoring of potassium and creatinine serum levels is recommended. There is no experience regarding the administration of Karvea in patients with a recent kidney transplantation.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Hypertensive patients with type 2 diabetes and renal disease</span></u><span lang="EN-GB">:</span><span lang="EN-GB" style="layout-grid-mode:line"> the effects of irbesartan both on renal and cardiovascular events were not uniform across all subgroups, in an analysis carried out in the study with patients with advanced renal disease. In particular, they appeared less favourable in women and non-white subjects (see section 5.1).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Dual blockade of the renin-angiotensin-aldosterone system (RAAS):</span></u><span lang="EN-GB"> there is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).  If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Hyperkalaemia</span></u><span lang="EN-GB">: as with other medicinal products that affect the renin-angiotensin-aldosterone system, hyperkalaemia may occur during the treatment with Karvea, especially in the presence of renal impairment, overt proteinuria due to diabetic renal disease, and/or heart failure. Close monitoring of serum potassium in patients at risk is recommended (see section 4.5).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Hypoglycaemia: </span></u><span lang="EN-GB">Karvea may induce hypoglycaemia, particularly in diabetic patients. In patients treated with insulin or antidiabetics an appropriate blood glucose monitoring should be considered; a dose adjustment of insulin or antidiabetics may be required when indicated (see section 4.5).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Lithium</span></u><span lang="EN-GB">: the combination of lithium and Karvea is not recommended (see section 4.5).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy</span></u><span lang="EN-GB">: as with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Primary aldosteronism</span></u><span lang="EN-GB">: patients with primary aldosteronism generally will not respond to antihypertensive medicinal products acting through inhibition of the renin-angiotensin system. Therefore, the use of Karvea is not recommended.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">General</span></u><span lang="EN-GB">: in patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with angiotensinconverting enzyme inhibitors or angiotensin-II receptor antagonists that affect this system has been associated with acute hypotension, azotaemia, oliguria, or rarely acute renal failure (see section 4.5). As with any antihypertensive agent, excessive blood pressure decrease in patients with ischaemic cardiopathy or ischaemic cardiovascular disease could result in a myocardial infarction or stroke.</span></p><p class="EMEABodyText"><span lang="EN-GB">As observed for angiotensin converting enzyme inhibitors, irbesartan and the other angiotensin antagonists are apparently less effective in lowering blood pressure in black people than in non-blacks, possibly because of higher prevalence of low-renin states in the black hypertensive population (see section 5.1).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Pregnancy:</span></u><span lang="EN-GB"> angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. </span><span lang="EN-GB">Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with </span><span lang="EN-GB">AIIRAs</span><span lang="EN-GB"> should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Paediatric population</span></u><span lang="EN-GB">: irbesartan has been studied in paediatric populations aged 6 to 16 years old but the current data are insufficient to support an extension of the use in children until further data become available (see sections 4.8, 5.1 and 5.2).</span></p><p class="EMEABodyText"></p><p class="MsoNormal"><u><span lang="EN-GB">Excipients</span></u><span lang="FR">:</span></p><p class="EMEABodyText"><span lang="EN-GB">Karvea 75 mg film-coated tablet contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Karvea 75 mg film-coated tablet contains sodium. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.5     Interaction with other medicinal products and other forms of interaction"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><u><span lang="EN-GB">Diuretics and other antihypertensive agents</span></u><span lang="EN-GB">: other antihypertensive agents may increase the hypotensive effects of irbesartan; however Karvea has been safely administered with other antihypertensive agents, such as beta-blockers, long-acting calcium channel blockers, and thiazide diuretics. Prior treatment with high dose diuretics may result in volume depletion and a risk of hypotension when initiating therapy with Karvea (see section 4.4).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Aliskiren-containing products or ACE-inhibitors</span></u><span lang="EN-GB">: clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Potassium supplements and potassium-sparing diuretics</span></u><span lang="EN-GB">:based on experience with the use of other medicinal products that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium and is, therefore, not recommended (see section 4.4).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Lithium</span></u><span lang="EN-GB">:reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors. Similar effects have been very rarely reported with irbesartan so far. Therefore, this combination is not recommended (see section 4.4). If the combination proves necessary, careful monitoring of serum lithium levels is recommended.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Non-steroidal anti-inflammatory drugs</span></u><span lang="EN-GB">: <span style="color:black">when angiotensin II antagonists are administered simultaneously with non-steroidal anti-inflammatory drugs (i.e. selective COX-2 inhibitors, acetylsalicylic acid (&gt; 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.</span></span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">As with ACE inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function. The combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Repaglinide:</span></u><span lang="EN-GB" style="color:black"> irbesartan has the potential to inhibit OATP1B1. In a clinical study, it was reported that irbesartan increased the C<sub>max</sub> and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3‑fold, respectively, when administered 1 hour before repaglinide. In another study, no relevant pharmacokinetic interaction was reported, when the two drugs were co-administered. Therefore, dose adjustment of antidiabetic treatment such as repaglinide may be required (see section 4.4).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Additional information on irbesartan interactions</span></u><span lang="EN-GB">: <span style="color:black">in clinical studies, the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic interactions were observed when irbesartan was coadministered with warfarin, a medicinal product metabolised by CYP2C9. The effects of CYP2C9 inducers such as rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The pharmacokinetic of digoxin was not altered by coadministration of irbesartan.</span></span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.6     Fertility, pregnancy and lactation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Pregnancy</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks may exist for this class of drugs. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Exposure to AIIRA therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).</span></p><p class="EMEABodyText"><span lang="EN-GB">Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.</span></p><p class="EMEABodyText"><span lang="EN-GB">Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3 and 4.4).</span></p><p class="EMEABodyText"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Breast-feeding</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText"><span lang="EN-GB">Because no information is available regarding the use of Karvea during breast-feeding, Karvea is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">It is unknown whether irbesartan or its metabolites are excreted in human milk. </span></p><p class="EMEABodyText"><span lang="EN-GB">Available pharmacodynamic/toxicological data in rats have shown excretion of irbesartan or its metabolites in milk (for details see 5.3).</span></p><p class="EMEABodyText"> </p><p class="EMEABodyText"><u><span lang="EN-GB">Fertility</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText">Irbesartan had no effect upon fertility of treated rats and their offspring up to the dose levels inducing the first signs of parental toxicity (see section 5.3). </p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.7     Effects on ability to drive and use machines"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <div style="border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt"> <p class="EMEABodyText" style="border:none;padding:0in"><span lang="EN-GB">The use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4). The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 and 4.4).</span></p> </div><p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Based on its pharmacodynamic properties, irbesartan is unlikely to affect the ability to drive and use machines. When driving vehicles or operating machines, it should be taken into account that dizziness or weariness may occur during treatment.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.8     Undesirable effects"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><span lang="EN-GB">In placebo-controlled trials in patients with hypertension, the overall incidence of adverse events did not differ between the irbesartan (56.2%) and the placebo groups (56.5%). Discontinuation due to any clinical or laboratory adverse event was less frequent for irbesartan-treated patients (3.3%) than for placebo-treated patients (4.5%). The incidence of adverse events was not related to dose (in the recommended dose range), gender, age, race, or duration of treatment.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">In diabetic hypertensive patients with microalbuminuria and normal renal function, orthostatic dizziness and orthostatic hypotension were reported in 0.5% of the patients (i.e., uncommon) but in excess of placebo.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">The following table presents the adverse drug reactions that were reported in placebo-controlled trials in which 1,965 hypertensive patients received irbesartan. Terms marked with a star (*) refer to the adverse reactions that were additionally reported in &gt; 2% of diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria and in excess of placebo.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">The frequency of adverse reactions listed below is defined using the following convention:</span></p><p class="EMEABodyText"><span lang="EN-GB">very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to &lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Adverse reactions additionally reported from post–marketing experience are also listed. These adverse reactions are derived from spontaneous reports.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Blood and lymphatic system disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       anaemia, thrombocytopenia</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Immune system disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       hypersensitivity reactions such as angioedema, rash, urticaria, anaphylactic reaction, anaphylactic shock</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Metabolism and nutrition disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       hyperkalaemia, hypoglycaemia</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Nervous system disorders</span></u></p><p class="EMEABodyText"><span lang="EN-GB">Common:         dizziness, orthostatic dizziness*</span></p><p class="EMEABodyText"><span lang="EN-GB">Not known:       vertigo, headache</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Ear and labyrinth disorder</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       tinnitus</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Cardiac disorders</span></u></p><p class="EMEABodyText"><span lang="EN-GB">Uncommon:      tachycardia</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Vascular disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Common:         orthostatic hypotension*</span></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Uncommon:      flushing</span></p><p class="EMEABodyText"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Respiratory, thoracic and mediastinal disorders</span></u></p><p class="EMEABodyText"><span lang="EN-GB">Uncommon:      cough</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Gastrointestinal disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Common:         nausea/vomiting</span></p><p class="EMEABodyText"><span lang="EN-GB">Uncommon:      diarrhoea, dyspepsia/heartburn</span></p><p class="EMEABodyText"><span lang="EN-GB">Not known:       dysgeusia</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Hepatobiliary disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Uncommon:      jaundice</span></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       hepatitis, abnormal liver function</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Skin and subcutaneous tissue disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       leukocytoclastic vasculitis</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Musculoskeletal and connective tissue disorders </span></u></p><p class="EMEABodyText"><span lang="EN-GB">Common:         musculoskeletal pain*</span></p><p class="EMEABodyText" style="margin-left:1.0in;text-indent:-1.0in"><span lang="EN-GB">Not known:       arthralgia, myalgia (in some cases associated with increased plasma creatine kinase levels), muscle cramps</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Renal and urinary disorders</span></u></p><p class="EMEABodyText" style="margin-left:1.0in;text-indent:-1.0in;page-break-after: avoid"><span lang="EN-GB">Not known:        impaired renal function including cases of renal failure in patients at risk (see section 4.4)</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="text-align:justify;page-break-after:avoid"><u><span lang="EN-GB">Reproductive system and breast disorders</span></u></p><p class="EMEABodyText"><span lang="EN-GB">Uncommon:      sexual dysfunction</span></p><p class="EMEABodyText" style="text-align:justify"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">General disorders and administration site conditions</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Common:         fatigue</span></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Uncommon:      chest pain</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Investigations</span></u></p><p class="EMEABodyText" style="margin-left:1.0in;text-indent:-1.0in"><span lang="EN-GB">Very common:  Hyperkalaemia* occurred more often in diabetic patients treated with irbesartan than with placebo. In diabetic hypertensive patients with microalbuminuria and normal renal function, hyperkalaemia (≥ 5.5 mEq/L) occurred in 29.4% of the patients in the irbesartan 300 mg group and 22% of the patients in the placebo group. In diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria, hyperkalaemia (≥ 5.5 mEq/L) occurred in 46.3% of the patients in the irbesartan group and 26.3% of the patients in the placebo group.</span></p><p class="EMEABodyText" style="margin-left:1.0in;text-indent:-1.0in"><span lang="EN-GB">Common:         significant increases in plasma creatine kinase were commonly observed (1.7%) in irbesartan treated subjects. None of these increases were associated with identifiable clinical musculoskeletal events.<br/> In 1.7% of hypertensive patients with advanced diabetic renal disease treated with irbesartan, a decrease in haemoglobin*, which was not clinically significant, has been observed.</span></p><p class="EMEABodyText"><i><u><span lang="EN-GB"></span></u></i></p><p class="EMEABodyText"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="EMEABodyText"><span lang="EN-GB">I</span><span lang="EN-GB">n a randomised trial of 318 hypertensive children and adolescents aged 6 to 16 years, the following adverse reactions occurred in the 3-week double-blind phase: headache (7.9%), hypotension (2.2%), dizziness (1.9%), cough (0.9%). In the 26-week open-label period of this trial the most frequent laboratory abnormalities observed were creatinine increases (6.5%) and elevated CK values in 2% of child recipients.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Reporting of suspected adverse reactions </span></u></p><p class="EMEABodyText"><span lang="EN-GB">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via <span style="background:silver">the national reporting system listed in Appendix V.</span> </span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.9     Overdose"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Experience in adults exposed to doses of up to 900 mg/day for 8 weeks revealed no toxicity. The most likely manifestations of overdose are expected to be hypotension and tachycardia; bradycardia might also occur from overdose. No specific information is available on the treatment of overdose with Karvea. The patient should be closely monitored, and the treatment should be symptomatic and supportive. Suggested measures include induction of emesis and/or gastric lavage. Activated charcoal may be useful in the treatment of overdose. Irbesartan is not removed by haemodialysis.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="5.       PHARMACOLOGICAL PROPERTIES"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="5.1     Pharmacodynamic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><span lang="EN-GB">Pharmacotherapeutic group: Angiotensin-II antagonists, plain.</span></p><p class="EMEABodyText"><span lang="EN-GB">ATC code: C09C A04.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Mechanism of action</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Irbesartan is a potent, orally active, selective angiotensin-II receptor (type AT<sub>1</sub>) antagonist. It is expected to block all actions of angiotensin-II mediated by the AT<sub>1</sub> receptor, regardless of the source or route of synthesis of angiotensin-II. The selective antagonism of the angiotensin-II (AT<sub>1</sub>) receptors results in increases in plasma renin levels and angiotensin-II levels, and a decrease in plasma aldosterone concentration. Serum potassium levels are not significantly affected by irbesartan alone at the recommended doses. Irbesartan does not inhibit ACE (kininase-II), an enzyme which generates angiotensin-II and also degrades bradykinin into inactive metabolites. Irbesartan does not require metabolic activation for its activity.</span></p><p class="EMEABodyText"></p><p class="EMEAHeading2"><u><span lang="EN-GB" style="font-weight:normal">Clinical efficacy</span></u></p><p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><i><span lang="EN-GB">Hypertension</span></i></p><p class="EMEABodyText"><span lang="EN-GB">Irbesartan lowers blood pressure with minimal change in heart rate. The decrease in blood pressure is dose-related for once a day doses with a tendency towards plateau at doses above 300 mg. Doses of 150-300 mg once daily lower supine or seated blood pressures at trough (i.e. 24 hours after dosing) by an average of 8-13/5-8 mm Hg (systolic/diastolic) greater than those associated with placebo.</span></p><p class="EMEABodyText"><span lang="EN-GB">Peak reduction of blood pressure is achieved within 3-6 hours after administration and the blood pressure lowering effect is maintained for at least 24 hours. At 24 hours the reduction of blood pressure was 60-70% of the corresponding peak diastolic and systolic responses at the recommended doses. Once daily dosing with 150 mg produced trough and mean 24 hour responses similar to twice daily dosing on the same total dose.</span></p><p class="EMEABodyText"><span lang="EN-GB">The blood pressure lowering effect of Karvea is evident within 1-2 weeks, with the maximal effect occurring by 4-6 weeks after start of therapy. The antihypertensive effects are maintained during long term therapy. After withdrawal of therapy, blood pressure gradually returns toward baseline. Rebound hypertension has not been observed.</span></p><p class="EMEABodyText"><span lang="EN-GB">The blood pressure lowering effects of irbesartan and thiazide-type diuretics are additive. In patients not adequately controlled by irbesartan alone, the addition of a low dose of hydrochlorothiazide (12.5 mg) to irbesartan once daily results in a further placebo-adjusted blood pressure reduction at trough of 7-10/3-6 mm Hg (systolic/diastolic).</span></p><p class="EMEABodyText"><span lang="EN-GB">The efficacy of Karvea is not influenced by age or gender. As is the case with other medicinal products that affect the renin-angiotensin system, black hypertensive patients have notably less response to irbesartan monotherapy. When irbesartan is administered concomitantly with a low dose of hydrochlorothiazide (e.g. 12.5 mg daily), the antihypertensive response in black patients approaches that of white patients.</span></p><p class="EMEABodyText"><span lang="EN-GB">There is no clinically important effect on serum uric acid or urinary uric acid secretion.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText"><span lang="EN-GB">Reduction of blood pressure with 0.5 mg/kg (low), 1.5 mg/kg (medium) and 4.5 mg/kg (high) target titrated doses of irbesartan was evaluated in 318 hypertensive or at risk (diabetic, family history of hypertension) children and adolescents aged 6 to 16 years over a three week period. At the end of the three weeks the mean reduction from baseline in the primary efficacy variable, trough seated systolic blood pressure (SeSBP) was 11.7 mmHg (low dose), 9.3 mmHg (medium dose), 13.2 mmHg (high dose). No significant difference was apparent between these doses. Adjusted mean change of trough seated diastolic blood pressure (SeDBP) was as follows: 3.8 mmHg (low dose), 3.2 mmHg (medium dose), 5.6 mmHg (high dose). Over a subsequent two week period where patients were re-randomized to either active medicinal product or placebo, patients on placebo had increases of 2.4 and 2.0 mmHg in SeSBP and SeDBP compared to +0.1 and -0.3 mmHg changes respectively in those on all doses of irbesartan (see section 4.2).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><i><span lang="EN-GB">Hypertension and type 2 diabetes with renal disease</span></i></p><p class="EMEABodyText"><span lang="EN-GB">The “Irbesartan Diabetic Nephropathy Trial (IDNT)” shows that irbesartan decreases the progression of renal disease in patients with chronic renal insufficiency and overt proteinuria. IDNT was a double blind, controlled, morbidity and mortality trial comparing Karvea, amlodipine and placebo. In 1,715 hypertensive patients with type 2 diabetes, proteinuria ≥ 900 mg/day and serum creatinine ranging from 1.0-3.0 mg/dl, the long-term effects (mean 2.6 years) of Karvea on the progression of renal disease and all-cause mortality were examined. Patients were titrated from 75 mg to a maintenance dose of 300 mg Karvea</span><span lang="EN-GB" style='font-family:"Times",serif'>, from 2.5 mg to 10 mg amlodipine, or placebo</span><span lang="EN-GB"> as tolerated. Patients in all treatment groups typically received between 2 and 4 antihypertensive agents (e.g., diuretics, beta blockers, alpha blockers) to reach a predefined blood pressure goal of ≤ 135/85 mmHg or a 10 mmHg reduction in systolic pressure if baseline was &gt; 160 mmHg. Sixty per cent (60%) of patients in the placebo group reached this target blood pressure whereas this figure was 76% and 78% in the irbesartan and amlodipine groups respectively. Irbesartan significantly reduced the relative risk in the primary combined endpoint of doubling serum creatinine, end-stage renal disease (ESRD) or all-cause mortality. Approximately 33% of patients in the irbesartan group reached the primary renal composite endpoint compared to 39% and 41% in the placebo and amlodipine groups [20% relative risk reduction versus placebo (p = 0.024) and 23% relative risk reduction compared to amlodipine (p = 0.006)]. When the individual components of the primary endpoint were analysed, no effect in all cause mortality was observed, while a positive trend in the reduction in ESRD and a significant reduction in doubling of serum creatinine were observed.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB" style="layout-grid-mode:line">Subgroups consisting of gender, race, age, duration of diabetes, baseline blood pressure, serum creatinine, and albumin excretion rate were assessed for treatment effect. In the female and black subgroups which represented 32% and 26% of the overall study population respectively, a renal benefit was not evident, </span>although the confidence intervals do not exclude it. As for the secondary endpoint of fatal and non-fatal cardiovascular events, there was no difference among the three groups in the overall population, although an increased incidence of non-fatal MI was seen for women and a decreased incidence of non-fatal MI was seen in males in the irbesartan group versus the placebo-based regimen. An increased incidence of non-fatal MI and stroke was seen in females in the irbesartan-based regimen versus the amlodipine-based regimen, while hospitalization due to heart failure was reduced in the overall population. However, no proper explanation for these findings in women has been identified.</p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">The study of the “Effects of Irbesartan on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus (IRMA 2)” shows that irbesartan 300 mg delays progression to overt proteinuria in patients with microalbuminuria. IRMA 2 was a placebo-controlled double blind morbidity study in 590 patients with type 2 diabetes, microalbuminuria (30-300 mg/day) and normal renal function (serum creatinine ≤ 1.5 mg/dl in males and &lt; 1.1 mg/dl in females). The study examined the long-term effects (2 years) of Karvea on the progression to clinical (overt) proteinuria (urinary albumin excretion rate (UAER) &gt; 300 mg/day, and an increase in UAER of at least 30% from baseline). The predefined blood pressure goal was ≤ 135/85 mmHg. Additional antihypertensive agents (excluding ACE inhibitors, angiotensin II receptor antagonists and dihydropyridine calcium blockers) were added as needed to help achieve the blood pressure goal. While similar blood pressure was achieved in all treatment groups, fewer subjects in the irbesartan 300 mg group (5.2%) than in the placebo (14.9%) or in the irbesartan 150 mg group (9.7%) reached the endpoint of overt proteinuria, demonstrating a 70% relative risk reduction versus placebo (p = 0.0004) for the higher dose. An accompanying improvement in the glomerular filtration rate (GFR) was not observed during the first three months of treatment. The slowing in the progression to clinical proteinuria was evident as early as three months and continued over the 2 year period. Regression to normoalbuminuria (&lt; 30 mg/day) was more frequent in the Karvea 300 mg group (34%) than in the placebo group (21%).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><i><span lang="EN-GB">Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</span></i></p><p class="EMEABodyText"><span lang="EN-GB">Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker. ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.</span></p><p class="EMEABodyText"><span lang="EN-GB">ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group that in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.2     Pharmacokinetic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Absorption</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">After oral administration, irbesartan is well absorbed: studies of absolute bioavailability gave values of approximately 60-80%. Concomitant food intake does not significantly influence the bioavailability of irbesartan. </span></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Distribution</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Plasma protein binding is approximately 96%, with negligible binding to cellular blood components. The volume of distribution is 53 - 93 litres. </span></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Biotransformation</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Following oral or intravenous administration of <sup><span style="position:relative; top:-1.0pt">14</span></sup>C irbesartan, 80-85% of the circulating plasma radioactivity is attributable to unchanged irbesartan. Irbesartan is metabolised by the liver via glucuronide conjugation and oxidation. The major circulating metabolite is irbesartan glucuronide (approximately 6%). <i>In vitro</i> studies indicate that irbesartan is primarily oxidised by the cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Linearity/non-linearity</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg. A less than proportional increase in oral absorption at doses beyond 600 mg (twice the maximal recommended dose) was observed; the mechanism for this is unknown. Peak plasma concentrations are attained at 1.5 - 2 hours after oral administration. The total body and renal clearance are 157 - 176 and 3 - 3.5 ml/min, respectively. The terminal elimination half-life of irbesartan is 11 - 15 hours. Steady-state plasma concentrations are attained within 3 days after initiation of a once-daily dosing regimen. Limited accumulation of irbesartan (&lt; 20%) is observed in plasma upon repeated once-daily dosing. In a study, somewhat higher plasma concentrations of irbesartan were observed in female hypertensive patients. However, there was no difference in the half-life and accumulation of irbesartan. No dosage adjustment is necessary in female patients. Irbesartan AUC and C<span class="EMEASubscript">max</span> values were also somewhat greater in older subjects (≥ 65 years) than those of young subjects (18 - 40 years). However the terminal half-life was not significantly altered. No dosage adjustment is necessary in older people.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Elimination</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Irbesartan and its metabolites are eliminated by both biliary and renal pathways. After either oral or IV administration of <sup><span style="position:relative;top:-1.0pt">14</span></sup>C irbesartan, about 20% of the radioactivity is recovered in the urine, and the remainder in the faeces. Less than 2% of the dose is excreted in the urine as unchanged irbesartan.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText"><span lang="EN-GB">The pharmacokinetics of irbesartan were evaluated in 23 hypertensive children after the administration of single and multiple daily doses of irbesartan (2 mg/kg) up to a maximum daily dose of 150 mg for four weeks. Of those 23 children, 21 were evaluable for comparison of pharmacokinetics with adults (twelve children over 12 years, nine children between 6 and 12 years). Results showed that C<span class="EMEASubscript">max</span>, AUC and clearance rates were comparable to those observed in adult patients receiving 150 mg irbesartan daily. A limited accumulation of irbesartan (18%) in plasma was observed upon repeated once daily dosing.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Renal impairment</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">In patients with renal impairment or those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan are not significantly altered. Irbesartan is not removed by haemodialysis.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Hepatic impairment</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">In patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly altered. </span></p><p class="EMEABodyText"><span lang="EN-GB">Studies have not been performed in patients with severe hepatic impairment.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.3Preclinical safety data"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">There was no evidence of abnormal systemic or target organ toxicity at clinically relevant doses. In non-clinical safety studies, high doses of irbesartan (≥ 250 mg/kg/day in rats and ≥ 100 mg/kg/day in macaques) caused a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit). At very high doses (≥ 500 mg/kg/day) degenerative changes in the kidney (such as interstitial nephritis, tubular distension, basophilic tubules, increased plasma concentrations of urea and creatinine) were induced by irbesartan in the rat and the macaque and are considered secondary to the hypotensive effects of the medicinal product which led to decreased renal perfusion. Furthermore, irbesartan induced hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at ≥ 90 mg/kg/day, in macaques at ≥ 10 mg/kg/day). All of these changes were considered to be caused by the pharmacological action of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia/ hypertrophy of the renal juxtaglomerular cells does not appear to have any relevance.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">There was no evidence of mutagenicity, clastogenicity or carcinogenicity.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Fertility and reproductive performance were not affected in studies of male and female rats even at oral doses of irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), including mortality at the highest dose. No significant effects on the number of corpora lutea, implants, or live foetuses were observed. Irbesartan did not affect survival, development, or reproduction of offspring. Studies in animals indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses. Irbesartan is excreted in the milk of lactating rats.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Animal studies with irbesartan showed transient toxic effects (increased renal pelvic cavitation, hydroureter or subcutaneous oedema) in rat foetuses, which were resolved after birth. In rabbits, abortion or early resorption were noted at doses causing significant maternal toxicity, including mortality. No teratogenic effects were observed in the rat or rabbit.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="6.       PHARMACEUTICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="6.1     List of excipients"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Tablet core:</span></p><p class="EMEABodyText"><span lang="IT">Lactose monohydrate</span></p><p class="EMEABodyText"><span lang="IT">Microcrystalline cellulose</span></p><p class="EMEABodyText"><span lang="IT">Croscarmellose sodium</span></p><p class="EMEABodyText"><span lang="IT">Hypromellose</span></p><p class="EMEABodyText"><span lang="IT">Silicon dioxide</span></p><p class="EMEABodyText"><span lang="IT">Magnesium stearate.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="IT">Film-coating:</span></p><p class="EMEABodyText"><span lang="IT">Lactose monohydrate</span></p><p class="EMEABodyText"><span lang="IT">Hypromellose</span></p><p class="EMEABodyText"><span lang="IT">Titanium dioxide</span></p><p class="EMEABodyText"><span lang="IT">Macrogol 3000</span></p><p class="EMEABodyText"><span lang="IT">Carnauba wax.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.2     Incompatibilities"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><span lang="EN-GB">Not applicable.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.3     Shelf life"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><span lang="EN-GB">3 years.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.4     Special precautions for storage"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><span lang="EN-GB">Do not store above 30°C.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.5     Nature and contents of container"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><span lang="EN-GB">Cartons of 14 film-coated tablets in PVC/PVDC/Aluminium blisters.<br/> Cartons of 28 film-coated tablets in PVC/PVDC/Aluminium blisters.</span></p><p class="EMEABodyText"><span lang="EN-GB">Cartons of 30</span><span lang="EN-GB"> film-coated tablets in PVC/PVDC/Aluminium blisters.</span></p><p class="EMEABodyText"><span lang="EN-GB">Cartons of 56 film-coated tablets in PVC/PVDC/Aluminium blisters.<br/> Cartons of 84 film-coated tablets in PVC/PVDC/Aluminium blisters.</span></p><p class="EMEABodyText"><span lang="EN-GB">Cartons of 90</span><span lang="EN-GB"> film-coated tablets in PVC/PVDC/Aluminium blisters.</span></p><p class="EMEABodyText"><span lang="EN-GB">Cartons of 98 film-coated tablets in PVC/PVDC/Aluminium blisters.<br/> Cartons of 56 x 1 film-coated tablet in PVC/PVDC/Aluminium perforated unit dose blisters.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Not all pack sizes may be marketed.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.6     Special precautions for disposal"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><span lang="EN-GB">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="7.       MARKETING AUTHORISATION HOLDER"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEAAddress"><span lang="FR">sanofi-aventis groupe<br/> 54, rue La Boétie<br/> F-75008 Paris - France</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="8.       MARKETING AUTHORISATION NUMBERS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEABodyText"><span lang="SL">EU/1/97/049/016-020<br/> EU/1/97/049/031<br/> EU/1/97/049/034<br/> EU/1/97/049/037</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="9.       DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEABodyText"><span lang="EN-GB">Date of first authorisation: 27 August 1997<br/> Date of latest renewal: 27 August 2007</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="10.     DATE OF REVISION OF THE TEXT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu</span></p><b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; text-transform:uppercase'><br clear="all" style="page-break-before:always"/> </span></b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; text-transform:uppercase'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
	
		
		
    	    
				
			    
						
		               
<section>
			<title value="1.       NAME OF THE MEDICINAL PRODUCT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEABodyText"><span lang="EN-GB">Karvea 150 mg film-coated tablets.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="2.       QUALITATIVE AND QUANTITATIVE COMPOSITION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEABodyText"><span lang="EN-GB">Each film-coated tablet contains 150 mg of irbesartan.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Excipient with known effect</span></u><span lang="EN-GB">: 51.00 mg of lactose monohydrate per film-coated tablet.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">For the full list of excipients, see section 6.1.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="3.       PHARMACEUTICAL FORM"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Film-coated tablet.</span></p><p class="EMEABodyText"><span lang="EN-GB">White to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2872 engraved on the other side.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="4.       CLINICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="4.1     Therapeutic indications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Karvea is indicated in adults for the treatment of essential hypertension.</span></p><p class="EMEABodyText"><span lang="EN-GB">It is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen (see sections 4.3, 4.4, 4.5 and 5.1).</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.2     Posology and method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Posology</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">The usual recommended initial and maintenance dose is 150 mg once daily, with or without food. Karvea at a dose of 150 mg once daily generally provides a better 24 hour blood pressure control than 75 mg. However, initiation of therapy with 75 mg could be considered, particularly in haemodialysed patients and in the elderly over 75 years.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">In patients insufficiently controlled with 150 mg once daily, the dose of Karvea can be increased to 300 mg, or other antihypertensive agents can be added (see sections 4.3, 4.4, 4.5 and 5.1). In particular, the addition of a diuretic such as hydrochlorothiazide has been shown to have an additive effect with Karvea (see section 4.5).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">In hypertensive type 2 diabetic patients, therapy should be initiated at 150 mg irbesartan once daily and titrated up to 300 mg once daily as the preferred maintenance dose for treatment of renal disease.</span></p><p class="EMEABodyText"><span lang="EN-GB">The demonstration of renal benefit of Karvea in hypertensive type 2 diabetic patients is based on studies where irbesartan was used in addition to other antihypertensive agents, as needed, to reach target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Special Populations</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText"><i><span lang="EN-GB">Renal impairment</span></i></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">No dosage adjustment is necessary in patients with impaired renal function. A lower starting dose (75 mg) should be considered for patients undergoing haemodialysis (see section 4.4).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><i><span lang="EN-GB">Hepatic impairment</span></i></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. There is no clinical experience in patients with severe hepatic impairment.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><i><span lang="EN-GB">Older people</span></i></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Although consideration should be given to initiating therapy with 75 mg in patients over 75 years of age, dosage adjustment is not usually necessary forolder people.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><i><span lang="EN-GB">Paediatric population</span></i></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">The safety and efficacy of Karvea in children aged 0 to 18 has not been established. Currently available data are described in section 4.8, 5.1 and 5.2 but no recommendation on a posology can be made.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Method of Administration</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">For oral use.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.3     Contraindications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.</span></p><p class="EMEABodyText"><span lang="EN-GB">Second and third trimesters of pregnancy (see sections 4.4 and 4.6).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">The concomitant use of Karvea with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (glomerular filtration rate (GFR) &lt;60 ml/min/1.73m<sup>2</sup>) (see sections 4.5 and 5.1).</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.4     Special warnings and precautions for use"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Intravascular volume depletion</span></u><span lang="EN-GB">: symptomatic hypotension, especially after the first dose, may occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting. Such conditions should be corrected before the administration of Karvea.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Renovascular hypertension</span></u><span lang="EN-GB">: there is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with medicinal products that affect the renin-angiotensin-aldosterone system. While this is not documented with Karvea, a similar effect should be anticipated with angiotensin-II receptor antagonists.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Renal impairment and kidney transplantation</span></u><span lang="EN-GB">: when Karvea is used in patients with impaired renal function, a periodic monitoring of potassium and creatinine serum levels is recommended. There is no experience regarding the administration of Karvea in patients with a recent kidney transplantation.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Hypertensive patients with type 2 diabetes and renal disease</span></u><span lang="EN-GB">:</span><span lang="EN-GB" style="layout-grid-mode:line"> the effects of irbesartan both on renal and cardiovascular events were not uniform across all subgroups, in an analysis carried out in the study with patients with advanced renal disease. In particular, they appeared less favourable in women and non-white subjects (see section 5.1).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Dual blockade of the renin-angiotensin-aldosterone system (RAAS): t</span></u><span lang="EN-GB">here is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).  If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Hyperkalaemia</span></u><span lang="EN-GB">: as with other medicinal products that affect the renin-angiotensin-aldosterone system, hyperkalaemia may occur during the treatment with Karvea, especially in the presence of renal impairment, overt proteinuria due to diabetic renal disease, and/or heart failure. Close monitoring of serum potassium in patients at risk is recommended (see section 4.5).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Hypoglycaemia</span></u><span lang="EN-GB">: Karvea may induce hypoglycaemia, particularly in diabetic patients. In patients treated with insulin or antidiabetics an appropriate blood glucose monitoring should be considered; a dose adjustment of insulin or antidiabetics may be required when indicated (see section 4.5).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Lithium</span></u><span lang="EN-GB">: the combination of lithium and Karvea is not recommended (see section 4.5).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy</span></u><span lang="EN-GB">: as with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Primary aldosteronism</span></u><span lang="EN-GB">: patients with primary aldosteronism generally will not respond to antihypertensive medicinal products acting through inhibition of the renin-angiotensin system. Therefore, the use of Karvea is not recommended.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">General</span></u><span lang="EN-GB">: in patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with angiotensinconverting enzyme inhibitors or angiotensin-II receptor antagonists that affect this system has been associated with acute hypotension, azotaemia, oliguria, or rarely acute renal failure (see section 4.5). As with any antihypertensive agent, excessive blood pressure decrease in patients with ischaemic cardiopathy or ischaemic cardiovascular disease could result in a myocardial infarction or stroke.</span></p><p class="EMEABodyText"><span lang="EN-GB">As observed for angiotensin converting enzyme inhibitors, irbesartan and the other angiotensin antagonists are apparently less effective in lowering blood pressure in black people than in non-blacks, possibly because of higher prevalence of low-renin states in the black hypertensive population (see section 5.1).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Pregnancy:</span></u><span lang="EN-GB"> angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. </span><span lang="EN-GB">Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with </span><span lang="EN-GB">AIIRAs</span><span lang="EN-GB"> should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</span></p><p class="EMEABodyText"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Paediatric population</span></u><span lang="EN-GB">: irbesartan has been studied in paediatric populations aged 6 to 16 years old but the current data are insufficient to support an extension of the use in children until further data become available (see sections 4.8, 5.1 and 5.2).</span></p><p class="EMEABodyText"></p><p class="MsoNormal"><u><span lang="EN-GB">Excipients</span></u><span lang="FR">:</span></p><p class="EMEABodyText"><span lang="EN-GB">Karvea 150 mg film-coated tablet contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="FR">Karvea 150 mg fil -coated tablet contains sodium. </span><span lang="EN-GB">This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.5     Interaction with other medicinal products and other forms of interaction"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><u><span lang="EN-GB">Diuretics and other antihypertensive agents</span></u><span lang="EN-GB">: other antihypertensive agents may increase the hypotensive effects of irbesartan; however Karvea has been safely administered with other antihypertensive agents, such as beta-blockers, long-acting calcium channel blockers, and thiazide diuretics. Prior treatment with high dose diuretics may result in volume depletion and a risk of hypotension when initiating therapy with Karvea (see section 4.4).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Aliskiren-containing products or ACE-inhibitors</span></u><span lang="EN-GB">: clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Potassium supplements and potassium-sparing diuretics</span></u><span lang="EN-GB">:based on experience with the use of other medicinal products that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium and is, therefore, not recommended (see section 4.4).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Lithium</span></u><span lang="EN-GB">:reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors. Similar effects have been very rarely reported with irbesartan so far. Therefore, this combination is not recommended (see section 4.4). If the combination proves necessary, careful monitoring of serum lithium levels is recommended.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Non-steroidal anti-inflammatory drugs</span></u><span lang="EN-GB">: <span style="color:black">when angiotensin II antagonists are administered simultaneously with non-steroidal anti-inflammatory drugs (i.e. selective COX-2 inhibitors, acetylsalicylic acid (&gt; 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.</span></span></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">As with ACE inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function. The combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Repaglinide:</span></u><span lang="EN-GB" style="color:black"> irbesartan has the potential to inhibit OATP1B1. In a clinical study, it was reported that irbesartan increased the C<sub>max</sub> and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3‑fold, respectively, when administered 1 hour before repaglinide. In another study, no relevant pharmacokinetic interaction was reported, when the two drugs were co-administered. Therefore, dose adjustment of antidiabetic treatment such as repaglinide may be required (see section 4.4).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Additional information on irbesartan interactions</span></u><span lang="EN-GB">: <span style="color:black">in clinical studies, the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic interactions were observed when irbesartan was coadministered with warfarin, a medicinal product metabolised by CYP2C9. The effects of CYP2C9 inducers such as rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The pharmacokinetic of digoxin was not altered by coadministration of irbesartan.</span></span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.6     Fertility, pregnancy and lactation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Pregnancy</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks may exist for this class of drugs. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Exposure to AIIRA therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).</span></p><p class="EMEABodyText"><span lang="EN-GB">Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.</span></p><p class="EMEABodyText"><span lang="EN-GB">Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3 and 4.4).</span></p><p class="EMEABodyText"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Breast-feeding</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText"><span lang="EN-GB">Because no information is available regarding the use of Karvea during breast-feeding, Karvea is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">It is unknown whether irbesartan or its metabolites are excreted in human milk. </span></p><p class="EMEABodyText"><span lang="EN-GB">Available pharmacodynamic/toxicological data in rats have shown excretion of irbesartan or its metabolites in milk (for details see 5.3).</span></p><p class="EMEABodyText"> </p><p class="EMEABodyText"><u><span lang="EN-GB">Fertility</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText">Irbesartan had no effect upon fertility of treated rats and their offspring up to the dose levels inducing the first signs of parental toxicity (see section 5.3). </p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.7     Effects on ability to drive and use machines"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <div style="border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt"> <p class="EMEABodyText" style="border:none;padding:0in"><span lang="EN-GB">The use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4). The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 and 4.4).</span></p> </div><p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Based on its pharmacodynamic properties, irbesartan is unlikely to affect the ability to drive and use machines. When driving vehicles or operating machines, it should be taken into account that dizziness or weariness may occur during treatment.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.8     Undesirable effects"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><span lang="EN-GB">In placebo-controlled trials in patients with hypertension, the overall incidence of adverse events did not differ between the irbesartan (56.2%) and the placebo groups (56.5%). Discontinuation due to any clinical or laboratory adverse event was less frequent for irbesartan-treated patients (3.3%) than for placebo-treated patients (4.5%). The incidence of adverse events was not related to dose (in the recommended dose range), gender, age, race, or duration of treatment.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">In diabetic hypertensive patients with microalbuminuria and normal renal function, orthostatic dizziness and orthostatic hypotension were reported in 0.5% of the patients (i.e., uncommon) but in excess of placebo.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">The following table presents the adverse drug reactions that were reported in placebo-controlled trials in which 1,965 hypertensive patients received irbesartan. Terms marked with a star (*) refer to the adverse reactions that were additionally reported in &gt; 2% of diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria and in excess of placebo.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">The frequency of adverse reactions listed below is defined using the following convention:</span></p><p class="EMEABodyText"><span lang="EN-GB">very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to &lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Adverse reactions additionally reported from post–marketing experience are also listed. These adverse reactions are derived from spontaneous reports.</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Blood and lymphatic system disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       anaemia, thrombocytopenia</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Immune system disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       hypersensitivity reactions such as angioedema, rash, urticaria, anaphylactic reaction, anaphylactic shock</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Metabolism and nutrition disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       hyperkalaemia, hypoglycaemia</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Nervous system disorders</span></u></p><p class="EMEABodyText"><span lang="EN-GB">Common:         dizziness, orthostatic dizziness*</span></p><p class="EMEABodyText"><span lang="EN-GB">Not known:       vertigo, headache</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Ear and labyrinth disorder</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       tinnitus</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Cardiac disorders</span></u></p><p class="EMEABodyText"><span lang="EN-GB">Uncommon:      tachycardia</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Vascular disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Common:         orthostatic hypotension*</span></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Uncommon:      flushing</span></p><p class="EMEABodyText"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Respiratory, thoracic and mediastinal disorders</span></u></p><p class="EMEABodyText"><span lang="EN-GB">Uncommon:      cough</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Gastrointestinal disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Common:         nausea/vomiting</span></p><p class="EMEABodyText"><span lang="EN-GB">Uncommon:      diarrhoea, dyspepsia/heartburn</span></p><p class="EMEABodyText"><span lang="EN-GB">Not known:       dysgeusia</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Hepatobiliary disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Uncommon:      jaundice</span></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       hepatitis, abnormal liver function</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Skin and subcutaneous tissue disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       leukocytoclastic vasculitis</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Musculoskeletal and connective tissue disorders </span></u></p><p class="EMEABodyText"><span lang="EN-GB">Common:         musculoskeletal pain*</span></p><p class="EMEABodyText" style="margin-left:1.0in;text-indent:-1.0in"><span lang="EN-GB">Not known:       arthralgia, myalgia (in some cases associated with increased plasma creatine kinase levels), muscle cramps</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Renal and urinary disorders</span></u></p><p class="EMEABodyText" style="margin-left:1.0in;text-indent:-1.0in;page-break-after: avoid"><span lang="EN-GB">Not known:       impaired renal function including cases of renal failure in patients at risk (see section 4.4)</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="text-align:justify;page-break-after:avoid"><u><span lang="EN-GB">Reproductive system and breast disorders</span></u></p><p class="EMEABodyText"><span lang="EN-GB">Uncommon:      sexual dysfunction</span></p><p class="EMEABodyText" style="text-align:justify"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">General disorders and administration site conditions</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Common:         fatigue</span></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Uncommon:      chest pain</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Investigations</span></u></p><p class="EMEABodyText" style="margin-left:1.0in;text-indent:-1.0in"><span lang="EN-GB">Very common:  Hyperkalaemia* occurred more often in diabetic patients treated with irbesartan than with placebo. In diabetic hypertensive patients with microalbuminuria and normal renal function, hyperkalaemia (≥ 5.5 mEq/L) occurred in 29.4% of the patients in the irbesartan 300 mg group and 22% of the patients in the placebo group. In diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria, hyperkalaemia (≥ 5.5 mEq/L) occurred in 46.3% of the patients in the irbesartan group and 26.3% of the patients in the placebo group.</span></p><p class="EMEABodyText" style="margin-left:1.0in;text-indent:-1.0in"><span lang="EN-GB">Common:         significant increases in plasma creatine kinase were commonly observed (1.7%) in irbesartan treated subjects. None of these increases were associated with identifiable clinical musculoskeletal events.<br/> In 1.7% of hypertensive patients with advanced diabetic renal disease treated with irbesartan, a decrease in haemoglobin*, which was not clinically significant, has been observed.</span></p><p class="EMEABodyText"><i><u><span lang="EN-GB"></span></u></i></p><p class="EMEABodyText"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">I</span><span lang="EN-GB">n a randomised trial of 318 hypertensive children and adolescents aged 6 to 16 years, the following adverse reactions occurred in the 3-week double-blind phase: headache (7.9%), hypotension (2.2%), dizziness (1.9%), cough (0.9%). In the 26-week open-label period of this trial the most frequent laboratory abnormalities observed were creatinine increases (6.5%) and elevated CK values in 2% of child recipients.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Reporting of suspected adverse reactions </span></u></p><p class="EMEABodyText"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText"><span lang="EN-GB">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via <span style="background:silver">the national reporting system listed in Appendix V.</span> </span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.9     Overdose"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Experience in adults exposed to doses of up to 900 mg/day for 8 weeks revealed no toxicity. The most likely manifestations of overdose are expected to be hypotension and tachycardia; bradycardia might also occur from overdose. No specific information is available on the treatment of overdose with Karvea. The patient should be closely monitored, and the treatment should be symptomatic and supportive. Suggested measures include induction of emesis and/or gastric lavage. Activated charcoal may be useful in the treatment of overdose. Irbesartan is not removed by haemodialysis.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="5.       PHARMACOLOGICAL PROPERTIES"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="5.1     Pharmacodynamic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><span lang="EN-GB">Pharmacotherapeutic group: Angiotensin-II antagonists, plain.</span></p><p class="EMEABodyText"><span lang="EN-GB">ATC code: C09C A04.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Mechanism of action</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Irbesartan is a potent, orally active, selective angiotensin-II receptor (type AT<sub>1</sub>) antagonist. It is expected to block all actions of angiotensin-II mediated by the AT<sub>1</sub> receptor, regardless of the source or route of synthesis of angiotensin-II. The selective antagonism of the angiotensin-II (AT<sub>1</sub>) receptors results in increases in plasma renin levels and angiotensin-II levels, and a decrease in plasma aldosterone concentration. Serum potassium levels are not significantly affected by irbesartan alone at the recommended doses. Irbesartan does not inhibit ACE (kininase-II), an enzyme which generates angiotensin-II and also degrades bradykinin into inactive metabolites. Irbesartan does not require metabolic activation for its activity.</span></p><p class="EMEABodyText"></p><p class="EMEAHeading2"><u><span lang="EN-GB" style="font-weight:normal">Clinical efficacy</span></u></p><p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><i><span lang="EN-GB">Hypertension</span></i></p><p class="EMEABodyText"><span lang="EN-GB">Irbesartan lowers blood pressure with minimal change in heart rate. The decrease in blood pressure is dose-related for once a day doses with a tendency towards plateau at doses above 300 mg. Doses of 150-300 mg once daily lower supine or seated blood pressures at trough (i.e. 24 hours after dosing) by an average of 8-13/5-8 mm Hg (systolic/diastolic) greater than those associated with placebo.</span></p><p class="EMEABodyText"><span lang="EN-GB">Peak reduction of blood pressure is achieved within 3-6 hours after administration and the blood pressure lowering effect is maintained for at least 24 hours. At 24 hours the reduction of blood pressure was 60-70% of the corresponding peak diastolic and systolic responses at the recommended doses. Once daily dosing with 150 mg produced trough and mean 24 hour responses similar to twice daily dosing on the same total dose.</span></p><p class="EMEABodyText"><span lang="EN-GB">The blood pressure lowering effect of Karvea is evident within 1-2 weeks, with the maximal effect occurring by 4-6 weeks after start of therapy. The antihypertensive effects are maintained during long term therapy. After withdrawal of therapy, blood pressure gradually returns toward baseline. Rebound hypertension has not been observed.</span></p><p class="EMEABodyText"><span lang="EN-GB">The blood pressure lowering effects of irbesartan and thiazide-type diuretics are additive. In patients not adequately controlled by irbesartan alone, the addition of a low dose of hydrochlorothiazide (12.5 mg) to irbesartan once daily results in a further placebo-adjusted blood pressure reduction at trough of 7-10/3-6 mm Hg (systolic/diastolic).</span></p><p class="EMEABodyText"><span lang="EN-GB">The efficacy of Karvea is not influenced by age or gender. As is the case with other medicinal products that affect the renin-angiotensin system, black hypertensive patients have notably less response to irbesartan monotherapy. When irbesartan is administered concomitantly with a low dose of hydrochlorothiazide (e.g. 12.5 mg daily), the antihypertensive response in black patients approaches that of white patients.</span></p><p class="EMEABodyText"><span lang="EN-GB">There is no clinically important effect on serum uric acid or urinary uric acid secretion.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText"><span lang="EN-GB">Reduction of blood pressure with 0.5 mg/kg (low), 1.5 mg/kg (medium) and 4.5 mg/kg (high) target titrated doses of irbesartan was evaluated in 318 hypertensive or at risk (diabetic, family history of hypertension) children and adolescents aged 6 to 16 years over a three week period. At the end of the three weeks the mean reduction from baseline in the primary efficacy variable, trough seated systolic blood pressure (SeSBP) was 11.7 mmHg (low dose), 9.3 mmHg (medium dose), 13.2 mmHg (high dose). No significant difference was apparent between these doses. Adjusted mean change of trough seated diastolic blood pressure (SeDBP) was as follows: 3.8 mmHg (low dose), 3.2 mmHg (medium dose), 5.6 mmHg (high dose). Over a subsequent two week period where patients were re-randomized to either active medicinal product or placebo, patients on placebo had increases of 2.4 and 2.0 mmHg in SeSBP and SeDBP compared to +0.1 and -0.3 mmHg changes respectively in those on all doses of irbesartan (see section 4.2).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><i><span lang="EN-GB">Hypertension and type 2 diabetes with renal disease</span></i></p><p class="EMEABodyText"><span lang="EN-GB">The “Irbesartan Diabetic Nephropathy Trial (IDNT)” shows that irbesartan decreases the progression of renal disease in patients with chronic renal insufficiency and overt proteinuria. IDNT was a double blind, controlled, morbidity and mortality trial comparing Karvea, amlodipine and placebo. In 1,715 hypertensive patients with type 2 diabetes, proteinuria ≥ 900 mg/day and serum creatinine ranging from 1.0-3.0 mg/dl, the long-term effects (mean 2.6 years) of Karvea on the progression of renal disease and all-cause mortality were examined. Patients were titrated from 75 mg to a maintenance dose of 300 mg Karvea</span><span lang="EN-GB" style='font-family:"Times",serif'>, from 2.5 mg to 10 mg amlodipine, or placebo</span><span lang="EN-GB"> as tolerated. Patients in all treatment groups typically received between 2 and 4 antihypertensive agents (e.g., diuretics, beta blockers, alpha blockers) to reach a predefined blood pressure goal of ≤ 135/85 mmHg or a 10 mmHg reduction in systolic pressure if baseline was &gt; 160 mmHg. Sixty per cent (60%) of patients in the placebo group reached this target blood pressure whereas this figure was 76% and 78% in the irbesartan and amlodipine groups respectively. Irbesartan significantly reduced the relative risk in the primary combined endpoint of doubling serum creatinine, end-stage renal disease (ESRD) or all-cause mortality. Approximately 33% of patients in the irbesartan group reached the primary renal composite endpoint compared to 39% and 41% in the placebo and amlodipine groups [20% relative risk reduction versus placebo (p = 0.024) and 23% relative risk reduction compared to amlodipine (p = 0.006)]. When the individual components of the primary endpoint were analysed, no effect in all cause mortality was observed, while a positive trend in the reduction in ESRD and a significant reduction in doubling of serum creatinine were observed.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB" style="layout-grid-mode:line">Subgroups consisting of gender, race, age, duration of diabetes, baseline blood pressure, serum creatinine, and albumin excretion rate were assessed for treatment effect. In the female and black subgroups which represented 32% and 26% of the overall study population respectively, a renal benefit was not evident, </span>although the confidence intervals do not exclude it. As for the secondary endpoint of fatal and non-fatal cardiovascular events, there was no difference among the three groups in the overall population, although an increased incidence of non-fatal MI was seen for women and a decreased incidence of non-fatal MI was seen in males in the irbesartan group versus the placebo-based regimen. An increased incidence of non-fatal MI and stroke was seen in females in the irbesartan-based regimen versus the amlodipine-based regimen, while hospitalization due to heart failure was reduced in the overall population. However, no proper explanation for these findings in women has been identified.</p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">The study of the “Effects of Irbesartan on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus (IRMA 2)” shows that irbesartan 300 mg delays progression to overt proteinuria in patients with microalbuminuria. IRMA 2 was a placebo-controlled double blind morbidity study in 590 patients with type 2 diabetes, microalbuminuria (30-300 mg/day) and normal renal function (serum creatinine ≤ 1.5 mg/dl in males and &lt; 1.1 mg/dl in females). The study examined the long-term effects (2 years) of Karvea on the progression to clinical (overt) proteinuria (urinary albumin excretion rate (UAER) &gt; 300 mg/day, and an increase in UAER of at least 30% from baseline). The predefined blood pressure goal was ≤ 135/85 mmHg. Additional antihypertensive agents (excluding ACE inhibitors, angiotensin II receptor antagonists and dihydropyridine calcium blockers) were added as needed to help achieve the blood pressure goal. While similar blood pressure was achieved in all treatment groups, fewer subjects in the irbesartan 300 mg group (5.2%) than in the placebo (14.9%) or in the irbesartan 150 mg group (9.7%) reached the endpoint of overt proteinuria, demonstrating a 70% relative risk reduction versus placebo (p = 0.0004) for the higher dose. An accompanying improvement in the glomerular filtration rate (GFR) was not observed during the first three months of treatment. The slowing in the progression to clinical proteinuria was evident as early as three months and continued over the 2 year period. Regression to normoalbuminuria (&lt; 30 mg/day) was more frequent in the Karvea 300 mg group (34%) than in the placebo group (21%).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><i><span lang="EN-GB">Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</span></i></p><p class="EMEABodyText"><span lang="EN-GB">Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker. ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</span></p><p class="EMEABodyText"><span lang="EN-GB">These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.</span></p><p class="EMEABodyText"><span lang="EN-GB">ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</span></p><p class="EMEABodyText"><span lang="EN-GB">ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.2     Pharmacokinetic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Absorption</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">After oral administration, irbesartan is well absorbed: studies of absolute bioavailability gave values of approximately 60-80%. Concomitant food intake does not significantly influence the bioavailability of irbesartan. </span></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Distribution</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Plasma protein binding is approximately 96%, with negligible binding to cellular blood components. The volume of distribution is 53 - 93 litres. </span></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Biotransformation</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Following oral or intravenous administration of <sup><span style="position:relative; top:-1.0pt">14</span></sup>C irbesartan, 80-85% of the circulating plasma radioactivity is attributable to unchanged irbesartan. Irbesartan is metabolised by the liver via glucuronide conjugation and oxidation. The major circulating metabolite is irbesartan glucuronide (approximately 6%). <i>In vitro</i> studies indicate that irbesartan is primarily oxidised by the cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Linearity / non-linearity</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg. A less than proportional increase in oral absorption at doses beyond 600 mg (twice the maximal recommended dose) was observed; the mechanism for this is unknown. Peak plasma concentrations are attained at 1.5 - 2 hours after oral administration. The total body and renal clearance are 157 - 176 and 3 - 3.5 ml/min, respectively. The terminal elimination half-life of irbesartan is 11 - 15 hours. Steady-state plasma concentrations are attained within 3 days after initiation of a once-daily dosing regimen. Limited accumulation of irbesartan (&lt; 20%) is observed in plasma upon repeated once-daily dosing. In a study, somewhat higher plasma concentrations of irbesartan were observed in female hypertensive patients. However, there was no difference in the half-life and accumulation of irbesartan. No dosage adjustment is necessary in female patients. Irbesartan AUC and C<span class="EMEASubscript">max</span> values were also somewhat greater in older subjects (≥ 65 years) than those of young subjects (18 - 40 years). However the terminal half-life was not significantly altered. No dosage adjustment is necessary in older people.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Elimination</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Irbesartan and its metabolites are eliminated by both biliary and renal pathways. After either oral or IV administration of <sup><span style="position:relative;top:-1.0pt">14</span></sup>C irbesartan, about 20% of the radioactivity is recovered in the urine, and the remainder in the faeces. Less than 2% of the dose is excreted in the urine as unchanged irbesartan.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText"><span lang="EN-GB">The pharmacokinetics of irbesartan were evaluated in 23 hypertensive children after the administration of single and multiple daily doses of irbesartan (2 mg/kg) up to a maximum daily dose of 150 mg for four weeks. Of those 23 children, 21 were evaluable for comparison of pharmacokinetics with adults (twelve children over 12 years, nine children between 6 and 12 years). Results showed that C<span class="EMEASubscript">max</span>, AUC and clearance rates were comparable to those observed in adult patients receiving 150 mg irbesartan daily. A limited accumulation of irbesartan (18%) in plasma was observed upon repeated once daily dosing.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Renal impairment</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">In patients with renal impairment or those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan are not significantly altered. Irbesartan is not removed by haemodialysis.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Hepatic impairment</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">In patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly altered. </span></p><p class="EMEABodyText"><span lang="EN-GB">Studies have not been performed in patients with severe hepatic impairment.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.3Preclinical safety data"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">There was no evidence of abnormal systemic or target organ toxicity at clinically relevant doses. In non-clinical safety studies, high doses of irbesartan (≥ 250 mg/kg/day in rats and ≥ 100 mg/kg/day in macaques) caused a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit). At very high doses (≥ 500 mg/kg/day) degenerative changes in the kidney (such as interstitial nephritis, tubular distension, basophilic tubules, increased plasma concentrations of urea and creatinine) were induced by irbesartan in the rat and the macaque and are considered secondary to the hypotensive effects of the medicinal product which led to decreased renal perfusion. Furthermore, irbesartan induced hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at ≥ 90 mg/kg/day, in macaques at ≥ 10 mg/kg/day). All of these changes were considered to be caused by the pharmacological action of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia/ hypertrophy of the renal juxtaglomerular cells does not appear to have any relevance.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">There was no evidence of mutagenicity, clastogenicity or carcinogenicity.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Fertility and reproductive performance were not affected in studies of male and female rats even at oral doses of irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), including mortality at the highest dose. No significant effects on the number of corpora lutea, implants, or live foetuses were observed. Irbesartan did not affect survival, development, or reproduction of offspring. Studies in animals indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses. Irbesartan is excreted in the milk of lactating rats.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Animal studies with irbesartan showed transient toxic effects (increased renal pelvic cavitation, hydroureter or subcutaneous oedema) in rat foetuses, which were resolved after birth. In rabbits, abortion or early resorption were noted at doses causing significant maternal toxicity, including mortality. No teratogenic effects were observed in the rat or rabbit.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="6.       PHARMACEUTICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="6.1     List of excipients"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Tablet core:</span></p><p class="EMEABodyText"><span lang="IT">Lactose monohydrate</span></p><p class="EMEABodyText"><span lang="IT">Microcrystalline cellulose</span></p><p class="EMEABodyText"><span lang="IT">Croscarmellose sodium</span></p><p class="EMEABodyText"><span lang="IT">Hypromellose</span></p><p class="EMEABodyText"><span lang="IT">Silicon dioxide</span></p><p class="EMEABodyText"><span lang="IT">Magnesium stearate.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="IT">Film-coating:</span></p><p class="EMEABodyText"><span lang="IT">Lactose monohydrate</span></p><p class="EMEABodyText"><span lang="IT">Hypromellose</span></p><p class="EMEABodyText"><span lang="IT">Titanium dioxide</span></p><p class="EMEABodyText"><span lang="IT">Macrogol 3000</span></p><p class="EMEABodyText"><span lang="IT">Carnauba wax.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.2     Incompatibilities"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><span lang="EN-GB">Not applicable.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.3     Shelf life"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><span lang="EN-GB">3 years.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.4     Special precautions for storage"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><span lang="EN-GB">Do not store above 30°C.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.5     Nature and contents of container"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><span lang="EN-GB">Cartons of 14 film-coated tablets in PVC/PVDC/Aluminium blisters.<br/> Cartons of 28 film-coated tablets in PVC/PVDC/Aluminium blisters.</span></p><p class="EMEABodyText"><span lang="EN-GB">Cartons of 30</span><span lang="EN-GB"> film-coated tablets in PVC/PVDC/Aluminium blisters.</span></p><p class="EMEABodyText"><span lang="EN-GB">Cartons of 56 film-coated tablets in PVC/PVDC/Aluminium blisters.<br/> Cartons of 84 film-coated tablets in PVC/PVDC/Aluminium blisters.</span></p><p class="EMEABodyText"><span lang="EN-GB">Cartons of 90</span><span lang="EN-GB"> film-coated tablets in PVC/PVDC/Aluminium blisters.</span></p><p class="EMEABodyText"><span lang="EN-GB">Cartons of 98 film-coated tablets in PVC/PVDC/Aluminium blisters.<br/> Cartons of 56 x 1 film-coated tablet in PVC/PVDC/Aluminium perforated unit dose blisters.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Not all pack sizes may be marketed.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.6     Special precautions for disposal"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><span lang="EN-GB">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="7.       MARKETING AUTHORISATION HOLDER"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEAAddress"><span lang="FR">sanofi-aventis groupe<br/> 54, rue La Boétie<br/> F-75008 Paris - France</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="8.       MARKETING AUTHORISATION NUMBERS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEABodyText"><span lang="SL">EU/1/97/049/021-025<br/> EU/1/97/049/032<br/> EU/1/97/049/035<br/> EU/1/97/049/038</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="9.       DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEABodyText"><span lang="EN-GB">Date of first authorisation: 27 August 1997<br/> Date of latest renewal: 27 August 2007</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="10.     DATE OF REVISION OF THE TEXT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu</span></p><b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; text-transform:uppercase'><br clear="all" style="page-break-before:always"/> </span></b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; text-transform:uppercase'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
	
		
		
    	    
				
			    
						
		               
<section>
			<title value="1.       NAME OF THE MEDICINAL PRODUCT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEABodyText"><span lang="EN-GB">Karvea 300 mg film-coated tablets.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="2.       QUALITATIVE AND QUANTITATIVE COMPOSITION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEABodyText"><span lang="EN-GB">Each film-coated tablet contains 300 mg of irbesartan.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Excipient with known effect</span></u><span lang="EN-GB">: 102.00 mg of lactose monohydrate per film-coated tablet.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">For the full list of excipients, see section 6.1.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="3.       PHARMACEUTICAL FORM"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Film-coated tablet.</span></p><p class="EMEABodyText"><span lang="EN-GB">White to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2873 engraved on the other side.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="4.       CLINICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="4.1     Therapeutic indications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Karvea is indicated in adults for the treatment of essential hypertension.</span></p><p class="EMEABodyText"><span lang="EN-GB">It is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen (see sections 4.3, 4.4, 4.5 and 5.1).</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.2     Posology and method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Posology</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">The usual recommended initial and maintenance dose is 150 mg once daily, with or without food. Karvea at a dose of 150 mg once daily generally provides a better 24 hour blood pressure control than 75 mg. However, initiation of therapy with 75 mg could be considered, particularly in haemodialysed patients and in the elderly over 75 years.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">In patients insufficiently controlled with 150 mg once daily, the dose of Karvea can be increased to 300 mg, or other antihypertensive agents can be added (see sections 4.3, 4.4, 4.5 and 5.1). In particular, the addition of a diuretic such as hydrochlorothiazide has been shown to have an additive effect with Karvea (see section 4.5).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">In hypertensive type 2 diabetic patients, therapy should be initiated at 150 mg irbesartan once daily and titrated up to 300 mg once daily as the preferred maintenance dose for treatment of renal disease.</span></p><p class="EMEABodyText"><span lang="EN-GB">The demonstration of renal benefit of Karvea in hypertensive type 2 diabetic patients is based on studies where irbesartan was used in addition to other antihypertensive agents, as needed, to reach target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Special Populations</span></u></p><p class="EMEABodyText"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText"><i><span lang="EN-GB">Renal impairment</span></i></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">No dosage adjustment is necessary in patients with impaired renal function. A lower starting dose (75 mg) should be considered for patients undergoing haemodialysis (see section 4.4).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><i><span lang="EN-GB">Hepatic impairment</span></i></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. There is no clinical experience in patients with severe hepatic impairment.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><i><span lang="EN-GB">Older people</span></i></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Although consideration should be given to initiating therapy with 75 mg in patients over 75 years of age, dosage adjustment is not usually necessary forolder people.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><i><span lang="EN-GB">Paediatric population</span></i></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">The safety and efficacy of Karvea in children aged 0 to 18 has not been established. Currently available data are described in section 4.8, 5.1 and 5.2 but no recommendation on a posology can be made.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Method of Administration</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">For oral use.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.3     Contraindications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.</span></p><p class="EMEABodyText"><span lang="EN-GB">Second and third trimesters of pregnancy (see sections 4.4 and 4.6).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">The concomitant use of Karvea with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (glomerular filtration rate (GFR) &lt;60 ml/min/1.73m<sup>2</sup>) (see sections 4.5 and 5.1).</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.4     Special warnings and precautions for use"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Intravascular volume depletion</span></u><span lang="EN-GB">: symptomatic hypotension, especially after the first dose, may occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting. Such conditions should be corrected before the administration of Karvea.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Renovascular hypertension</span></u><span lang="EN-GB">: there is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with medicinal products that affect the renin-angiotensin-aldosterone system. While this is not documented with Karvea, a similar effect should be anticipated with angiotensin-II receptor antagonists.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Renal impairment and kidney transplantation</span></u><span lang="EN-GB">: when Karvea is used in patients with impaired renal function, a periodic monitoring of potassium and creatinine serum levels is recommended. There is no experience regarding the administration of Karvea in patients with a recent kidney transplantation.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Hypertensive patients with type 2 diabetes and renal disease</span></u><span lang="EN-GB">:</span><span lang="EN-GB" style="layout-grid-mode:line"> the effects of irbesartan both on renal and cardiovascular events were not uniform across all subgroups, in an analysis carried out in the study with patients with advanced renal disease. In particular, they appeared less favourable in women and non-white subjects (see section 5.1).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Dual blockade of the renin-angiotensin-aldosterone system (RAAS</span></u><span lang="EN-GB">): there is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).  If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Hyperkalaemia</span></u><span lang="EN-GB">: as with other medicinal products that affect the renin-angiotensin-aldosterone system, hyperkalaemia may occur during the treatment with Karvea, especially in the presence of renal impairment, overt proteinuria due to diabetic renal disease, and/or heart failure. Close monitoring of serum potassium in patients at risk is recommended (see section 4.5).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Hypoglycaemia</span></u><span lang="EN-GB">: Karvea may induce hypoglycaemia, particularly in diabetic patients. In patients treated with insulin or antidiabetics an appropriate blood glucose monitoring should be considered; a dose adjustment of insulin or antidiabetics may be required when indicated (see section 4.5).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Lithium</span></u><span lang="EN-GB">: the combination of lithium and Karvea is not recommended (see section 4.5).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy</span></u><span lang="EN-GB">: as with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Primary aldosteronism</span></u><span lang="EN-GB">: patients with primary aldosteronism generally will not respond to antihypertensive medicinal products acting through inhibition of the renin-angiotensin system. Therefore, the use of Karvea is not recommended.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">General</span></u><span lang="EN-GB">: in patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with angiotensinconverting enzyme inhibitors or angiotensin-II receptor antagonists that affect this system has been associated with acute hypotension, azotaemia, oliguria, or rarely acute renal failure (see section 4.5). As with any antihypertensive agent, excessive blood pressure decrease in patients with ischaemic cardiopathy or ischaemic cardiovascular disease could result in a myocardial infarction or stroke.</span></p><p class="EMEABodyText"><span lang="EN-GB">As observed for angiotensin converting enzyme inhibitors, irbesartan and the other angiotensin antagonists are apparently less effective in lowering blood pressure in black people than in non-blacks, possibly because of higher prevalence of low-renin states in the black hypertensive population (see section 5.1).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Pregnancy:</span></u><span lang="EN-GB"> angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. </span><span lang="EN-GB">Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with </span><span lang="EN-GB">AIIRAs</span><span lang="EN-GB"> should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</span></p><p class="EMEABodyText"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Paediatric population</span></u><span lang="EN-GB">: irbesartan has been studied in paediatric populations aged 6 to 16 years old but the current data are insufficient to support an extension of the use in children until further data become available (see sections 4.8, 5.1 and 5.2).</span></p><p class="EMEABodyText"></p><p class="MsoNormal"><u><span lang="EN-GB">Excipients</span></u><span lang="FR">:</span></p><p class="EMEABodyText"><span lang="EN-GB">Karvea 300 mg film-coated tablet contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Karvea 300 mg film-coated tablet contains sodium. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.5     Interaction with other medicinal products and other forms of interaction"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><u><span lang="EN-GB">Diuretics and other antihypertensive agents</span></u><span lang="EN-GB">: other antihypertensive agents may increase the hypotensive effects of irbesartan; however Karvea has been safely administered with other antihypertensive agents, such as beta-blockers, long-acting calcium channel blockers, and thiazide diuretics. Prior treatment with high dose diuretics may result in volume depletion and a risk of hypotension when initiating therapy with Karvea (see section 4.4).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Aliskiren-containing products or ACE-inhibitors</span></u><span lang="EN-GB">: clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Potassium supplements and potassium-sparing diuretics</span></u><span lang="EN-GB">:based on experience with the use of other medicinal products that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium and is, therefore, not recommended (see section 4.4).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Lithium</span></u><span lang="EN-GB">:reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors. Similar effects have been very rarely reported with irbesartan so far. Therefore, this combination is not recommended (see section 4.4). If the combination proves necessary, careful monitoring of serum lithium levels is recommended.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Non-steroidal anti-inflammatory drugs</span></u><span lang="EN-GB">: <span style="color:black">when angiotensin II antagonists are administered simultaneously with non-steroidal anti-inflammatory drugs (i.e. selective COX-2 inhibitors, acetylsalicylic acid (&gt; 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.</span></span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB" style="color:black">As with ACE inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function. The combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Repaglinide:</span></u><span lang="EN-GB" style="color:black"> irbesartan has the potential to inhibit OATP1B1. In a clinical study, it was reported that irbesartan increased the C<sub>max</sub> and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3‑fold, respectively, when administered 1 hour before repaglinide. In another study, no relevant pharmacokinetic interaction was reported, when the two drugs were co-administered. Therefore, dose adjustment of antidiabetic treatment such as repaglinide may be required (see section 4.4).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Additional information on irbesartan interactions</span></u><span lang="EN-GB">: <span style="color:black">in clinical studies, the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic interactions were observed when irbesartan was coadministered with warfarin, a medicinal product metabolised by CYP2C9. The effects of CYP2C9 inducers such as rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The pharmacokinetic of digoxin was not altered by coadministration of irbesartan.</span></span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.6     Fertility, pregnancy and lactation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Pregnancy</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks may exist for this class of drugs. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Exposure to AIIRA therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).</span></p><p class="EMEABodyText"><span lang="EN-GB">Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.</span></p><p class="EMEABodyText"><span lang="EN-GB">Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3 and 4.4).</span></p><p class="EMEABodyText"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Breast-feeding</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText"><span lang="EN-GB">Because no information is available regarding the use of Karvea during breast-feeding, Karvea is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">It is unknown whether irbesartan or its metabolites are excreted in human milk. </span></p><p class="EMEABodyText"><span lang="EN-GB">Available pharmacodynamic/toxicological data in rats have shown excretion of irbesartan or its metabolites in milk (for details see 5.3).</span></p><p class="EMEABodyText"> </p><p class="EMEABodyText"><u><span lang="EN-GB">Fertility</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText">Irbesartan had no effect upon fertility of treated rats and their offspring up to the dose levels inducing the first signs of parental toxicity (see section 5.3). </p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.7     Effects on ability to drive and use machines"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <div style="border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt"> <p class="EMEABodyText" style="border:none;padding:0in"><span lang="EN-GB">The use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4). The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 and 4.4).</span></p> </div><p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Based on its pharmacodynamic properties, irbesartan is unlikely to affect the ability to drive and use machines. When driving vehicles or operating machines, it should be taken into account that dizziness or weariness may occur during treatment.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.8     Undesirable effects"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><span lang="EN-GB">In placebo-controlled trials in patients with hypertension, the overall incidence of adverse events did not differ between the irbesartan (56.2%) and the placebo groups (56.5%). Discontinuation due to any clinical or laboratory adverse event was less frequent for irbesartan-treated patients (3.3%) than for placebo-treated patients (4.5%). The incidence of adverse events was not related to dose (in the recommended dose range), gender, age, race, or duration of treatment.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">In diabetic hypertensive patients with microalbuminuria and normal renal function, orthostatic dizziness and orthostatic hypotension were reported in 0.5% of the patients (i.e., uncommon) but in excess of placebo.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">The following table presents the adverse drug reactions that were reported in placebo-controlled trials in which 1,965 hypertensive patients received irbesartan. Terms marked with a star (*) refer to the adverse reactions that were additionally reported in &gt; 2% of diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria and in excess of placebo.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">The frequency of adverse reactions listed below is defined using the following convention:</span></p><p class="EMEABodyText"><span lang="EN-GB">very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to &lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Adverse reactions additionally reported from post–marketing experience are also listed. These adverse reactions are derived from spontaneous reports.</span></p><p class="EMEABodyText"><b></b></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Blood and lymphatic system disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       anaemia, thrombocytopenia</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Immune system disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       hypersensitivity reactions such as angioedema, rash, urticaria, anaphylactic reaction, anaphylactic shock</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Metabolism and nutrition disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       hyperkalaemia, hypoglycaemia</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Nervous system disorders</span></u></p><p class="EMEABodyText"><span lang="EN-GB">Common:         dizziness, orthostatic dizziness*</span></p><p class="EMEABodyText"><span lang="EN-GB">Not known:       vertigo, headache</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Ear and labyrinth disorder</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       tinnitus</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Cardiac disorders</span></u></p><p class="EMEABodyText"><span lang="EN-GB">Uncommon:      tachycardia</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Vascular disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Common:         orthostatic hypotension*</span></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Uncommon:      flushing</span></p><p class="EMEABodyText"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Respiratory, thoracic and mediastinal disorders</span></u></p><p class="EMEABodyText"><span lang="EN-GB">Uncommon:      cough</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Gastrointestinal disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Common:         nausea/vomiting</span></p><p class="EMEABodyText"><span lang="EN-GB">Uncommon:      diarrhoea, dyspepsia/heartburn</span></p><p class="EMEABodyText"><span lang="EN-GB">Not known:       dysgeusia</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Hepatobiliary disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Uncommon:      jaundice</span></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       hepatitis, abnormal liver function</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Skin and subcutaneous tissue disorders</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Not known:       leukocytoclastic vasculitis</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Musculoskeletal and connective tissue disorders </span></u></p><p class="EMEABodyText"><span lang="EN-GB">Common:         musculoskeletal pain*</span></p><p class="EMEABodyText" style="margin-left:1.0in;text-indent:-1.0in"><span lang="EN-GB">Not known:       arthralgia, myalgia (in some cases associated with increased plasma creatine kinase levels), muscle cramps</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Renal and urinary disorders</span></u></p><p class="EMEABodyText" style="margin-left:1.0in;text-indent:-1.0in;page-break-after: avoid"><span lang="EN-GB">Not known:        impaired renal function including cases of renal failure in patients at risk (see section 4.4)</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="text-align:justify;page-break-after:avoid"><u><span lang="EN-GB">Reproductive system and breast disorders</span></u></p><p class="EMEABodyText"><span lang="EN-GB">Uncommon:      sexual dysfunction</span></p><p class="EMEABodyText" style="text-align:justify"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">General disorders and administration site conditions</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Common:         fatigue</span></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Uncommon:      chest pain</span></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Investigations</span></u></p><p class="EMEABodyText" style="margin-left:1.0in;text-indent:-1.0in"><span lang="EN-GB">Very common:  Hyperkalaemia* occurred more often in diabetic patients treated with irbesartan than with placebo. In diabetic hypertensive patients with microalbuminuria and normal renal function, hyperkalaemia (≥ 5.5 mEq/L) occurred in 29.4% of the patients in the irbesartan 300 mg group and 22% of the patients in the placebo group. In diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria, hyperkalaemia (≥ 5.5 mEq/L) occurred in 46.3% of the patients in the irbesartan group and 26.3% of the patients in the placebo group.</span></p><p class="EMEABodyText" style="margin-left:1.0in;text-indent:-1.0in"><span lang="EN-GB">Common:         significant increases in plasma creatine kinase were commonly observed (1.7%) in irbesartan treated subjects. None of these increases were associated with identifiable clinical musculoskeletal events.<br/> In 1.7% of hypertensive patients with advanced diabetic renal disease treated with irbesartan, a decrease in haemoglobin*, which was not clinically significant, has been observed.</span></p><p class="EMEABodyText"><i><u><span lang="EN-GB"></span></u></i></p><p class="EMEABodyText"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">I</span><span lang="EN-GB">n a randomised trial of 318 hypertensive children and adolescents aged 6 to 16 years, the following adverse reactions occurred in the 3-week double-blind phase: headache (7.9%), hypotension (2.2%), dizziness (1.9%), cough (0.9%). In the 26-week open-label period of this trial the most frequent laboratory abnormalities observed were creatinine increases (6.5%) and elevated CK values in 2% of child recipients.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Reporting of suspected adverse reactions </span></u></p><p class="EMEABodyText"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText"><span lang="EN-GB">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via <span style="background:silver">the national reporting system listed in Appendix V.</span> </span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.9     Overdose"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Experience in adults exposed to doses of up to 900 mg/day for 8 weeks revealed no toxicity. The most likely manifestations of overdose are expected to be hypotension and tachycardia; bradycardia might also occur from overdose. No specific information is available on the treatment of overdose with Karvea. The patient should be closely monitored, and the treatment should be symptomatic and supportive. Suggested measures include induction of emesis and/or gastric lavage. Activated charcoal may be useful in the treatment of overdose. Irbesartan is not removed by haemodialysis.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="5.       PHARMACOLOGICAL PROPERTIES"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="5.1     Pharmacodynamic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><span lang="EN-GB">Pharmacotherapeutic group: Angiotensin-II antagonists, plain.</span></p><p class="EMEABodyText"><span lang="EN-GB">ATC code: C09C A04.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Mechanism of action</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Irbesartan is a potent, orally active, selective angiotensin-II receptor (type AT<sub>1</sub>) antagonist. It is expected to block all actions of angiotensin-II mediated by the AT<sub>1</sub> receptor, regardless of the source or route of synthesis of angiotensin-II. The selective antagonism of the angiotensin-II (AT<sub>1</sub>) receptors results in increases in plasma renin levels and angiotensin-II levels, and a decrease in plasma aldosterone concentration. Serum potassium levels are not significantly affected by irbesartan alone at the recommended doses. Irbesartan does not inhibit ACE (kininase-II), an enzyme which generates angiotensin-II and also degrades bradykinin into inactive metabolites. Irbesartan does not require metabolic activation for its activity.</span></p><p class="EMEABodyText"></p><p class="EMEAHeading2"><u><span lang="EN-GB" style="font-weight:normal">Clinical efficacy</span></u></p><p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><i><span lang="EN-GB">Hypertension</span></i></p><p class="EMEABodyText"><span lang="EN-GB">Irbesartan lowers blood pressure with minimal change in heart rate. The decrease in blood pressure is dose-related for once a day doses with a tendency towards plateau at doses above 300 mg. Doses of 150-300 mg once daily lower supine or seated blood pressures at trough (i.e. 24 hours after dosing) by an average of 8-13/5-8 mm Hg (systolic/diastolic) greater than those associated with placebo.</span></p><p class="EMEABodyText"><span lang="EN-GB">Peak reduction of blood pressure is achieved within 3-6 hours after administration and the blood pressure lowering effect is maintained for at least 24 hours. At 24 hours the reduction of blood pressure was 60-70% of the corresponding peak diastolic and systolic responses at the recommended doses. Once daily dosing with 150 mg produced trough and mean 24 hour responses similar to twice daily dosing on the same total dose.</span></p><p class="EMEABodyText"><span lang="EN-GB">The blood pressure lowering effect of Karvea is evident within 1-2 weeks, with the maximal effect occurring by 4-6 weeks after start of therapy. The antihypertensive effects are maintained during long term therapy. After withdrawal of therapy, blood pressure gradually returns toward baseline. Rebound hypertension has not been observed.</span></p><p class="EMEABodyText"><span lang="EN-GB">The blood pressure lowering effects of irbesartan and thiazide-type diuretics are additive. In patients not adequately controlled by irbesartan alone, the addition of a low dose of hydrochlorothiazide (12.5 mg) to irbesartan once daily results in a further placebo-adjusted blood pressure reduction at trough of 7-10/3-6 mm Hg (systolic/diastolic).</span></p><p class="EMEABodyText"><span lang="EN-GB">The efficacy of Karvea is not influenced by age or gender. As is the case with other medicinal products that affect the renin-angiotensin system, black hypertensive patients have notably less response to irbesartan monotherapy. When irbesartan is administered concomitantly with a low dose of hydrochlorothiazide (e.g. 12.5 mg daily), the antihypertensive response in black patients approaches that of white patients.</span></p><p class="EMEABodyText"><span lang="EN-GB">There is no clinically important effect on serum uric acid or urinary uric acid secretion.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText"><span lang="EN-GB">Reduction of blood pressure with 0.5 mg/kg (low), 1.5 mg/kg (medium) and 4.5 mg/kg (high) target titrated doses of irbesartan was evaluated in 318 hypertensive or at risk (diabetic, family history of hypertension) children and adolescents aged 6 to 16 years over a three week period. At the end of the three weeks the mean reduction from baseline in the primary efficacy variable, trough seated systolic blood pressure (SeSBP) was 11.7 mmHg (low dose), 9.3 mmHg (medium dose), 13.2 mmHg (high dose). No significant difference was apparent between these doses. Adjusted mean change of trough seated diastolic blood pressure (SeDBP) was as follows: 3.8 mmHg (low dose), 3.2 mmHg (medium dose), 5.6 mmHg (high dose). Over a subsequent two week period where patients were re-randomized to either active medicinal product or placebo, patients on placebo had increases of 2.4 and 2.0 mmHg in SeSBP and SeDBP compared to +0.1 and -0.3 mmHg changes respectively in those on all doses of irbesartan (see section 4.2).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><i><span lang="EN-GB">Hypertension and type 2 diabetes with renal disease</span></i></p><p class="EMEABodyText"><span lang="EN-GB">The “Irbesartan Diabetic Nephropathy Trial (IDNT)” shows that irbesartan decreases the progression of renal disease in patients with chronic renal insufficiency and overt proteinuria. IDNT was a double blind, controlled, morbidity and mortality trial comparing Karvea, amlodipine and placebo. In 1,715 hypertensive patients with type 2 diabetes, proteinuria ≥ 900 mg/day and serum creatinine ranging from 1.0-3.0 mg/dl, the long-term effects (mean 2.6 years) of Karvea on the progression of renal disease and all-cause mortality were examined. Patients were titrated from 75 mg to a maintenance dose of 300 mg Karvea</span><span lang="EN-GB" style='font-family:"Times",serif'>, from 2.5 mg to 10 mg amlodipine, or placebo</span><span lang="EN-GB"> as tolerated. Patients in all treatment groups typically received between 2 and 4 antihypertensive agents (e.g., diuretics, beta blockers, alpha blockers) to reach a predefined blood pressure goal of ≤ 135/85 mmHg or a 10 mmHg reduction in systolic pressure if baseline was &gt; 160 mmHg. Sixty per cent (60%) of patients in the placebo group reached this target blood pressure whereas this figure was 76% and 78% in the irbesartan and amlodipine groups respectively. Irbesartan significantly reduced the relative risk in the primary combined endpoint of doubling serum creatinine, end-stage renal disease (ESRD) or all-cause mortality. Approximately 33% of patients in the irbesartan group reached the primary renal composite endpoint compared to 39% and 41% in the placebo and amlodipine groups [20% relative risk reduction versus placebo (p = 0.024) and 23% relative risk reduction compared to amlodipine (p = 0.006)]. When the individual components of the primary endpoint were analysed, no effect in all cause mortality was observed, while a positive trend in the reduction in ESRD and a significant reduction in doubling of serum creatinine were observed.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB" style="layout-grid-mode:line">Subgroups consisting of gender, race, age, duration of diabetes, baseline blood pressure, serum creatinine, and albumin excretion rate were assessed for treatment effect. In the female and black subgroups which represented 32% and 26% of the overall study population respectively, a renal benefit was not evident, </span>although the confidence intervals do not exclude it. As for the secondary endpoint of fatal and non-fatal cardiovascular events, there was no difference among the three groups in the overall population, although an increased incidence of non-fatal MI was seen for women and a decreased incidence of non-fatal MI was seen in males in the irbesartan group versus the placebo-based regimen. An increased incidence of non-fatal MI and stroke was seen in females in the irbesartan-based regimen versus the amlodipine-based regimen, while hospitalization due to heart failure was reduced in the overall population. However, no proper explanation for these findings in women has been identified.</p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">The study of the “Effects of Irbesartan on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus (IRMA 2)” shows that irbesartan 300 mg delays progression to overt proteinuria in patients with microalbuminuria. IRMA 2 was a placebo-controlled double blind morbidity study in 590 patients with type 2 diabetes, microalbuminuria (30-300 mg/day) and normal renal function (serum creatinine ≤ 1.5 mg/dl in males and &lt; 1.1 mg/dl in females). The study examined the long-term effects (2 years) of Karvea on the progression to clinical (overt) proteinuria (urinary albumin excretion rate (UAER) &gt; 300 mg/day, and an increase in UAER of at least 30% from baseline). The predefined blood pressure goal was ≤ 135/85 mmHg. Additional antihypertensive agents (excluding ACE inhibitors, angiotensin II receptor antagonists and dihydropyridine calcium blockers) were added as needed to help achieve the blood pressure goal. While similar blood pressure was achieved in all treatment groups, fewer subjects in the irbesartan 300 mg group (5.2%) than in the placebo (14.9%) or in the irbesartan 150 mg group (9.7%) reached the endpoint of overt proteinuria, demonstrating a 70% relative risk reduction versus placebo (p = 0.0004) for the higher dose. An accompanying improvement in the glomerular filtration rate (GFR) was not observed during the first three months of treatment. The slowing in the progression to clinical proteinuria was evident as early as three months and continued over the 2 year period. Regression to normoalbuminuria (&lt; 30 mg/day) was more frequent in the Karvea 300 mg group (34%) than in the placebo group (21%).</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><i><span lang="EN-GB">Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</span></i></p><p class="EMEABodyText"><span lang="EN-GB">Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker. ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</span></p><p class="EMEABodyText"><span lang="EN-GB">These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.</span></p><p class="EMEABodyText"><span lang="EN-GB">ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</span></p><p class="EMEABodyText"><span lang="EN-GB">ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.2     Pharmacokinetic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Absorption</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">After oral administration, irbesartan is well absorbed: studies of absolute bioavailability gave values of approximately 60-80%. Concomitant food intake does not significantly influence the bioavailability of irbesartan. </span></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Distribution</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Plasma protein binding is approximately 96%, with negligible binding to cellular blood components. The volume of distribution is 53 - 93 litres. </span></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Biotransformation</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Following oral or intravenous administration of <sup><span style="position:relative; top:-1.0pt">14</span></sup>C irbesartan, 80-85% of the circulating plasma radioactivity is attributable to unchanged irbesartan. Irbesartan is metabolised by the liver via glucuronide conjugation and oxidation. The major circulating metabolite is irbesartan glucuronide (approximately 6%). <i>In vitro</i> studies indicate that irbesartan is primarily oxidised by the cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Linarity / non-linearity</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg. A less than proportional increase in oral absorption at doses beyond 600 mg (twice the maximal recommended dose) was observed; the mechanism for this is unknown. Peak plasma concentrations are attained at 1.5 - 2 hours after oral administration. The total body and renal clearance are 157 - 176 and 3 - 3.5 ml/min, respectively. The terminal elimination half-life of irbesartan is 11 - 15 hours. Steady-state plasma concentrations are attained within 3 days after initiation of a once-daily dosing regimen. Limited accumulation of irbesartan (&lt; 20%) is observed in plasma upon repeated once-daily dosing. In a study, somewhat higher plasma concentrations of irbesartan were observed in female hypertensive patients. However, there was no difference in the half-life and accumulation of irbesartan. No dosage adjustment is necessary in female patients. Irbesartan AUC and C<span class="EMEASubscript">max</span> values were also somewhat greater in older subjects (≥ 65 years) than those of young subjects (18 - 40 years). However the terminal half-life was not significantly altered. No dosage adjustment is necessary in older people.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Elimination</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Irbesartan and its metabolites are eliminated by both biliary and renal pathways. After either oral or IV administration of <sup><span style="position:relative;top:-1.0pt">14</span></sup>C irbesartan, about 20% of the radioactivity is recovered in the urine, and the remainder in the faeces. Less than 2% of the dose is excreted in the urine as unchanged irbesartan.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="EMEABodyText" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="EMEABodyText"><span lang="EN-GB">The pharmacokinetics of irbesartan were evaluated in 23 hypertensive children after the administration of single and multiple daily doses of irbesartan (2 mg/kg) up to a maximum daily dose of 150 mg for four weeks. Of those 23 children, 21 were evaluable for comparison of pharmacokinetics with adults (twelve children over 12 years, nine children between 6 and 12 years). Results showed that C<span class="EMEASubscript">max</span>, AUC and clearance rates were comparable to those observed in adult patients receiving 150 mg irbesartan daily. A limited accumulation of irbesartan (18%) in plasma was observed upon repeated once daily dosing.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Renal impairment</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">In patients with renal impairment or those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan are not significantly altered. Irbesartan is not removed by haemodialysis.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><u><span lang="EN-GB">Hepatic impairment</span></u></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">In patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly altered. </span></p><p class="EMEABodyText"><span lang="EN-GB">Studies have not been performed in patients with severe hepatic impairment.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.3Preclinical safety data"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">There was no evidence of abnormal systemic or target organ toxicity at clinically relevant doses. In non-clinical safety studies, high doses of irbesartan (≥ 250 mg/kg/day in rats and ≥ 100 mg/kg/day in macaques) caused a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit). At very high doses (≥ 500 mg/kg/day) degenerative changes in the kidney (such as interstitial nephritis, tubular distension, basophilic tubules, increased plasma concentrations of urea and creatinine) were induced by irbesartan in the rat and the macaque and are considered secondary to the hypotensive effects of the medicinal product which led to decreased renal perfusion. Furthermore, irbesartan induced hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at ≥ 90 mg/kg/day, in macaques at ≥ 10 mg/kg/day). All of these changes were considered to be caused by the pharmacological action of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia/ hypertrophy of the renal juxtaglomerular cells does not appear to have any relevance.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">There was no evidence of mutagenicity, clastogenicity or carcinogenicity.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Fertility and reproductive performance were not affected in studies of male and female rats even at oral doses of irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), including mortality at the highest dose. No significant effects on the number of corpora lutea, implants, or live foetuses were observed. Irbesartan did not affect survival, development, or reproduction of offspring. Studies in animals indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses. Irbesartan is excreted in the milk of lactating rats.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Animal studies with irbesartan showed transient toxic effects (increased renal pelvic cavitation, hydroureter or subcutaneous oedema) in rat foetuses, which were resolved after birth. In rabbits, abortion or early resorption were noted at doses causing significant maternal toxicity, including mortality. No teratogenic effects were observed in the rat or rabbit.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="6.       PHARMACEUTICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="6.1     List of excipients"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText" style="page-break-after:avoid"><span lang="EN-GB">Tablet core:</span></p><p class="EMEABodyText"><span lang="IT">Lactose monohydrate</span></p><p class="EMEABodyText"><span lang="IT">Microcrystalline cellulose</span></p><p class="EMEABodyText"><span lang="IT">Croscarmellose sodium</span></p><p class="EMEABodyText"><span lang="IT">Hypromellose</span></p><p class="EMEABodyText"><span lang="IT">Silicon dioxide</span></p><p class="EMEABodyText"><span lang="IT">Magnesium stearate.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="IT">Film-coating:</span></p><p class="EMEABodyText"><span lang="IT">Lactose monohydrate</span></p><p class="EMEABodyText"><span lang="IT">Hypromellose</span></p><p class="EMEABodyText"><span lang="IT">Titanium dioxide</span></p><p class="EMEABodyText"><span lang="IT">Macrogol 3000</span></p><p class="EMEABodyText"><span lang="IT">Carnauba wax.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.2     Incompatibilities"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><span lang="EN-GB">Not applicable.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.3     Shelf life"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><span lang="EN-GB">3 years.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.4     Special precautions for storage"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><span lang="EN-GB">Do not store above 30°C.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.5     Nature and contents of container"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><span lang="EN-GB">Cartons of 14 film-coated tablets in PVC/PVDC/Aluminium blisters.<br/> Cartons of 28 film-coated tablets in PVC/PVDC/Aluminium blisters.</span></p><p class="EMEABodyText"><span lang="EN-GB">Cartons of 30</span><span lang="EN-GB"> film-coated tablets in PVC/PVDC/Aluminium blisters.</span></p><p class="EMEABodyText"><span lang="EN-GB">Cartons of 56 film-coated tablets in PVC/PVDC/Aluminium blisters.<br/> Cartons of 84 film-coated tablets in PVC/PVDC/Aluminium blisters.</span></p><p class="EMEABodyText"><span lang="EN-GB">Cartons of 90</span><span lang="EN-GB"> film-coated tablets in PVC/PVDC/Aluminium blisters.</span></p><p class="EMEABodyText"><span lang="EN-GB">Cartons of 98 film-coated tablets in PVC/PVDC/Aluminium blisters.<br/> Cartons of 56 x 1 film-coated tablet in PVC/PVDC/Aluminium perforated unit dose blisters.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Not all pack sizes may be marketed.</span></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.6     Special precautions for disposal"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading2"></p><p class="EMEABodyText"><span lang="EN-GB">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="7.       MARKETING AUTHORISATION HOLDER"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEAAddress"><span lang="FR">sanofi-aventis groupe<br/> 54, rue La Boétie<br/> F-75008 Paris - France</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="8.       MARKETING AUTHORISATION NUMBERS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEABodyText"><span lang="SL">EU/1/97/049/026-030<br/> EU/1/97/049/033<br/> EU/1/97/049/036<br/> EU/1/97/049/039</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="9.       DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEAHeading1"></p><p class="EMEABodyText"><span lang="EN-GB">Date of first authorisation: 27 August 1997<br/> Date of latest renewal: 27 August 2007</span></p><p class="EMEABodyText"></p><p class="EMEABodyText"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="10.     DATE OF REVISION OF THE TEXT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="EMEABodyText"></p><p class="EMEABodyText"><span lang="EN-GB">Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu</span></p><p class="EMEABodyText"></p><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
	
</section>
							<!-- sections can repeat as necessary -->
						</Composition>
					</resource>
				</entry>
				
			</Bundle>
		</resource>
	</entry>
</Bundle>